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Breast cancer remains one of the main causes of cancer-related deaths in women worldwide. 
In the past years, advances in breast cancer treatment have been made, namely with the 
introduction of preoperative neoadjuvant chemotherapy (NACT) in selected cases of 
inflammatory/inoperable or advanced tumors (size larger than 2 cm and/or disease extension 
to the axillary lymph node). This treatment is effective in reducing the size of the primary 
tumor, allowing breast conservation. However, less than half of the patients achieve a 
pathological complete response and residual disease after NACT is a strong predictor of 
relapse. Hence, it is essential to find a suitable marker of response to this treatment, to 
promptly direct NACT non-responder patients to alternative therapies. 
Tumor infiltrating lymphocytes (TILs), specifically CD8+ cytotoxic T cells (CTLs) have been 
appointed as biomarkers of response. However, the clinical usefulness of this biomarker is still 
controversial and their evaluation is not yet implemented. This controversy could be explained 
by the fact that tumor cells can escape the immune system by releasing cytokines or 
expressing immune checkpoint inhibitors, dampening CTLs activity. HLA-DR, a T cell activation 
marker, could be a more reliable biomarker of response to NACT, than the presence of CTLs 
per se, since it may reflect the overall immune status of the tumor microenvironment and 
their functionality.   
To get more insights into the immune component of the tumor microenvironment, fresh 
biopsies, surgical specimens and blood were collected from breast cancer patients. In order 
to assess the differences between breast cancer aggressiveness, the patients were divided in 
two groups: the ones that have metastasis in the axillary lymph node and the ones that don’t 
have. Although the immunophenotype was similar in both groups of patients, a significant 
difference was observed for the expression level of HLA-DR in CTLs and regulatory T cells 
(Tregs). Indeed, patients without axillary lymph node metastasis had higher level of HLA-DR in 
CTLs and lower in Tregs when compared to patients with axillary lymph node metastasis.  
Given this result, we wondered if this immune trait could be used to predict response to NACT. 
In biopsies of two independent cohorts of breast cancer patients selected for NACT, we 
observed that high HLA-DR expression level in CTLs was strongly correlated with good 
response to NACT, with a high sensitivity (94.12% and 80% in cohort 1 and 2, respectively) and 
specificity (100% and 85.71% in cohort 1 and 2, respectively). Therefore we propose that HLA-
DR expression level in CTLs above a threshold value, calculated by a ROC curve, would identify 
patients that would be responders to NACT. Additionally, by multivariable analysis, we noted 
that HLA-DR expression in CTLs was an independent predictor of response to NACT. 
Interestingly, HLA-DR expression in CTLs also have the likelihood of being a prognostic marker 
of breast cancer patients’ outcome, since a progression-free survival analysis revealed that 
patients with low levels of HLA-DR in CTLs tend to relapse sooner. 
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Moreover, we observed that this immune feature was systemically reflected. Indeed, with the 
assessment of HLA-DR expression level in circulating CTLs we could differentiate breast cancer 
aggressiveness and even response to NACT, although in a less striking manner when compared 
to the analysis of HLA-DR expression level in intratumor CTLs. 
To characterize HLA-DR+ CTLs, we performed a gene expression as well as a broad surface 
markers’ expression analysis. When comparing to HLA-DR negative CTLs, HLA-DR+ CTLs had 
higher expression of cytotoxicity-related molecules Granzyme B, IFN-, Perforin, TNF-, Eomes 
and lower expression of Tbet. Additionally, they had a high proliferative capacity (high Ki67 
levels) and an intermediate level of exhaustion markers, namely PD-1, Tim3 and CD127. These 
results suggest that HLA-DR+ CTLs had a phenotype closer to effector memory T cells (TEM), 
which have the capacity to home to tissues and to recirculate, rapidly release effector 
molecules and differentiate in effector CTLs.    
Then, we developed a 3D culture platform to shed some light on the functionality of these 
HLA-DR+ CTLs and their contribution for NACT success. Namely, we used two different breast 
cancer cell lines (MCF-7 and MDA-MB-231) and allowed them to spontaneously form 
spheroids. Peripheral blood mononuclear cells (PBMCs) isolated from NACT-responders and 
non-responders were added to the culture, infiltrating the 3D tumor-like structure. 
Interestingly, the PBMCs from NACT-responders were able by themselves to reduce the 
viability of the breast cancer cell line; whereas the PBMCs from NACT non-responders showed 
no effect. This emphasizes that the immune cells from NACT-responders are activated and 
have cytotoxic capacities; on the opposite, the immune cells from NACT non-responders are 
immunosuppressed and cannot exert their cytotoxic function. Furthermore, we added 
doxorubicin (a NACT agent) to the 3D co-culture and observed that NACT-responders’ PBMCs 
had a synergistic effect with this drug in decreasing the tumor cells’ viability. On the contrary, 
the addition of doxorubicin and NACT non-responders’ PBMCs did not alter the viability of the 
tumor cells. With these in vitro assays we validated the clinical observations. 
To confirm that the anti-tumor activity of NACT-responders’ PBMCs were indeed due to HLA-
DR+ CTLs, which are more abundant in the blood of these patients than in the blood of NACT 
non-responders, we took advantage of the 3D system implemented. In fact, sorted HLA-DR+ 
CTLs, but not HLA-DR negative CTLs, reduce the viability of MCF-7, attesting the cytotoxic 
capacity and anti-tumor properties of HLA-DR+ CTLs.  
To investigate if it would be possible to revert the immunosuppressed phenotype of NACT 
non-responders’ CTLs we stimulated their PBMCs with PMA/ionomycin or by T cell receptor 
(TCR) engagement. Notably, both stimuli raised the HLA-DR levels in CTLs in NACT non-
responders’ PBMCs allowing these cells to reduce the viability of the breast cancer cells, 
similarly to NACT-responders’ PBMCs. The observed effect was even more striking with the 
addition of doxorubicin. This result opens the possibility to develop new treatments for breast 




In this regard, we tested if immune checkpoint blockade (that are already approved for the 
treatment of other cancer types) could allow NACT non-responders’ CTLs activation. However, 
neither PD-1 nor PD-L1 blockade increased the cytotoxic effect of NACT non-responders’ CTLs, 
probably due to the low levels of PD-1 in the circulating CTLs of these patients. Nonetheless, 
our 3D cultures would be an ideal platform to screen other immune-modulating molecules. 
Overall, this thesis revealed a new biomarker to predict breast cancer patients’ response to 
NACT – HLA-DR-expressing CTLs, that should be mainly assessed in the biopsy, but with a 
systemic reflection. Moreover, we developed a 3D co-culture platform of breast cancer cell 
lines and patient-derived immune cells that allowed us to validate the clinical observations 
and clarify the anti-tumor function of HLA-DR+ CTLs; and that could be further used to 
evaluate new therapeutic strategies for NACT non-responders. Actually, considering that CTLs 
expressing high levels of HLA-DR are required in the tumor microenvironment for NACT to be 
effective, we believe that stimulating the NACT non-responders’ CTLs should be a promising 






O cancro da mama é uma das principais causas de morte por cancro em mulheres. 
Recentemente, têm havido diversos avanços no tratamento do cancro da mama, sobretudo 
com a introdução da quimioterapia neoadjuvante (NACT, na sigla em inglês). A NACT 
prescreve-se antes da cirurgia em tumores inflamados/inoperáveis ou em casos de cancro da 
mama avançado, isto é, tumores de dimensão superior a 2 cm e/ou com metástases nos 
nódulos linfáticos da axila. Esta terapia permite reduzir o tamanho do tumor, possibilitando 
uma cirurgia que conserve o tecido mamário, ao invés da mastectomia. No entanto, apenas 
metade das doentes conseguem atingir uma resposta patológica completa. Deste modo, é 
urgente encontrar marcadores preditivos de resposta à NACT, para prontamente direcionar 
para terapias alternativas as doentes não-respondedoras. 
Os linfócitos capazes de infiltrar o tecido tumoral (TILs, na sigla em inglês), em particular as 
células T citotóxicas (CTLs, na sigla em inglês), têm sido descritas como biomarcadores de 
resposta ao tratamento. No entanto, este biomarcador ainda não é usado na rotina clinica, o 
que pode ser explicado pelo facto de as células tumorais terem mecanismos para escapar ao 
ambiente imunitário, nomeadamente através da produção e libertação de citocinas anti-
inflamatórias e expressão de checkpoints imunitários que diminuem a função das CTLs. Um 
marcador de ativação das células T, como o HLA-DR, é potencialmente um biomarcador da 
resposta à NACT mais robusto, dado que reflete este ambiente tumoral e a função das CTLs.        
Para melhor compreender o microambiente imunitário no tumor usámos biópsias e peças 
cirúrgicas a fresco, bem como amostras de sangue de doentes com cancro da mama. Para 
entender as diferenças entre a agressividade do cancro da mama, dividimos as doentes de 
acordo com o estado dos nódulos linfáticos da axila: com ou sem metástases. A principal 
diferença encontrada entre os dois grupos foi o estado de ativação das CTLs e das Tregs, isto 
é, o nível de expressão de HLA-DR nestas células. Em especial, as doentes sem metástases nos 
nódulos linfáticos da axila apresentavam CTLs com elevado nível de expressão de HLA-DR e 
Tregs com baixo nível de expressão de HLA-DR, quando comparadas com doentes com 
metástases nos nódulos linfáticos da axila. 
Perguntámo-nos então se estas características imunes também poderiam ser usadas como 
marcadores preditivos de resposta à NACT. Para tal, estabelecemos duas coortes 
independentes de doentes de cancro da mama selecionadas para NACT. Observámos que o 
nível de expressão de HLA-DR, em especial nas CTLs, correlacionava-se com resposta à NACT 
com alta especificidade (100% e 85.71% na coorte 1 e 2, respetivamente) e elevada 
sensibilidade (94.12% na coorte 1 e 80% na 2). Assim, propomos que doentes com nível de 
HLA-DR nas CTLs acima do limite calculado pela curva ROC serão respondedores à NACT. 
Adicionalmente, com uma análise multivariada, concluímos que o nível de expressão de HLA-
DR em CTLs é um biomarcador independente. 
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O nível de expressão de HLA-DR em CTLs também pode ser um possível marcador de 
prognóstico, já que a análise da sobrevivência sem progressão da doença demonstrou que 
doentes com nível baixo de expressão de HLA-DR em CTLs têm recaída da doença mais cedo. 
Descobrimos igualmente que este biomarcador reflete-se de um modo sistémico. A análise do 
nível de expressão de HLA-DR em CTLs em circulação também nos permitiu distinguir entre 
doentes com e sem resposta à NACT. No entanto, esta distinção com as células do sangue não 
revelou ser tão eficaz quanto a análise do biomarcador em CTLs tumorais. 
Para melhor caracterizar as HLA-DR+ CTLs, procedemos a uma análise de expressão genética 
e a uma detalhada caracterização de diferentes marcadores de superfície. Quando 
comparadas às CTLs sem expressão de HLA-DR, descobrimos que as HLA-DR+ CTLs têm maior 
expressão em moléculas de citotoxicidade, como a Granzima B, Perforina, IFN-, TNF-, Eomes 
e menor expressão de Tbet. Adicionalmente, as células HLA-DR+ CTLs têm maior capacidade 
proliferativa, demonstrada pelo nível de Ki67, e apresentam um nível intermédio de 
marcadores de exaustão, nomeadamente PD-1, Tim3 e CD127. Concluímos que as HLA-DR+ 
CTLs têm um fenótipo similar ao das células T de memória efectoras (TEM) que têm a 
capacidade de permanecerem nos tecidos e de recircularem, libertam rapidamente moléculas 
efectoras e podem diferenciar-se em CTLs efectoras. 
Posteriormente, desenvolvemos uma plataforma de culturas 3D para compreender melhor a 
função das HLA-DR+ CTLs e a sua contribuição para o sucesso da NACT. Nomeadamente, 
usamos duas linhas celulares de cancro da mama (MCF-7 e MDA-MB-231) e deixamo-las 
formarem espontaneamente esferoides. As células mononucleares do sangue (PBMCs, na sigla 
em inglês), isoladas de doentes com e sem resposta à NACT, foram adicionadas à cultura e 
foram capazes de infiltrar as estruturas 3D. Na co-cultura com as PBMCs de respondedoras à 
NACT, a viabilidade das células tumorais diminuiu, ao contrário das PBMCs de não-
respondedores à NACT. Este resultado demonstra que as células imunes de doentes com 
resposta à NACT estão ativadas e são citotóxicas; já as células imunes de doentes sem resposta 
à NACT estão imunossuprimidas e não conseguem realizar a sua função citotóxica. 
Adicionámos ainda um fármaco normalmente usado na NACT – doxorrubicina, e observámos 
um efeito sinergístico com as PBMCs das doentes respondedoras à NACT, o qual diminuía ainda 
mais a viabilidade das células tumorais. Por outro lado, a adição de doxorrubicina a culturas 
com PBMCs das doentes não-respondedoras à NACT não produziu qualquer efeito na 
viabilidade das células tumorais. 
Para confirmar que a atividade anti-tumoral das respondedoras à NACT era devido à presença 
de HLA-DR+ CTLs, usamos os modelos 3D criados. Na verdade, HLA-DR+ CTLs sorteadas, ao 
contrário das CTLs sem HLA-DR, reduziram a viabilidade das MCF-7, atestando a sua 
capacidade citotóxica e anti-tumoral. 
Para verificar se era possível reverter o fenótipo de imunossupressão das PBMCs das doentes 
não-respondedoras à NACT, estas foram estimuladas de modo a aumentar o nível de expressão 




respondedoras à NACT passam a ter um efeito citotóxico e a viabilidade das células tumorais 
diminui. Este efeito foi potenciado com a adição da doxorrubicina. Este resultado abre a 
possibilidade de desenvolver novos tratamentos para doentes de cancro da mama em que os 
tumores não sejam suscetíveis à NACT. Deste modo, testámos se o uso de anticorpos contra 
os checkpoints imunológicos permitia a ativação das CTLs das não-respondedoras. No entanto, 
nem o bloqueio de PD-1 nem de PD-L1 conseguiu aumentar o efeito citotóxico das CTLs das 
não-respondedoras, provavelmente devido à reduzida percentagem de CTLs positivas para PD-
1 nestas doentes.  
No global, nesta tese, revelamos um novo biomarcador capaz de prever a resposta à NACT em 
doentes com cancro da mama. Este marcador, nível de expressão de HLA-DR nas CTLs, analisa-
se em biópsias pré-tratamento mas tem representação sistémica. Desenvolvemos ainda uma 
cultura 3D com linhas celulares de cancro da mama e células imunes isoladas de doentes que 
não só validou os resultados clínicos como também pode ser usada como uma plataforma para 
testar tratamentos alternativos para as doentes não-respondedoras à NACT. De facto, a 
estimulação das PBMCs, e o consequente aumento do nível de expressão de HLA-DR nas CTLs, 
é algo que pretendemos explorar no futuro como uma possível terapêutica para o cancro da 
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Chapter I - Introduction 
 
1. Cancer Immune Features 
 
For many years, cancer was seen as a group of abnormally proliferating cells that had lost the 
capacity of apoptosis. This proliferation could arise from genetically differences, new point 
mutations, or from the accumulation of DNA repair errors. Nowadays, it is known that cancer 
is a complex and evolving tissue composed of several cell types, namely tumor cells, fibroblasts 
and immune cells. Altogether, these different cell types compose the tumor 
microenvironment. Cancer progression depends not only on the attributes of tumor cells but 
on the complex interactions that occur on the tumor microenvironment.  
To help clarify the biology of cancer, Hanahan et al have proposed six hallmarks that define 
tumor origin, growth and dissemination (1). To this first classification, the authors added 
another four hallmarks (2), that are explained in the next subsection.  
      
1.1. Hallmarks of Cancer 
 
The hallmarks of cancer are an enumeration of the characteristics of a tumor, or by other 
words, what defines a tumor (Figure I-1). The first six hallmarks were sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis and activating invasion and metastasis (1). Here it is depicted the basis 
of a tumor – the abnormal proliferation with release of growth factors and evasion to growth 
suppressive molecules; the inability to undergo apoptosis; the need to release angiogenic 
factors to develop new blood vessels in order to transport more nutrients and oxygen to a 
demanding tissue; and the capacity to invade the tissue boundaries and spread to distant 
locations.  
Following this first publication, the authors made a second revision noticing that the six 
hallmarks were not sufficient to characterize a tumor. In this second revision, the authors 
included a paradigm shift in the field – the importance of the immune system.  
These new four hallmarks were the genome instability and mutation, the deregulation of 
cellular energetics, the avoidance of immune destruction and the capacity to employ a tumor-
promoting inflammation (Figure I-1). The succession of genomic alterations or mutations and 
the genomic instability are essential for the development of distinct clones. These clones 
adapt differently to the environment and subsequently, the fittest ones are selected, leading 
to tumor growth and progression. The need to reprogram cellular energetics arises from the 
high rates of proliferation seen in tumor cells. Tumor cells opt to switch their metabolism to 
glycolysis to obtain faster energy, even in the presence of oxygen, in a process called aerobic 
glycolysis or the Warburg effect (3). 






Figure I-1 Hallmarks of Cancer. Adapted from Hanahan et al Cell 2011 (2).  
 
These first two new hallmarks complete the previously published ones as what defines the 
functional characteristics that ultimately allow the tumor to survive, proliferate and invade 
the tissue boundaries. On the presence of an abnormal cell, the immune system should be 
able to eliminate it and develop a memory to those antigens. Nevertheless, it is important to 
note that tumor cells evolve and give rise to complex tissues even in the presence of a 
surveilling immune system. In fact, tumors are heavily infiltrated by different immune 
populations (4), and have developed several mechanisms to escape the anti-tumor immune 
response, which will be described in this introduction. Thus, one of the hallmarks is to avoid 
immune destruction. Additionally, tumors can take advantage of the inflammatory process 
and use them in their favor, completing the last hallmark – tumor-promoting inflammation. 
During inflammation, the release, to the tumor microenvironment, of a high amount of growth 
and survival factors and also pro-tumor cytokines occur. Matrix degrading enzymes can also 
be produced during inflammation, which can facilitate adjacent tissue invasion by tumor cells. 
Moreover, TGF- is normally released in an inflammatory process and it is a known inductor 
of epithelial to mesenchymal transition, which empowers the tumor cells with a 
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mesenchymal-like phenotype, acquiring the capacity to invade the tissue and form metastasis 
(4,5).  
 
1.2. Tumor Immune Surveillance 
 
As referred, the immune system have a pivotal role in eliminating tumor cells or, on the other 
hand, in assisting tumor growth and progression. Indeed, it is known that virtually all solid 
cancer types can be infiltrated by immune cells in distinct ranges (6).  
The theoretical notion that immune cells can control tumor cells and contribute for tumor 
elimination or settlement, appeared at the beginning of the 20th century, developed by Paul 
Ehrlich. In the 50s the formulation of immune surveillance by recognition of tumor-specific 
antigens was elaborated (7,8). This theoretical hypothesis was validated by experimental 
procedures with immunosuppressed mice, where an increase in spontaneous or chemically 
induced tumors was observed (9,10). Additionally, mice with an immunodeficient system had 
higher susceptibility to develop viral-related tumors. Nevertheless, other groups disproved 
these results, mainly due to inadequate technical abilities at the time, and the idea of tumor 
immune surveillance was left behind.  
Only in the mid-70s and throughout the 80s and 90s the tumor immune surveillance was again 
investigated, and experiments with nude mice (with an inhibited immune system) were 
executed. There, the authors confirmed that these mice, without immune system, develop 
more chemically induced tumors. Also in these decades, other authors demonstrated that 
antigen presenting cells had the capacity to process and present tumor antigens to other 
immune cells (11). Additionally, the capacity to develop effector and memory immune cells 
were also revealed in these decades (11).  
Besides the experimental data, there are clinical evidences that tumor immune surveillance 
occurs. Namely, there is an increased incidence of cancer (normally from a viral origin (12,13)) 
in patients with immunodeficiency, such as HIV patients (14). Patients who were submitted to 
organ transplants and were prescribed with immunosuppressive drugs also have an increased 
risk of developing cancer (15). Also, the older population has increased incidence of cancer, 
which could be explained by the fact that with age the capacity of the immune system 
decreases, resulting in less tumor immune surveillance (16). Additionally, patients with 
melanoma, breast, ovary, bladder, colorectal and prostate cancer had longer survival rates 
when the percentage of lymphocytes infiltrating the tumor was increased (17–22).   
However, as previously stated, some cancer cells manage to bypass this immune surveillance 
step. Throughout the years, in order to better understand this relationship between cancer 
and the immune system, the field of Immuno-Oncology has been growing and nowadays, 
immune cells and their released cytokines are considered one of the pillars of either tumor 




suppression or progression. In the next section, this tumor-immune crosstalk is going to be 
discussed.    
 
2. Tumor-Immune Interplay at the Cellular Level 
 
The leukocytes that populate the tumor microenvironment can be divided into lymphocytes 
and myeloid cells. Within lymphocytes there are natural killer (NK) cells, B and T lymphocytes; 
and within myeloid cells there are neutrophils, macrophages, dendritic cells and myeloid 
derived suppressor cells. Each subtype of immune cell population will have an important role 
in tumor elimination or progression. The role in tumor progression/regression of the most 
noteworthy immune cell populations for this work will be detailed below. 
  
2.1. The role of Tumor Infiltrating Lymphocytes in the Tumor Microenvironment 
 
T cells are seen as the main immune cell population for tumor cell clearance. However, there 
are several types of T cells, and each can have distinct and even opposite roles in the tumor 
microenvironment. The T cells here described are divided in CD4+ T cells, which include helper 
T cells (Th) and regulatory T cells (Tregs); and CD8+ T cells, which are also called cytotoxic T 
cells (CTLs) (Figure I-2).  
Th cells include different subtypes, e.g. Th1, Th2, Th17, among others, depending mainly on 
the released cytokines (23). Th cells are able to infiltrate the tumor microenvironment and 
assist in CTLs’ priming, for instance (24). The role of Th cells depends on the activation 
performed by the presentation of tumor antigens (normally defined as neoantigens that 
derive from abnormal expression of proteins) by antigen presenting cells (APCs), such as 
dendritic cells or macrophages, detailed in the next subsection. Antigen presentation is 
achieved, after antigen recognition and processing, by showing the antigen associated with 
class II major histocompatibility molecules (MHC II) at APCs’ surface. This antigen presentation 
by the APCs (first signal), together with co-stimulation (second signal) and cytokines release 
(third signal), will activate Th cells, inducing for instance IFN- production and consequent 
stimulation of CTLs.  
Th cells were shown to have anti-tumor activity (25); however, due to the different subsets 
with distinct activities, Th cells can also assist in tumor progression. The first action is mainly 
performed by the Th1 subtype (Figure I-2), which releases high levels of IFN- and TNF-, 
known to have anti-tumor properties. Namely, they induce CTLs function and inhibit 
angiogenesis (23). The presence of Th1 subset at the tumor site was associated with improved 
prognosis in gastric, colorectal, ovarian and hepatocellular cancers (26–29).  
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Th2 cells release IL-4, IL-6 and IL-10 and as such can have dual roles in tumor progression. 
However, due to the production of a highly anti-inflammatory cytokine (IL-10) that has the 
capacity of stimulating more pro-tumor immune cells (Figure I-2), Th2 cells were characterized 
as a poor prognostic predictor in pancreatic and gynecologic cancers (23). 
Tregs are an immunosuppressive subset of CD4+ T cells, characterized by the expression of 
the transcription factor FOXP3. Tregs are necessary for the homeostasis maintenance in 
physiological conditions and therefore, due to their immunosuppressive phenotype, can have 
a pivotal role in preventing autoimmune diseases and in promoting cancer progression 
(reviewed in (30)). In fact, Tregs have the capacity to suppress the function of Th1 and CTLs, 
consequently improving tumor development (Figure I-2). This suppression can be mediated 
by the cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) expressed at their surface (31), 
or by the release of immunosuppressive cytokines, namely IL-10 and TGF- (32). As such, Tregs 
are associated with poor prognosis in ovarian and breast cancers, for instance (33,34). 
Nevertheless, some studies claim that Tregs have a protective role and lead to a favorable 
prognosis in colon and breast cancer (35,36).      
CTLs are T cells that express the CD8 molecule, that also recognize antigens, but in this case, 
the antigen has to be presented by class I MHC. Normally, in the tumor microenvironment, 
CTLs are considered to be crucial for the elimination of tumor cells, even more than Th1 cells, 
due to their overwhelming cytotoxic capacity (Figure I-2) (37). CTLs eliminate tumor cells by 
two mechanisms – the release of perforin and granzyme B or the connection between Fas and 
FasL. Perforin will induce the formation of pores in the membrane of tumor cells and granzyme 
B will pass through those pores and act as a protease, cleaving several substrates in the 
cytoplasm, inducing tumor cell apoptosis (38). CTLs can also kill tumor cells by the interaction 
between Fas on the surface of tumor cells and FasL on the surface of CTLs. This interaction will 
induce a caspase cascade and lead to tumor cell apoptosis (39). Moreover, CTLs also produce 
IFN- and TNF- that will boost cytotoxicity against the tumor cells (40). Its action can be 
suppressed by Tregs or tumor cells, by the escape mechanisms that are going to be further 
discussed in this introduction. CTLs presence in the tumor microenvironment is a good 
prognosis factor in breast and colorectal cancer, among others (41,42). Additionally, there is 
a correlation between intratumor CTLs and the reduction of tumor size (37). 
Besides these immune cell populations, there are several others that can infiltrate the tumor 
and have different roles in the tumor progression. These other lymphocytes are B cells, NK 
cells, Th17, Th22, to name a few. The role of these lymphocytes in the tumor 
microenvironment is not going to be detailed in this introduction, since these cells are not the 
focus of this thesis.      





Figure I-2 The role of some tumor infiltrating immune cells on cancer elimination/progression. Figure 
executed with Biorender.  
 
2.2. The role of Myeloid Cells in the Tumor Microenvironment 
 
Although T cells are the ultimate effectors in tumor cell elimination, the myeloid cells can also 
have an important role in either tumor clearance or progression (Figure I-2). These myeloid 
cells comprise macrophages, dendritic cells, myeloid derived suppressor cells and neutrophils. 
The macrophages in a tumor microenvironment are denominated as tumor-associated 
macrophages (TAMs). TAMs can be divided into M1 and M2 subtypes, probably due to 
environmental cues (43). Briefly, M1 polarization occurs in an IFN--rich environment, 
whereas M2 polarization should occur with stimulation of IL-4 or IL-10, for instance (44). M1 
is recognized as a pro-inflammatory subtype of macrophages and upon activation can release 
pro-inflammatory cytokines, such as TNF- (43). These cytokines alongside enhanced antigen 
presentation will lead to Th1 responses (45). On the other hand, M2 macrophages can secrete 
TGF-, IL-1, IL-6, to name a few. These released cytokines will enhance the 
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immunosuppressive responses in the tumor microenvironment, inhibiting the function of 
effector T cells. Immunosuppression can also be performed by direct contact with the 
employment of the immune checkpoint axis PD-1/PD-L1, which will be further explained in 
this introduction. Moreover, they can induce angiogenesis and tumor invasion. TAMs can also 
be a prognosis factor – they are associated with worst survival in breast, pancreatic and 
bladder cancer (46–48); and with favorable outcome in colorectal cancer (49). This dichotomy 
in macrophages action is important to maintain tissue homeostasis, but the mechanisms 
undertaken by these cells can be hijacked by the tumor cells in order to trigger more anti-
inflammatory or pro-tumor responses by TAMs.   
Dendritic cells (DCs) are professional APCs capable of presenting tumor antigens by class II 
MHC to Th cells, ultimately leading to tumor cell elimination, as explained in section 2.1. 
Besides antigen presentation, DCs can produce cytokines, such as IFN-, TNF- and IL-12, 
which constitute the third signal required to activate T cell responses (50). However, the anti-
tumor DCs function can be impaired in the tumor microenvironment. For instance, the 
presence of IL-10 in the environment has been shown to inhibit cytokine production by DCs 
(51). Additionally, the hypoxic conditions in the tumor microenvironment and lower pH, due 
to a shift in the tumor cell metabolism towards lactate production, can also limit the function 
of DCs (50). Instead, they can became tolerogenic and contribute to tumor tolerance. 
Neutrophils are the most abundant leukocytes in circulation and are essential in host defense 
(52). They can also have important roles in a tumor microenvironment, which can be both 
anti- or pro-tumor (53). Similarly to M1/M2 macrophage polarization, neutrophils can be 
divided into N1 (anti-tumor) and N2 (pro-tumor). The most cancer-related subtype is the N2, 
which can be induced by TGF- (53). N2 neutrophils can release reactive oxygen species (ROS), 
which can potentiate the inhibition of effector T cells function, cancer-promoting 
inflammation and cancer progression (54). In addition, they can produce VEGF, inducing 
angiogenesis (55), and initiate TGF--mediated metastasis (56). Neutrophils are recognized as 
a poor prognostic factor in several cancers, especially when the ratio between circulating 
neutrophils and lymphocytes is taken into account (57–59).   
Myeloid derived suppressor cells (MDSCs) include polymorphonuclear cells (PMN-MDSCs), 
closely related to neutrophils, and monocytic cells (M-MDSCs), more similar to monocytes 
(60). These cells are normally associated with pathological conditions, such as cancer and 
chronic inflammation and are expanded in an IL-6 and IL-10 rich environment (61). MDSCs 
have a suppressive role and when activated release ROS, nitric oxide and arginase, leading to 
the inhibition of T cell responses (61). These cells can also release VEGF, assisting in 
angiogenesis, and metalloproteinases that can cleave the extracellular matrix and lead to 
tumor cell invasion (61). 
Taking into account the variety of immune cell populations that can be find in the tumor 
microenvironment, and their different roles, to achieve a proper immune surveillance and 




tumor cell elimination, different players and conditions have to come together in a 
coordinated fashion.  
 
2.3. The Cancer Immunity Cycle 
 
The tumor-immune interplay include a series of steps, in what was described by Chen and 
colleagues as the Cancer Immunity Cycle, represented in Figure I-3 (62). In the beginning, 
when cancer cells arise, immune cells have the potential to effectively eliminate them. For 
that to occur, the first step is to expose tumor antigens to the immune cells, therefore 
triggering an anti-tumor immune response. This antigen exhibition can be improved with the 
tumor cell death in a process known as immunogenic cell death, which will be detailed further 
on in this introduction. The released antigens are captured by antigen presenting cells (APCs), 
such as dendritic cells or macrophages, present in the tumor microenvironment (step 2). 
These antigens are processed intracellularly and presented at the APCs’ surface by class I or 
class II MHC to T cells, mainly in the lymph nodes (step 3). Interactions are established 
between APCs and T cells, comprising the connection between MHC molecules in APCs and 
the T cell receptor (TCR) in T cells (first signal) as well as costimulatory signals, such as the 
contact between CD28 in the T cells and CD80/CD86 in the APCs (second signal). Additionally, 
for a proper T cell activation, pro-inflammatory cytokines are released by the APCs (third 
signal). The presentation of antigens by MHC molecules is made either to helper T cells if the 
presentation is performed by class II MHC or to cytotoxic T cells in the case of class I MHC 
presentation. Overall, the interaction between both cell types is essential for the activation of 
T cells and the establishment of effector T cells against specific tumor antigens. Then, the 
primed and activated T cells travel from the lymph nodes to the tumor microenvironment 
(step 4), becoming tumor infiltrated T cells (step 5). Both helper T cells (Th) and cytotoxic T 
cells (CTLs) recognize the tumor antigens present in the tumor microenvironment (step 6) and 
especially the CTLs are able to eliminate the tumor cells (step 7). The elimination of tumor 
cells will boost the release of more tumor antigens, restarting the cycle again.        
For the Cancer Immunity Cycle to occur, leading to tumor cell elimination by the CTLs, tumors 
have to be recognized by the immune system. The factors in play for this recognition to occur 
are summarized in the Cancer Immunogram. The Cancer Immunogram, published in 2016 by 
Blank et al (63), comprises seven characteristics:   
(i) tumor foreignness, which consists in the ability of cancer cells to express 
immunogenic antigens (such as neoantigens) that will induce T cell responses;  
(ii) an host with healthy immune system - normal lymphocyte and neutrophil counts 
and functionalities;  
(iii) immune cells able to infiltrate the tumor;  
(iv) tumor cells without inhibitory immune checkpoints (that will be further 
characterized in this introduction), otherwise these molecules can engage with 
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their receptors in T cells, blocking their activity and impairing the anti-tumor 
response;  
(v) absence of soluble inhibitors such as anti-inflammatory cytokines; 
(vi) a metabolism suitable with immune cells activities, since tumor cells can shift their 
metabolism to aerobic glycolysis, releasing lactic acid, decreasing the pH of the 
microenvironment, thus impairing anti-tumor responses;  
(vii) tumor sensitivity to immune effectors, for instance, to cytotoxic molecules 




Figure I-3 Cancer Immunity Cycle. Adapted from Chen et al Immunity 2013 (62). Scheme elaborated 
with Biorender. 
 
However, in cancer patients, the Cancer Immunity Cycle and consequently the Immunogram 
can be compromised in several ways. The release of tumor antigens (step 1) can be hampered 
by the inhibition of cancer cells apoptosis, for instance. Additionally, the tumor antigens can 
be recognized as self instead of as foreign by antigen presenting cells, leading to APCs with a 
tolerogenic profile. The APCs can be present in the tumor microenvironment but can be 
suppressed by factors released from the tumor cells, such as anti-inflammatory cytokines (64). 




The interaction between APCs and T cells in the lymph nodes (step 2) can lead to poor T cell 
activation or to a balance shifted towards the activation of regulatory T cells instead of effector 
T cells. The infiltration of T cells in the tumor bed (step 5) can be inhibited by the endothelium 
of the blood vessels present in the tumor, for instance by altering the adhesion molecules 
essential for the penetration of T cells in the tumor mass (65). The recognition of tumor cells 
by T cells (step 6) can also be hindered either by the presence of an immunosuppressive 
environment that will inhibit the action of CTLs (66) or by the downregulation of class I MHC 
present in the tumor cells (67), leading to the withdrawal of tumor antigens. The hypoxic 
conditions and/or the lower pH detected in the tumor microenvironment, due to the 
metabolic shift observed in tumor cells, can ultimately lead to inhibition of CTLs’ function, 
reducing their ability to eliminate target tumor cells (step 7) (68,69). 
Thus, for the Cancer Immunity Cycle to occur leading to the tumor cells elimination by immune 
cells, the mechanisms of the effective immune response should weigh more than the 
immunosuppressive mechanisms, in the tumor microenvironment, in order to favor immune 
surveillance. Although this situation is usually observed upon the appearance of the tumor, 
with the time and with the selection of immune resistant tumor cells (a process known as 
immunoediting) the immunosuppression may become more dominant than the immune 
surveillance.  
 
2.4. The Three Steps of Immunoediting 
 
The term immunoediting was first elaborated by Dunn and colleagues (70). The 
immunoediting is composed of three different stages – elimination, equilibrium and escape, 
the three Es of immunoediting (Figure I-4). In the elimination phase, immune surveillance 
occurs following the Cancer Immunity Cycle described previously. If the immune system is 
capable of eliminating the tumor cells, there is no progression to the next stages of 
immunoediting. During elimination, cytotoxic T cells (CTLs) release several cytotoxic 
molecules, such as granzyme B and perforin. As explained above, perforin will induce the 
formation of pores in the membrane of tumor cells and granzyme B will pass through those 
pores and act as a protease, cleaving several substrates in the cytoplasm, inducing tumor cell 
apoptosis (38).  
Nevertheless, tumors can be composed of different tumor cell variants. Some variants can 
evolve to produce mechanisms to remain unseen by the immune system, for instance by 
downregulating the expression of class I MHC. During the equilibrium phase, there is 
elimination by CTLs of some tumor clones, but others that are generated by genetic instability 
and the appearance of new mutations (one of the cancer hallmarks), evolve with the capacity 
to escape the immune surveillance. During this selection, an equilibrium is achieved between 
eliminated and immune-resistant tumor cells, enabling further tumor growth containment, 
but not eradication. This phase – when immune cells are able to contain the tumor, can last 
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Figure I-4 Immunoediting – elimination, equilibrium and escape. Adapted from Dunn et al Nature 
Immunology 2002 (70). The figure was prepared with Biorender.  
 
The third phase is the escape phase, where the tumor clones that survived the immune 
surveillance and acquired mechanisms to escape the immune system, are able to proliferate 
leading to tumor growth and eventually tumor metastization.  
Combining the knowledge from Immunoediting phases with Cancer Immunity Cycle and the 
Cancer Immunogramm, it becomes clear that specifically the CTLs are undoubtedly necessary 
for tumor cells’ elimination.  
 
2.5. T cell activation  
 
T cells, especially the CTLs, can be present in the tumor microenvironment but can be 
suppressed by several mechanisms, therefore possessing their cytotoxic response inhibited. 
So, the ability to become activated and remain active is essential for their anti-tumor capacity. 
Actually, the activation of CTLs is referred in the Cancer Immunogram as the ultimate effector 
to eliminate tumor cells (63). CTLs activation can be observed by the upregulation of distinct 
activation markers such as CD69, CD25 and HLA-DR. CD69 is an early activation marker, which 
is upregulated in 4 hours after the stimulation, leading to high intracellular calcium levels and 
production of IL-2, IL-4 and TNF- (71–73). 12 hours after the activation, CD25 (IL-2 receptor) 




is upregulated, leading to the production of higher levels of IFN- and TNF- (73), initiating 
cell proliferation and differentiation (74). HLA-DR is the last activation marker, being 
upregulated 24/48 hours after the activation (73,75). HLA-DR is a class II MHC molecule, 
normally expressed in antigen presenting cells. However, it is upregulated in activated T cells 
and is associated with increased IFN- production. It is believed that HLA-DR expression is 
important in the formation of T cell-T cell synapsis, leading to an amplification of IFN- 
production and other CTLs-related functions due to a rapid positive feedback (76).   
 
3. The Role of Tumor-produced Cytokines  
 
As it is possible to observe in the previous sections, the immune response dictated by the 
different immune cell populations depends not only on cell-cell contact but also on released 
cytokines. Cytokines are important players in a tumor microenvironment to provide the 
necessary growth conditions, and can also regulate cellular trafficking and different signaling 
pathways. These molecules can be released not only by immune cells but also by tumor cells. 
The role of cytokines released by the immune cells was described in the previous subsections 
of this introduction. Here, it will be described briefly the role of different cytokines released 
by the tumor cells in the tumor microenvironment. Specifically, we will focus on the cytokines 
that will be further analyzed in this work – IL-1, IL-6, IL-8, IL-10, IL-17, IL-23 and TGF-  (Figure 
I-5).  
IL-1 was shown to be upregulated in tumor cells of colon and lung cancer and melanoma 
(77,78), normally associated with a worse prognosis. IL-1 is capable of inducing the 
production of metalloproteinases, essential for the degradation of the extracellular matrix and 
consequent tumor invasion (79). IL-1 can also induce the expression of VEGF to stimulate 
angiogenesis (80) and can stimulate other cells in the tumor microenvironment to produce IL-
8, IL-6 and TGF- This cytokine also contributes in an autocrine fashion to improve tumor cell 
proliferation (Figure I-5, (81)). 
IL-6 is produced by tumor cells, of the breast and lung cancer and hepatocellular carcinoma, 
as an example (reviewed in (82)). IL-6 can control the expression of anti-apoptotic proteins 
(83), induce metalloproteinases secretion (84), and lead to VEGF production (85), contributing 
to tumor cell survival, invasion and angiogenesis (Figure I-5).  
IL-8 is also able to promote angiogenic response (86) in the tumor microenvironment. 
Additionally, it was observed, mainly in cancer cell line models, that autocrine IL-8 action is 
able to induce tumor cell proliferation, migration and invasion (86–88). Moreover, it recruits 
neutrophils and may act indirectly on tumor metastasis (Figure I-5, (89)).  
IL-10 is an immunosuppressive cytokine that can be produced by tumor cells with the main 
aim to limit effector anti-tumor immune response. It is also involved in resistance to apoptosis, 
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described in lung and breast cancer (90,91), and can promote angiogenesis (Figure I-5, (92)). 
IL-10 was described as a poor prognostic factor in breast cancer (93).  
IL-17 has been detected in several types of cancer, including breast, prostate, gastric, 
colorectal and lung cancers (94–98). Similarly to the abovementioned cytokines, IL-17 can 
induce the expression of metalloproteinases to help in tumor cell invasion and progression 
(99). IL-17 stimulates regulatory T cells (Tregs), which will inhibit CTLs effector function (Figure 
I-5, (94)). Moreover, IL-17 levels are associated with poor disease outcome in breast cancer 
patients (94).  
 
Figure I-5 The role of tumor-produced cytokines. Tumor cells can produce IL-1, IL-6, IL-8, IL-10, IL-17, 
IL-23 and TGF- and each have a different role in tumor progression. IL-1 induces angiogenesis and 
metalloproteinases production, which will degrade the extracellular matrix. IL-6 also induces 
angiogenesis and inhibits tumor cell apoptosis. IL-8 induces angiogenesis and N2 neutrophils. IL-10 
induces angiogenesis and regulatory T cells (Tregs), inhibits tumor cell apoptosis and cytotoxic T cells 
(CTLs) function. IL-17 induces metalloproteinases production and Tregs’ function, which consequently 
will inhibit CTLs cytotoxic capacity. This last function of IL-17 is shared with IL-23. TGF- stimulate the 
M2 macrophages and N2 neutrophils, which have an immunosuppressive phenotype also culminating 
in the inhibition of CTLs cytotoxic function. This scheme was prepared with Biorender.  
 
IL-23 is known to induce IL-17-producing helper T cells (100). IL-23 is upregulated in several 
types of cancer, including colon, ovarian, lung, breast cancer and melanoma (101). With in 
vivo analysis, IL-23 was shown to be associated with tumor incidence and resistance to therapy 
(101). As there seems to be a pathway between IL-17 and IL-23, the latter cytokine can also 




indirectly reduce the cytotoxic function of CTLs, by improving IL-17 induction of Tregs (Figure 
I-5). Indeed in in vivo models, IL-23 was found to be responsible for the reduction of CTLs 
infiltration in tumor tissues (101). 
TGF- is one of the inductors of epithelial to mesenchymal transition. This is the process where 
epithelial cells, in this case the tumor cells, gain mesenchymal characteristics and 
consequently acquire the capacity to invade (102). TGF- when produced by tumor cells leads 
to increased tumor growth (103) and immunosuppressive action on different immune cells 
(104), reducing immune-derived tumor cell elimination (Figure I-5). Moreover, TGF- induces 
macrophages polarization towards an M2 phenotype (105) and neutrophils polarization 
towards an N2 phenotype (53), increasing the immunosuppressive microenvironment (Figure 
I-5).  
 
4. The Chemotherapeutic Treatment Modulates Immune Features 
 
As it is possible to observe from this introduction, the immune system and, especially, the 
immune cells that are capable to infiltrate the tumor, are fundamental for the tumor 
elimination or progression. Moreover, the presence of certain immune cells or their released 
molecules can influence the response to treatment – CTLs can eliminate tumor cells, 
improving the patients’ outcome. Nevertheless, the treatment applied to the patients also 
influences the immune response.  
One of the most studied ways by which chemotherapy boosts tumor-immune responses is by 
inducing the immunogenic cell death of tumor cells. During cell death, the release of damage-
associated molecular patterns (DAMPs) can occur, which will trigger a “danger” state in the 
immune system (106). However, for these DAMPs to initiate an immune response, the dying 
cell has to have tumor associated antigens, like neoantigens, which normally resulted from 
accumulated mutations that occur in the tumorigenesis process (107).   
Mechanistically, during tumor immunogenic cell death driven by chemotherapeutic agents, 
chaperones from the endoplasmic reticulum are transferred to the plasma membrane of the 
apoptotic cell, which will increase antigen uptake by dendritic cells. Additionally, the dying 
cells release ATP to the extracellular space, essential for dendritic cell recruitment and 
activation. Activated and antigen loaded dendritic cells can then trigger tumor-specific T cell 
responses, as explained previously. Moreover, the dying tumor cells secrete type I IFN and 
CXCL10, which will recruit T cells and induce the proliferation of tumor-specific T cells 
(reviewed in (108)).  
A well-recognized example is the effect of anthracyclines, a class of chemotherapeutic agents, 
which have an immunostimulatory capacity, based on immunogenic cell death, thus triggering 
immunological responses, and furthermore eliminating immunosuppressive barriers created 
by a tumor (109). Doxorubicin, a type of anthracycline, was shown to promote immunogenic 
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cell death in mice models (110), and also was shown to induce the recruitment of myeloid 
cells (111). Cyclophosphamide, another chemotherapeutic drug, is able to induce Tregs 
depletion, favor Th1 and CTLs’ response and stimulate the tumor immunogenic cell death 
(112–114). Paclitaxel, normally used in chemotherapeutic regimens, favors 
immunosurveillance, pro-inflammatory macrophages and CTLs recruitment to the tumor 
(115,116). Moreover, paclitaxel helps in the maturation of dendritic cells and presentation of 
tumor antigens (117).  
Interestingly, many chemotherapeutic regimens employed nowadays are based on a 
combination of different drugs. This combination ideally will elicit a higher immunostimulatory 
response, with each drug having a different effect on the tumor immune microenvironment. 
For instance, a regimen composed of the abovementioned drugs should boost immunogenic 
cell death and depletion of immunosuppressive immune cells, such as Tregs, therefore 
increasing immune-mediated tumor clearance.   
Additionally, besides using a combination of chemotherapeutic agents, the addition of specific 
immune-based therapeutic approaches would, theoretically, increase the anti-tumor 
responses.  
 
5. Modulating Host Immune Features as Cancer Treatment Options 
 
As the immune system has a pivotal role in the regulation of tumor elimination or progression, 
clinicians have started to take advantage of immune processes to improve cancer treatments. 
Thus, immunotherapy has been gaining a massive interest, especially in the last decade (118). 
This treatment employs different strategies to help the host immune system to work better 
at recognizing and destroying specific cancer cells. Since the main aim of immunotherapy is to 
use and potentiate the patient’s own immune system, it holds the potential to become more 
precise, personalized and effective when compared to standard chemotherapeutic strategies. 
Moreover the secondary side effects should be reduced (119).   
Historically, the first immunotherapies arose in the 70s/80s with two main approaches. The 
use of the BCG vaccine (Bacillus Calmette–Guérin) in bladder cancer patients was tested in the 
late 70s (120). Using a local instillation of an attenuated form of Mycobacterium bovis induced 
a local inflammatory response and the immune cells recruited could have an effect against 
cancer cells. Secondly, IL-2 was used as a therapy in renal carcinoma in the 80s (121). IL-2 is 
an inducer of T cell differentiation and proliferation, and could increase T cell-mediated tumor 
cell elimination.   
Meanwhile, many other strategies to enhance the anti-tumor immune response, were/are 
being tested in clinical trials or even have been already approved. For instance, targeted 
antibodies, cancer vaccines, dendritic cell based vaccines, checkpoint inhibitors and cytokines. 
Although immunotherapy doesn´t always work for every patient, altogether it is a promising 




option for cancer therapy, either to be used alone or in combination with more conventional 
treatments such as surgery, chemotherapy and radiation to improve their effectiveness.  
Nowadays, two different types of immunotherapies have been most successfully used – the 
immune checkpoint blockade and the use of adoptive T cell therapy, which will be detailed 
afterwards.  
 
5.1. Immune checkpoint blockade 
 
As previously explained in this introduction, tumor cells have different mechanisms to escape 
the immune system. One of these mechanisms is to activate inhibitory immune checkpoints 
that will inhibit T cell function against tumor cells. Thus, the therapy using immune checkpoint 
blockade has the main goal of releasing this inhibitory connection between the tumor (or 
regulatory immune cells) and the effector immune cells, so that T cells can be activated and 
exert their anti-tumor functions.    
There are several types of immune checkpoints that have been used to develop these 
blockade therapies, namely the programmed cell death protein 1 (PD-1) and programmed cell 
death 1 ligand 1 (PD-L1) that composes the PD-1/PD-L1 axis (Figure I-6). Moreover, cytotoxic 
T lymphocyte-associated antigen 4 (CTLA4, Figure I-6) and T cell immunoglobulin and mucin 
protein 3 (Tim3) are other immune checkpoints that have the potential to be targeted in the 
clinic.  
In a tumor microenvironment, tumor cells are able to increase their PD-L1 expression to 
interact with PD-1 expressed on CTLs (Figure I-6, (122)), leading to the inhibition of their 
cytotoxic function. Additionally, antigen presenting cells (APCs) can also exhibit PD-L1 at their 
surface and inhibit CTLs (Figure I-6). PD-L1 expression is upregulated in several types of cancer, 
which is an advantage to be widely used as a therapeutic option (122). As such, there are 
antibodies against either PD-1 or PD-L1 with the objective to block PD-1/PD-L1 interaction and 
inhibit T cell anergy. Anti-PD-1 antibodies – nivolumab (from Bristol-Myers Squibb) and 
pembrolizumab (from MSD) are approved by the Federal Drug Administration (FDA) for 
different cancer types. Nivolumab is approved for bladder, lung, kidney, head and neck, 
colorectal and liver cancers (118). Pembrolizumab is approved for lymphoma, head and neck, 
lung, bladder, cervical and liver cancers (118). 




Figure I-6 Immune checkpoint blockade therapy. (A) PD-1 is normally expressed on T cells, namely on 
cytotoxic T cells and binds to its ligand – PD-L1 that can be expressed either on tumor cells or antigen 
presenting cells, such as dendritic cells. CTLA4 can also be expressed on T cells which bind to 
CD80/CD86 on antigen presenting cells. The immune checkpoints when connected to their ligands give 
an inhibitory signal to T cells, reducing its function. (B) With the immune checkpoint blockade therapy, 
antibodies against PD-1, PD-L1 or CTLA4 remove the inhibitory function of these immune checkpoints, 
activating T cells to perform their anti-tumor function. Figure prepared with Biorender. 




Anti-PD-L1 antibodies, such as atezolizumab (from Roche), have been approved by the FDA to 
treat metastatic triple negative breast cancer, bladder and lung cancers (118). Nevertheless, 
it is important to take into account that these antibodies have a function in PD-L1+ tumors, 
which is not the case for all tumor types and even within the same tumor type, PD-L1 positivity 
is heterogeneous among patients.  
CTLA4 is also an immune checkpoint commonly expressed in T cells, namely regulatory T cells. 
CTLA4 binds to CD80 and CD86 present at the surface of APCs (123) and this binding competes 
with the co-stimulatory signal between CD28 and CD80/86 (123). As such, antibodies anti-
CTLA4 downregulate the suppressive function exerted on T cells, activating T cells. One of 
these anti-CTLA4 antibodies is ipilimumab (from Bristol-Myers Squibb), which is approved by 
the FDA for the treatment of melanoma, renal and colorectal carcinomas (118). 
Tim3 can be expressed on the surface of T cells, either Th or CTLs and was mainly related to 
immunosuppression on these cells (124,125), since its ligand – Galectin9 can be overexpressed 
on tumor cells, namely in melanoma (126). Antibodies against Tim3 have shown an improved 
anti-tumor efficacy on in vivo models (reviewed in (127)). In a clinical setting, tumor infiltrating 
lymphocytes were shown to express more Tim3 than their circulating counterparts (124). CTLs 
expressing Tim3 are often seen as exhausted T cells (124). Nevertheless, Tim3 was also 
determined to be expressed on Tregs and APCs. On tumor infiltrating Tregs, Tim3 positivity is 
normally associated with CTLA4+ Tregs (128). Tim3 could be one of the immune checkpoints 
that are activated when anti-CTLA4, -PD-1 or –PD-L1 therapies are prescribed, leading to 
therapy failure. A combination of distinct immune checkpoint blockade could be a strategy to 
increase anti-tumor efficacy.  
Indeed, several combined immune checkpoint blockade therapeutic options have been 
tested. Although immune checkpoints act to decrease CTLs activation and effector function, 
their mechanisms of action are different. For instance, when CTLA4 blockade is performed, 
tumor cells can increase their expression of PD-L1, maintaining the escape to the immune 
system by the PD-1/PD-L1 axis. The other way around is also possible. As such, anti-CTLA4 and 
anti-PD-1 have been used together in the clinic, namely nivolumab with ipilimumab, in the 
treatment of advanced melanoma, colorectal and renal cancers (129–131). 
In addition to the combination of immune checkpoint blockade, these therapies can also be 
combined with chemotherapy. As previously explained, chemotherapeutic agents can 
improve the antigenicity of the tumor by employing tumor immunogenic cell death with the 
release of tumor antigens associated with improved CTLs response. Moreover, chemotherapy 
can also deplete suppressive immune cells, such as Tregs, also improving CTLs response 
(109,110,112). Indeed, the combination of chemotherapy with anti-PD-1 is approved for the 
treatment of lung cancer (132). 
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5.2. Adoptive T cell Therapy 
 
Although immune checkpoint blockade has revolutionized cancer treatment, the patients’ 
response rate is still very heterogeneous. Indeed, response rates vary from 10-60% and a high 
percentage of cancer patients experience resistance to the treatment, as well as relapse (133).  
To overcome this issue, clinical studies with adoptive T cell therapy are starting to emerge 
(Figure I-7). This treatment uses T cells, namely CTLs, either from tumor infiltrating 
lymphocytes (TILs) or from the circulation. T cells are then stimulated ex vivo to proliferate, 
normally with supplemented IL-2, to perform effector functions and respond to tumor-specific 
cues. For this therapy to be successful normally the patients undergo a previous 
lymphodepletion, either by chemo or radiotherapy, followed by T cell administration (119).   
To obtain CTLs from TILs, a portion of the tumor has to be resected and fragmented to a single 
cell suspension. The CTLs are then cultured in facilities with good manufacturing practices in 
order to proliferate until around 1010 cells are obtained (134). The ex vivo culture and 
expansion of T cells is a limiting step since it is time-consuming: approximately 6 weeks from 
tumor resection until CTLs infusion in the patients (134).    
Besides using TILs-derived CTLs, these cells can be obtained systemically. CTLs from the 
peripheral blood can be placed in culture alongside APCs with the capacity to present specific 
tumor antigens, thus inducing tumor-specific CTLs (135). These cells will follow the same 
experimental steps as explained above.  
 
 
Figure I-7 The rationale of adoptive T cell therapy. Cytotoxic T cells (in blue) can be acquired directly 
from tumor infiltrating lymphocytes or from the peripheral blood. These cells are expanded ex vivo 
and reinfused in the patient. Figure performed with Biorender. 
 
In addition, CTLs derived from the peripheral blood can be engineered to express a chimeric 
antigen receptor (CAR), which consists in a modified T cell receptor (TCR) to enhance the T 
cells specificity towards tumor antigens (136). To obtain these cells, autologous T cells are 




harvested from the patient, genetically engineered, expanded in culture and then reinfused. 
One of the advantages of CAR T cells is that it is possible to design the CAR to recognize 
membrane moieties normally present in tumor cells, such as glycolipid structures, without the 
need of antigen presentation through the MHC, which can be downregulated in tumor cells. 
Thus, T cell specific tumor elimination can be enhanced, increasing the therapy response 
(136).  
 
6. Breast Cancer 
 
6.1 Breast Cancer Features 
 
Breast cancer is the most frequent type of cancer in women, accounting for up to 2 million 
new cases per year worldwide (Figure I-8) (137). Interestingly, when taking into account both 
males and females, breast cancer is the second most frequent type of cancer (137). The 
estimated mortality worldwide is more than 600,000 women per year, which represents 15% 
of cancer-related deaths in women (Figure I-8) (137). 
Breast cancer is not a single disease and can be divided into three different subtypes, based 
on the different molecular drivers of each subtype (Figure I-8). The most frequent subtype, 
which represents approximately 70% of the breast cancer patients, has an overexpression of 
the estrogen receptor (ER) and can also have an upregulation of the progesterone receptor 
(PR), hence this subtype is commonly referred to as hormone positive or ER+ breast cancer. 
The second subtype is characterized by an amplification of the HER2 gene (human epidermal 
growth factor receptor 2) and represents approximately 15% of the breast cancer cases. 
HER2+ breast cancer patients can also have upregulation of the hormone receptors. The third 
subtype is denominated triple negative breast cancer (TNBC), because it does not possess ER, 
PR or HER2 and also represents approximately 15% of the breast cancer patients.  
Besides the molecular-based classification, there is a histopathological classification that is 
correlated with the localization of the tumor. As such, breast cancer can be either ductal or 
lobular, depending if the tumor mass is in the milk-carrying ducts or in the milk-producing 
lobules (138).  
Breast cancer can be further classified by the TNM staging – T refers to the tumor size, N refers 
to the presence of cancer cells in the axillary lymph nodes and M refers to the presence of 
distant metastasis (Figure I-8). T is divided into T1 – tumor size less than 2 cm, T2 – tumor 
dimension less than 5 cm, T3 – tumors bigger than 5 cm and T4 – tumors spread in the chest 
wall, the skin or both or it can represent an inflammatory tumor (T4d). N correlates with the 
lymph node status: N0 corresponds to absence of swollen axillary lymph nodes, N1 and N2 
are related to detectable swollen and lumpy axillary lymph nodes and finally N3 is used to 
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describe detectable lymph nodes close to the collarbone. M is the number of distant 
metastasis (M) and can be either 0 (no metastasis) or 1 (presence of metastasis) (138).  
There are risk factors associated with breast cancer, such as age, familial and reproductive 
history (139). The majority of patients have more than 50 years old when they are diagnosed 
with breast cancer (139). Familial history of breast cancer, specifically inherited mutations in 
the BRCA1 and BRCA2 genes is also a risk factor (139,140). Additionally, women that had an 
early menarche, a late menopause, have denser breasts or a long term use of oral 
contraceptives also have a higher risk of developing breast cancer (139,140). The lifestyle can 
also be considered, namely alcohol consumption, smoking and high fat diet can contribute to 
increase the risk of developing breast cancer (140).   
Nevertheless, the first classification is clinically relevant since it will give the appropriate 
therapy for each patient, further detailed below. Additionally, survival is distinct between 
breast cancer molecular subtypes. Indeed, patients with breast cancer with a size smaller than 
2 cm and without axillary lymph node involvement have a survival of 99% for ER+ tumors, 94% 
for HER2+ tumors and 85% for TNBC. When the disease is spread to other organs, the median 
overall survival for primary breast tumors of ER+ or HER2+ is 5 years, whereas for TNBC it is 
only 1 year (141). 
 





Figure I-8 Breast Cancer - incidence and mortality in women worldwide; molecular subtypes and 
TNM staging. Breast cancer occurs in approximately 25% of the world female population and 
represents around 15% of cancer-related deaths in women worldwide. Breast cancer can be divided in 
three different molecular subtypes, which are distinctively represented in the population. TNM staging 
is used to characterize the breast tumors accordingly to their size (T), the presence of disease in the 
lymph nodes (N) and the presence of distant metastasis (M). Figure elaborated with Biorender.  
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6.2 Breast Cancer Treatment 
 
The treatment of breast cancer depends on the molecular subtype and if the cancer has 
already metastasized. For non-metastatic breast cancer, the therapy consists of a full 
mastectomy or a tumorectomy followed by radiotherapy. The removal of suspicious axillary 
lymph nodes can also be performed at surgery. The choice between a more conservative 
surgery or a mastectomy can derive from the diagnosis of the patient, for instance if several 
tumor loci are present (138). Systemic chemotherapy can be administered prior to the surgery 
(neoadjuvant chemotherapy) or post-surgery (adjuvant chemotherapy). In the first case, the 
surgery will be a conservative tumorectomy. For some patients both neo and adjuvant 
chemotherapies are prescribed. Briefly, neoadjuvant chemotherapy is administered in 
patients with inoperable or inflammatory tumors or patients that present a locally advanced 
disease, i.e. tumors with size larger than 2 cm and/or with disease extension to the axillary 
lymph node (142).  
There are several chemotherapeutic regimens that can be used. However, in this introduction, 
the focus will be on the combined therapy composed by anthracyclines, cyclophosphamide 
and taxanes, since it is the one prescribed to the cohort of patients analyzed in this thesis. 
Anthracyclines are DNA intercalating agents that can inhibit cellular replication (141). There 
are several types of anthracyclines, including doxorubicin, docetaxel, epirubicin, among 
others. Cyclophosphamide is able to form DNA crosslinks, leading to cell apoptosis (141). 
Taxanes, namely paclitaxel, alters the cellular cytoskeletal properties, leading to defects in the 
mitosis, inhibiting the process of cell division (141). These drugs have several side effects, and 
the most frequent ones are weakness, edema, myalgia, anemia, neutropenia and nausea, to 
name a few (143).  
For ER+ breast cancer patients, the gold standard treatment is the use of endocrine therapy, 
normally tamoxifen, for at least 5 years. Tamoxifen competes for the binding of estrogen to 
ER and inhibits estrogen-induced tumor growth. Besides tamoxifen, aromatase inhibitors can 
also be used; however, they are only effective in post-menopausal women (141). Aromatase 
is a crucial enzyme in the synthesis of estrogen. For pre-menopausal women, it is common to 
induce menopause by chemical castration, i.e. with ovarian suppressor agents (144). 
Tamoxifen can also be prescribed to the patient for 10 years since disease recurrence can 
occur decades after the first diagnosis. 10-years endocrine therapy was shown to have an 
improvement in breast cancer mortality; however, patients with longer endocrine therapy had 
a higher associated risk to develop endometrial cancer or thromboembolism (145). The 
decision for a 5 or 10-years treatment must rely on the clinicians that should only administer 
the second hypothesis in high-risk tumors. Chemotherapy is normally added to endocrine 
therapy in ER+ patients. The combined regimen of anthracyclines, cyclophosphamide and 
taxane were shown to reduce the risk of recurrence (141).  




For HER2+ breast cancer patients, there is a targeted therapy that consists of an antibody 
against HER2+ (trastuzumab). Several clinical trials have shown that the addition of 
trastuzumab for 1 year to chemotherapy increases the disease-free survival and overall 
survival in breast cancer patients, when compared to chemotherapy alone (146). Trastuzumab 
can be prescribed during neoadjuvant or adjuvant regimens and the preferred combination is 
with chemotherapy based on anthracyclines, cyclophosphamide and taxane.  
TNBC lacks a target to develop specific therapies. As such, the treatment relies mainly on 
chemotherapy. Again, chemotherapeutic treatment can be prescribed either in a neoadjuvant 
or adjuvant setting and can be composed of the same combined regimen as described above. 
Nevertheless, several therapeutic strategies are being developed to tackle this clinical need. 
Namely, some TNBC tumors have deficient mechanisms of DNA damage repair, so the use of  
poly (ADP-ribose) polymerase inhibitors (PARPi) and platinum agents can be considered (141). 
In addition, anti-VEGF drugs, namely bevacizumab, or ixabepilone that stabilizes microtubules 
are being tested in TNBC patients (see review (147)). Actually, olaparib (from AstraZeneca), 
which is a PARPi was approved by the FDA in 2018 for metastatic TNBC with BRCA mutation. 
Talazoparib (from Pfizer), another PARPi is also FDA approved for locally advanced or 
metastatic HER2 negative breast cancer with BRCA mutation. 
Another promising approach is the use of PI3K inhibitors, since PI3K is associated with tumor 
cells growth (148). Alpelisib (from Novartis) – a PI3K inhibitor, was approved by the FDA in 
2019 for ER+, HER2 negative, PI3K-mutated, advanced or metastatic breast cancer.  
 
6.3. Immuno-Oncology in Breast Cancer 
 
6.3.1 Predictive Biomarkers  
 
Although breast cancer has good survival rates when compared to other tumor types, the 
choice between treatment regimens is sometimes challenging for the clinicians. Moreover, 
when patients are selected for neoadjuvant chemotherapy (NACT), more than half will not 
respond to this treatment (142,149), which will delay effective therapeutic options. Hence, 
there is an urgent unmet clinical need, which is to find predictive markers of response, 
especially for neoadjuvant regimes.  
Though breast cancer is not considered to be very immunogenic (150), two emerging immune-
related markers have been studied for the prediction of breast cancer patients’ response to 
NACT: tumor infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR). The 
response to NACT is evaluated after the chemotherapy when patients are subjected to surgery 
– if no tumor mass is present after the therapy, the patients achieved a pathological complete 
response (pCR). Nevertheless, tumor cells can still be present in the breast after the surgery 
but with a down-staging (partial response) or not (no response).  
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TILs are normally assessed by immunohistochemistry counterstained with hematoxylin and 
eosin in formalin-fixed paraffin embedded tissue samples. This assessment is semi-
quantitative and can be performed either intratumor or in the stromal compartment (151). 
Although this method is easily applied in the daily routine, there are several antibodies that 
can be used to detect TILs as well as different techniques to quantify their presence. Thus, 
there was a need to standardize TILs assessment in breast cancer samples, which was achieved 
in a publication by the International TILs working group (151). 
TILs were shown to have a predictive value for pCR especially in HER2+ and TNBC subtypes. 
Several clinical trials have supported this idea. In the GeparDuo and GeparTrio trials, 40% of 
the breast cancer patients from the three subtypes with samples having >60% of stromal TILs 
achieved pCR, compared to only 10% pCR in samples with less than 60% of stromal TILs (152). 
In GeparQuattro, almost 50% of the HER2+ patients had a pCR when their samples had >50% 
of stromal TILs, contrarily to a pCR in 31% of patients with less than 50% of stromal TILs (153). 
In the GeparQuinto trial, approximately 35% of the TNBC patients achieved pCR when their 
samples had more than 60% stromal TILs present, compared to 14% pCR in <60% stromal TILs 
samples (154). In GeparSixto trial, 60% of the HER2+ and TNBC patients achieved pCR if their 
tumor samples had more than 60% of stromal TILs present, contrarily to an almost 35% pCR 
rate for patients with less than 60% stromal TILs present in their samples (155). In GeparNuevo 
trial, higher pCR rate in TNBC patients was achieved when the patients presented higher 
stromal TILs (more than 60%) (156). In the NeoALLTO trial (157) the authors demonstrated 
that TILs are an independent prognostic factor for HER2+ patients.   
Nevertheless, we have to take into account that TILs evaluation does not discriminate 
between the type of lymphocytes, since as it was described previously in this introduction, T 
lymphocytes (either the different subsets of Th, or CTLs or Tregs), B lymphocytes or NK cells 
can infiltrate the tumor and influence it in a different manner, as depicted in section 2.1. So 
their predictive value can be argued. Even infiltrating CTLs, per se, lack the robustness that a 
predictive biomarker should have, because their function can be hampered by tumor cells, 
through several mechanisms. For instance, by expressing inhibitory molecules like PD-L1 or by 
secreting immunosuppressive molecules such as IL-10 and TGF-β. Thus, it is still crucial to 
establish a more accurate breast cancer “immunological status” that reflects the overall 
strength of individual patients’ anti-tumor immune response that will ultimately influence 
NACT efficiency. 
Attempting to discriminate between TILs subset, some studies have performed 
immunohistochemistry with CD4 (Th and Tregs) or CD8 (CTLs) antibodies and correlate with 
pCR. In the three subtypes of breast cancer, a positive correlation between CD8+ TILs and pCR 
was found (115,158). The same correlation was found for CD4+ TILs (159). Nevertheless, high 
CD8 was also positively correlated with disease-free survival, but not pCR independently on 
the subtype of breast cancer (41). Other authors describe that a high ratio between CD8 and 
FOXP3 (a marker of Tregs), increases the chance of achieving a pCR in TNBC patients (160,161) 
and HER2+ breast cancer patients (161). In addition, another study performed in the three 




breast cancer subtypes defined that high CD8 and high FOXP3 was positively correlated with 
pCR (162).  
In spite of trying to define which type of TILs are fundamental for a good response to the 
treatment, the abovementioned studies lack the statistical power due to limited sample size 
when compared to the studies indicating TILs as a predictive factor for NACT response. 
Moreover, the same questions remain: although these studies are dividing some subsets of 
TILs, the CD4+ TILs, for instance, can be any type of helper T cells and even Tregs, which have 
distinct roles in tumor immunology. Moreover, the fact that CD8+ T cells (CTLs) and FOXP3+ T 
cells (Tregs) have the same tendency for pCR is debatable due to the fact that they have 
opposite roles. Hence, further studies that aim at scrutinize the TILs subsets and their role for 
NACT success should be performed.  
 
The neutrophil-to-lymphocyte ratio (NLR), contrarily to the TILs, is not assessed in the tumor, 
but in the peripheral blood. The rationale behind this marker is that tumor-promoting 
inflammation can be reflected systemically and, normally, inflammation leads to an increase 
in neutrophil count. 
In breast cancer, a high NLR is seen as a poor prognosis marker. In TNBC, it was published that 
patients with a NLR higher than 3, had poor prognosis (163). The same cut-off was calculated 
for another cohort of TNBC patients (164) and for a cohort with the three subtypes of breast 
cancer (165). Other authors calculated a cut-off for NLR in ER+ breast cancer patients’ blood 
of 2.25 (166) and 1.67 (167). Additionally, in cohorts of breast cancer patients with the 3 
different subtypes, the cut-off of NLR was calculated as 3.33 (168) and 2.1 (169). Meta-analysis 
of these studies revealed that lower NLR favors pCR (165).  
Nonetheless, there is no consensus on the threshold value for the NLR that could distinguish 
good or poor prognosis. Moreover, the studies referred above were composed of cohorts with 
variable number of breast cancer patients, which can lead to the different cut-off values that 
were calculated.  
Overall, both TILs and NRL could be markers to predict response to NACT; however, they are 
still not used in the clinic routine. Indeed, there are still many questions left without response 
– what NLR cut-off value should be used? Which patients would benefit from TILs assessment? 
And which would benefit with NLR analysis? Are we assessing only the chances to achieve pCR 
after NACT or the patients’ survival? 
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6.3.2. Immunotherapy  
 
As previously mentioned, approximately half of the patients that are selected to perform 
NACT will not respond to this treatment (142,149). Predictive markers can help in assessing a 
priori which patients will not respond to this treatment so that other therapies can be used 
for non-responder patients. The problem is that there are no alternative therapies for these 
patients. A surgery followed by adjuvant chemotherapy could be used, but only in operable 
tumors; and the chances of executing a conservative surgery decreases and probably a 
mastectomy has to be performed.   
As such, there is a lack of alternative therapeutic strategies for breast cancer patients. Again, 
breast cancer, compared to other types of tumors, such as melanoma, is not very 
immunogenic (150), which can explain the lack of success with immunotherapeutic 
approaches (170). For instance, the anti-PD-1/-PD-L1 therapy has a modest response in breast 
cancer patients (approximately 25% (171)), probably because (i) tumors could be poorly 
infiltrated with immune cells; (ii) PD-L1 expression is often observed in the immune 
components of breast tumors rather than in the tumor cells (172); and additionally (iii) PD-1 
expression on tumor infiltrating T cells is highly variable between patients (170).  
Nevertheless, several clinical trials are being conducted in breast cancer with the immune 
checkpoint blockade (Table I-1). The majority tackles TNBC patients and some test the 
immunotherapy in combination with chemotherapy.  
 
Table I-1 Ongoing clinical trials with immune checkpoint blockade therapy in breast cancer. 




Anti-PD-L1 + Paclitaxel + Epirubicin + 
Cylophosphamide 
TNBC 
NCT03197389 I Pembrolizumab HER2/TNBC 
NCT02838823 I Toripalimab TNBC 
NCT02819518 III 
Pembrolizumab + Paclitaxel or Pembrolizumab + 
Gemcitabine and Carboplatin or all together or 
without Pembrolizumab 
TNBC 
NCT03414684 II Nivolumab + Carboplatin or Carboplatin alone Metastatic TNBC 
NCT03616886 I/II Paclitaxel + Carboplatin and Durvalumab  Metastatic TNBC 
NCT02752685 II Pembrolizumab + Paclitaxel  Metastatic HER2- 
NCT02999477 I Pembrolizumab + Paclitaxel ER+ 
NCT03036488 III 
Pembrolizumab + Chemotherapy (Paclitaxel + 
Doxorubicin + Epirubicin + Cyclophosphamide + 
Carboplatin) or Chemotherapy alone 
TNBC 





Ipilimumab + Nivolumab + Chemotherapy 




Pembrolizumab + Chemotherapy (Paclitaxel + 
Doxorubicin + Epirubicin + Cyclophosphamide)  or  
Chemotherapy alone 
HER2- 
NCT02628132 I/II Durvalumab + Paclitaxel Metastatic TNBC 
NCT02648477 II Pembrolizumab+ Doxorubicin Metastatic HER2- 
NCT04060342 I/II Pembrolizumab + Paclitaxel or only Paclitaxel Metastatic TNBC 
NCT02447003 II Pembrolizumab Metastatic TNBC 
NCT02644369 II Pembrolizumab TNBC 
NCT04191135 II/III 
Pembrolizumab + Carboplatin + Gemcitabine with or 
without Olaparib  
Metastatic TNBC 
NCT03971045 II Pembrolizumab All 
NCT04042701 I Pembrolizumab + Trastuzumab deruxtecan Metastatic  
NCT02555657 III Pembrolizumab or Chemotherapy  Metastatic TNBC 
NCT02834013 II Ipilimumab + Nivolumab or Nivolumab only All 
 
Pembrolizumab - anti-PD-1; Toripalimab - anti-PD-1; Nivolumab - anti-PD-1; Durvalumab - anti-PD-L1; 
Ipilimumab - anti-CTLA4; Olaparib – PARP inhibitor. 
 
Recently, an approach employing adoptive T cell therapy was achieved successfully in a 
metastatic ER+ breast cancer patient (173), taking advantage of the major advances in next 
generation sequencing techniques. Briefly, tumor-specific mutations were assessed by whole 
exome sequencing and RNAseq of the tumor lesion and TILs were isolated from the tumor and 
cultured in the presence of IL-2. TILs that were reactive against the mutations found in the 
tumor (4 mutated proteins) were selected and reinfused in the patient after a proliferation 
phase. In addition to the TILs, the patient received IL-2 and pembrolizumab (anti-PD-1). The 
metastasis of the patient started to regress, and no visible lesions were observed 22 months 
after the TILs infusion.  
This study revealed that adoptive T cell therapy is an option for breast cancer patients. 
However, it is necessary to take into account that this treatment is clearly very costly, due to 
i) the specific techniques to find tumor antigens and ii) the facilities to grow autologous cells 
for clinical use. Moreover, it is very demanding, time-consuming to achieve a pure population 
of tumor-specific T cells that represents around 1010 cells and still requires validation, 
assessment of toxicity and potential off-target effects. Thus, extensive and robust 
investigation in this field is still required. 
 
In this thesis, a focus on breast cancer immune status was performed. Since, currently, breast 
cancer patients with locally advanced disease rely mainly on NACT, and taking into account 
that both TILs and NLR are debatable predictive markers, the need to find a reliable and 
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powerful predictive biomarker for the response of NACT will be tackled. Moreover, due to the 
lack of alternative treatments for breast cancer patients without response to NACT, in this 
thesis we developed a 3D system to test different therapeutic combinations in an effort to 
obtain new strategies especially for NACT non-responder patients. 
 



























Chapter II – Rationale and specific aims 
 
Breast Cancer is the second most frequent type of cancer worldwide. However, when taking 
into account only the female population, breast cancer is the most frequent cancer worldwide 
(137). The treatment for breast cancer is effective, especially for the estrogen receptor 
positive and HER2 subtypes. Nonetheless, when the disease is in an advanced state, the 
effectiveness of the treatment is severely reduced. For inflammatory/inoperable tumors or 
for locally advanced disease, i.e. tumors with more than 2 cm of diameter and/or with 
extension to the axillary lymph node, the treatment of choice is neoadjuvant chemotherapy 
(NACT), independently of the breast cancer subtype. This type of chemotherapy is prescribed 
before the surgery and lasts for six months, allowing the reduction of the tumor mass and/or 
the inflammatory process, and consequently permitting a more conservative surgery. Yet, 
more than half of the patients do not response to this treatment, never achieving a 
pathological complete response (142,149). Thus, there is an urgent unmet clinical need to find 
new biomarkers to predict the response to NACT. This is essential in order to distinguish a 
priori the patients who will not benefit from this treatment and promptly direct them to 
effective treatments, reducing unnecessary chemotherapy-related toxicity. Moreover, 
another foremost important clinical need is the development of new therapeutic strategies to 
offer to the NACT non-responder patients.  
 
Hence, the main focus of this thesis is to address both of these clinical needs and ultimately 
contribute to ameliorate the breast cancer prognosis and treatment. Specifically, we intended 
to: 
 
1. Identify new biomarkers to predict breast cancer patients’ response to neoadjuvant 
chemotherapy 
 
To identify new biomarkers to predict treatment response we have established a collaboration 
with 3 hospitals in the Lisbon area, to obtain biopsies, blood and surgical specimens of breast 
cancer patients. The hospitals were Hospital CUF Descobertas, Hospital Prof Doutor Fernando 
Fonseca and Hospital de Vila Franca de Xira. Our approach was to focus on immune cell 
populations and immune-related molecules (results in Chapter IV).  
Since the presence of tumor infiltrating lymphocytes (TILs) has been appointed as a predictor 
of response to NACT, we have deepened our analysis on TILs subtypes. Namely, cytotoxic T 
cells (CTLs), helper T cells (Th) and regulatory T cells (Tregs). Specifically, CTLs and Tregs have 
been gaining attention in the recent years because the first ones are able to eliminate tumor 
cells; while the last ones have the capacity to dampen the effector function of CTLs. However, 
the analysis of TILs is still controversial and not routinely implemented in the clinic. Indeed, 
due to their opposite effects (as it is the case of CTLs vs Tregs) they should not be analysed 
globally. Also the ability of tumors to engage mechanisms to escape immune surveillance and 




clearance by CTLs, have to be taken in account. Hence, our hypothesis was that the presence 
in the tumor microenvironment of TILs, per se, even considering specifically the CTLs or Tregs, 
was not enough to predict patients response to NACT, but their activation status could be. 
HLA-DR is a T cell activation marker (174), normally expressed in later stages of cell activation 
(73). Although HLA-DR is a well-known antigen presenting molecule, normally expressed on 
antigen presenting cells (such as dendritic cells), its expression on T cells has been described 
to be important in autoimmune diseases and viral infections (175–178). Moreover, in the 
context of HIV patients, it has been described that HLA-DR+ CTLs exhibit a high cytolytic 
potential (179,180).  
Although functionally, HLA-DR is related to antigen presenting cells, the HLA-DR+ CTLs were 
found to also have the machinery needed for antigen processing and loading on HLA-DR 
molecules. Additionally, these cells were found to be able to express CD86 and CD80, which 
are the co-stimulatory molecules of antigen presenting cells that are necessary for the proper 
T cell effector function (181). Moreover, it was described that T cell-T cell synapsis occur to 
allow T cells to secrete IFN- towards each other, compelling the differentiation of more 
protective T cells (76). These T cell-T cell interactions and mutual antigen presentation can be 
essential for mounting a suitable anti-tumor response. 
 
Taking together our hypothesis and the fact that T cell activation can be detected by HLA-DR 
expression, in Chapter IV, we evaluated HLA-DR expression on T cells in breast cancer samples, 
alongside other immune traits of the tumor microenvironment that could be related to CTLs’ 
activation or suppression, in order to find a reliable biomarker that could predict breast cancer 
patients response to NACT. Moreover, a comparison between biopsies, surgical specimens 
and peripheral blood was conducted to assess if the immune status encountered in the tumor 
is systemically represented. 
 
2. Characterize HLA-DR+ cytotoxic T cells  
 
To further characterize HLA-DR+ cytotoxic T cells (CTLs) and test if they are active and 
functional, with relevant cytotoxic abilities, we have analyzed deeply this cell type on Chapter 
V. This aim was achieved by flow cytometry and gene expression analysis of different immune 
molecules that might be related with CTLs function. Moreover, an additional characterization 
was performed to clarify HLA-DR+ CTLs immune profile, i.e., to see if these cells belong to an 
effector or exhausted subtype, or to a memory class of T cells. This study is relevant to further 
extend the knowledge regarding activated CTLs and their subtypes, which may contribute to 
pave the way for future development of efficient T cell-based immunotherapies.  
 
 




3. Establish a 3D in vitro platform of breast cancer cells and immune cells to validate HLA-DR+ 
cytotoxic T cells as a biomarker of response to conventional chemotherapy and explore new 
potential therapies.  
 
To tackle the second main objective of this thesis – develop new therapeutic strategies for 
breast cancer patients without response to conventional treatment, we have established a 3D 
in vitro system based on breast cancer cell lines spheroids. A 3D system is a more physiological 
representation of healthy tissues and also of pathological conditions when compared to 2D 
culture. 2D culture is based on a monolayer of polarized cells with only one side of their 
surface area attached to the substrate and the remaining surface in contact with the culture 
medium. This type of morphology can greatly limit tissue-specific functions. On the other 
hand, 3D in vitro cell culture models offer cell-cell and cell-matrix interactions, which will 
influence cell structure, cell signaling, cell adhesion and mechano-sensing. Moreover, the 
diffusion of oxygen and nutrients is hampered to the core of the structure and produced 
metabolites are also poorly diffused from the core to the surface of the 3D structure. 
Furthermore, the addition of different cell types is possible, creating a multicellular structure 
(182,183). Hence, this system recapitulates key architectural and cellular features of the 
tumor microenvironment. As such, 3D cell models are being used as an easy to work, reliable 
and reproducible preclinical tool for tumor drug screening and to clarify tumorigenesis 
mechanisms.  
For our aim, we developed a 3D structure of breast cancer cell lines in co-culture with patient-
derived immune cells by using a liquid overlay technique to allow a spontaneous 3D spheroid 
formation. The cancer cells were co-cultured with allogenic immune cells isolated from 
patients’ blood (PBMCs). This method was already proven to work in other reports and 
allogenic PBMCs have shown a capacity to produce several cytokines and eliminate target cells 
(184,185). The advantages of the allogenic system are the fact that they are simpler, 
reproducible and PBMCs derived from different patients can be used with the same system 
without the need of histocompatibility with the tumor cells.  
To take advantage of our platform, we executed an in vitro approach to better clarify the role 
of HLA-DR+ CTLs in the response of the spheroid to conventional chemotherapeutic agents 
(results in Chapter VI). Also, an in vitro study was conducted taking in account the HLA-DR+ 
CTLs/NACT response status to assess if we could replicate clinical observations with the 3D 
platform and therefore validate in vitro the biomarker robustness (results in Chapter VI). 
Finally, we took advantage of the model created, to test new therapeutic strategies for 
patients with a weak response to NACT. Namely, we tested in 3D co-cultures based on cancer 
cell lines and PBMCs particularly derived from NACT non-responder patients, several 
therapeutic agents in different combinations. For instance, we assessed the viability of cancer 
cells in the presence or absence of the referred PBMCs with doxorubicin (a common 
chemotherapeutic drug), with immune stimulus or other immunotherapeutic agents, such as 
the blocking antibodies against the PD-1/PD-L1 axis (Chapter VI).  




Altogether, we intend to develop a 3D platform with clinical representation to test new 
alternative strategies to treat patients without response to NACT, improving breast cancer 
















































Chapter III - Materials and Methods 
 
1. Patients’ samples 
 
Samples from breast cancer patients were provided by Hospital CUF Descobertas, Hospital 
Prof. Doutor Fernando Fonseca and Hospital de Vila Franca de Xira. Different types of samples 
were collected (biopsies, surgical specimens, whole blood and formalin-fixed paraffin 
embedded tissue) and each was differently processed, as detailed below.  
1.1 Biopsies and Surgical Specimens 
 
Biopsies, harvested before any treatment, and surgical specimens (either pre or post-
treatment) were immediately collected into a saline solution and then transferred to Transfix 
(Cytomark), a cellular antigen stabilization solution that also fix the cells. The samples were 
processed within three days post collection. The processing consisted in dissociate 
mechanically the tissue with a BD Medicon (BD Biosciences), filter the cell suspension in a 30 
m mesh (Sysmex), centrifuge at 300g for 5 minutes and resuspend the pellet in PBS 1X. This 
cellular suspension was then prepared for immunophenotyping by flow cytometry (section 4 
of this chapter).  
1.2. Formalin-fixed paraffin embedded tissue (FFPE) 
 
Formalin-fixed paraffin embedded (FFPE) tissue from 12 patients, whose biopsies or surgical 
specimens were previously immunophenotyped by flow cytometry, were chosen. 3 slices of 
each FFPE with 3 m of thickness were cut in a microtome (Leica) and transferred to a water 
bath to attach the tissue to separate slides and left to dry at 60ºC for 1h. The slides were kept 
at 4ºC until the immunofluorescence protocol (section 6 of this chapter).   
1.3. Blood 
 
Approximately 10 mL of whole blood was collected in Vacutainer tubes with EDTA (BD 
Biosciences). An aliquot was promptly prepared for immunophenotyping by flow cytometry 
(section 4 of this chapter). To obtain the plasma fraction, whole blood was centrifuged at 
13000 rpm for 10 min. Plasma was then frozen at -80ºC until further use for ELISA assays 
(section 7 of this chapter). Peripheral blood mononuclear cells (PBMCs) were isolated from 
whole blood, diluted in PBS 1X (1:1 ratio) and layered on top of Ficol solution (Biocol by Merck 
Millipore) in a 3:5 ratio (Ficol:blood). This solution was centrifuged at 2100 rpm for 30 min, 
without brake. After the centrifugation, the blood components were separated and the 
PBMCs layer isolated with a Pasteur pipette to a new falcon tube. 20 mL of PBS 1X was added 
and the sample centrifuged at 1300 rpm for 5 min, followed by a second wash with 10 mL of 
PBS 1X and centrifugation at 1000 rpm for 5 min. The number of PBMCs was counted on a 
Newbauer chamber and frozen in fetal bovine serum (FBS, Biowest) with 10% dimethyl 
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sulfoxide (DMSO, Sigma Aldrich) in a concentration of 5x106 to 1x107 cells per cryovial. The 
isolated PBMCs were maintained at -80ºC until further use.  
1.4. Patients inclusion criteria and characteristics 
 
211 patients diagnosed with breast cancer were included in this study. The inclusion criteria 
defined that patients should have an invasive breast tumor, have more than 18 years, 
understand the study in which they will participate and give informed consent. Exclusion 
criteria comprise patients with ductal in situ breast tumors or patients with auto-immune 
diseases, whose prior altered immune responses could influence the results of this study.  
The breast cancer patients were divided according to the therapeutic regime: a percentage of 
patients were submitted to surgery followed by adjuvant chemotherapy and the second group 
of patients were submitted to neoadjuvant chemotherapy (NACT). This last regimen is mainly 
approved for patients with inoperable tumors or patients that have locally advanced disease 
(tumors with more than 2 cm and/or with axillary lymph node metastasis), aiming at the 
reduction of the tumor mass before surgery, which may allow a more conservative 
intervention. In general, NACT consists of 4 cycles of doxorubicin (60 mg/m2) and 
cyclophosphamide (600 mg/m2) every three weeks, followed by 12 weeks of paclitaxel (80 
mg/m2). HER2 positive patients were also treated with Trastuzumab every three weeks. 
Altogether, NACT treatment lasts for 6 months.  
Patients’ samples acquired were divided as follows (and the samples were used for distinct 
procedures, exemplified in Figure III-1): 
- 53 biopsies, collected before the treatment, of patients that were selected for NACT 
(Pre-NACT) 
- 46 biopsies of patients that were not submitted to NACT (no-NACT) 
- 10 surgical specimens, collected after the treatment, of patients that were submitted 
to NACT (Post-NACT) 
- 88 surgical specimens of patients that were not submitted to NACT (no-NACT) 
- 31 blood samples, collected before the treatment, of patients that were submitted to 
NACT (Pre-NACT) 
- 54 blood samples of patients that were not submitted to NACT (no-NACT) 
No-NACT surgical specimens and blood samples were used in chapter IV with the objective of 
understanding the differences between the samples’ immunophenotype when comparing the 
axillary lymph node invasion status or other patients’ characteristics, such as age and body 
mass index. Furthermore, correlations between tumor immune status and circulating immune 
features were conducted.  
Pre-NACT biopsies and blood samples, as well as post-NACT surgical specimens, were used in 
chapter IV, aiming at identifying a novel reliable biomarker of patients’ response to NACT. This 
study was conducted in two phases: pilot and validation. The cohort used in the first phase 




included the first consecutive biopsies of patients selected for NACT from October 2016 to 
June 2018. The cohort used in the second phase included the first consecutive biopsies of 
patients selected for NACT, from September 2018 to July 2019. 
To summarize the patients included in this study and the samples collected, a flow chart was 
performed (Figure III-1). The patients’ clinical characteristics are described in Table III-1.  
 
Table III-1 Characteristics of patients enrolled in this study (age, body mass index, and menopause). 
Clinical data, such as subtype of breast cancer, grade, Ki67 (related to the tumor proliferation rate), 
tumor dimension, node status and response to treatment are also described. 
Age Median – 59 (range: 29-87) 
Body mass index (BMI) Median – 26.02 (range: 17.04–42.19) 
Post-menopause 64.61% 
ER+ (PR -/+) 68.93% 
HER2+ including triple positive breast cancer 16.38% 
TNBC 14.69% 
Grade 
G1 – 19.19% 
G2 – 54.07% 
G3 – 26.74% 
Ki67 Median – 20% (range: 1% - 98.40%) 
Dimension (mm) Median – 23 (range: 5-90) 
Axillary lymph node invasion status 
Negative – 56.36% 
Positive – 43.64% 
NACT response (first cohort) 
Good response – 43.33% 
Bad response – 56.67% 
NACT response (second cohort) 
Good response – 31.82% 

















Figure III-1 Flow chart of Breast Cancer patients enrolled in this study (A). (B) Flow chart of the 
biopsies, surgical specimens (C) and whole blood (D) collected for this study. *Data on the response to 
treatment still missing.   
 




Whole blood from 13 healthy donors was also collected in Vaccutainer tubes with EDTA (BD 
Biosciences). Whole blood and plasma were obtained and processed as above described and 




used in parallel with samples from breast cancer patients for comparison (Chapter IV). PBMCs 
were also used, but isolated from buffy coats (see section below).  
 
2.2. Buffy coats 
 
For some particular experiments, where a great amount of PBMCs (not necessarily from breast 
cancer patients) was required, buffy coats from 12 healthy donors provided by Instituto 
Português do Sangue e da Transplantação were used. The buffy coat was divided into three 
50 mL falcons (25 mL for each), diluted in a 1:1 ratio in PBS 1X, and centrifuged at 2500 rpm 
for 10 min, without brake. A leukocyte enriched layer was formed and removed to a single 
falcon. PBS 1X was added until reach a volume of 20 mL. This solution was layered on top of 
12 mL of Ficol with a Pasteur pipette and centrifuged at 2500 rpm for 20 min, without brake. 
The well-defined ring of PBMCs was formed, removed with a Pasteur pipette to a new falcon 
and washed with PBS 1X two times. Between washes the PBMCs solution was centrifuged first 
at 1400 rpm for 10 min with brake and after the second wash, the centrifugation step was at 
800 rpm for 5 min also with brake. The number of PBMCs was counted and frozen at -80ºC, 
until further use, as explained above.    
 
3. Ethics statement  
 
This study was accepted by the Ethical committees of Hospital CUF Descobertas, Hospital Prof. 
Doutor Fernando Fonseca, Hospital de Vila Franca de Xira and NOVA Medical School, 
Faculdade de Ciências Médicas da Universidade Nova de Lisboa. Furthermore, the study was 
also accepted by Comissão Nacional de Protecção de Dados (CNPD).  
Participants were recruited on a voluntary basis and written informed consent was obtained. 
Blood, biopsies and surgical specimens were collected during the patients’ clinical routine and 
were provided to the lab only when the patients’ diagnosis was not jeopardized.     
Sample processing was only performed at CEDOC/NOVA Medical School, according to the 
Declaration of Helsinki. Moreover, it complied with national legislation for the scientific use 
of human biological samples (Law n. 12/2005 and Decree-Law n. 131/2014).  
Clinical data from patients were managed in compliance with the EU and Portuguese 
legislation. Data were anonymized and stored securely in accordance with the EU's Data 
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Antibody staining for flow cytometry was performed in biopsies/surgical samples, as well as 
in whole blood samples. Briefly, after obtaining a cell suspension from biopsies/surgical 
samples collected in saline solution, staining with BD HorizonTM Fixable Viability Stain 450 (BD 
Biosciences) was used to select live cells, for 20 min in the dark at 4ºC. Followed by a wash 
step with PBS 1X and centrifugation at 300g for 5 min. Samples kept in Transfix were not 
stained with this viability dye. After this step, a cocktail of mouse anti-human monoclonal 
fluorescent antibodies (mAbs) was added and the mixture kept in the dark for 15 min at room 
temperature. In the case of whole blood, the staining protocol was similar but an additional 
step of red blood cell lysis was performed, with RBC lysis buffer (Biolegend), in the dark for 20 
min at 4ºC. A wash step was performed by adding 1 mL of PBS 1X and centrifuged at 300g for 
5 min. After the cell surface staining, whenever there were intracellular markers to be 
analyzed, cells were fixed and permeabilized with Fix/Perm kit (eBioscience) for 30 min at 
room temperature. Intracellular mAbs were added for 30 min, followed by a wash step by 
adding 1 mL of PBS 1X and centrifuged at 300g for 5 min. The samples were fixed with FlowFix 
(Polysciences). Data were acquired in BD FACS Canto II with FACSDiva Software v8.0.1 (BD 
Biosciences) and the results were analyzed using FlowJo software v10. 
The mAbs used were: anti-CD45-PercP (clone HI30), anti-CD3-PercP (HIT3a), anti-CD3-APC 
(UCHT1), anti-CD19-PE (HIB19), anti-CD15-PE (HI98), anti-CD161-FITC (HP-3G10), anti-CD4-
FITC (OKT4), anti-CD8-PE (HIT8a), anti-CD8-Pacific Blue (SK1), anti-HLA-DR-APC (L243), anti-
CD127-PE-Cy7 (A019D5), anti-CD1c-APC-Cy7 (L161), anti-CD163-PE (GHI/61), anti-CD206-APC-
Cy7 (15–2), anti-PD-1-FITC (EH12.2H7), anti-PD-L1-APC (29E2A3), anti-CTLA4-PE (L3D10), anti-
CD69-APC-Cy7 (FN50), anti-Tim3-APC (F38-2E2), anti-IL-8-APC (E8N1), anti-IFN--PE (4S.B3), 
anti-IFN--APC-Cy7 (4S.B3), anti-Granzyme B-FITC (QA16A02), anti-IL-1-FITC (JK1B-1), anti-IL-
2-PE-Cy7 (MQ1-17H12), anti-IL-2-PE (MQ1-17H12), anti-CD11b (ICRF44), anti-IL-6-APC (MQ2-
13A5), anti-IL-17-FITC (BL168), anti-IL-23/IL-12-PE (C11.5), anti-TGF--APC (TW4-6H10), anti-
CD69-PercP (FN50), anti-CD39-BV421 (A1), anti-Tim3-APC-Cy7 (F38-2E2), anti-Ki67-PE (Ki-67), 
all from Biolegend; anti-IDO-PE (eyedio), anti-IL-10-FITC (BT-10), anti-CD103-PE-Cy7 (B-Ly7) 
from eBioscience; anti-CD25-PE (MEM-181) and anti-CD11b-FITC (LT11) from ImmunoTools. 
 
4.2. Gating strategy 
 
Using the mAbs previously enumerated, the immune populations were defined as follows: 
cytotoxic T lymphocytes as CD45+/CD3+/CD8+; helper T lymphocytes as CD45+/CD3+/CD4+; 
regulatory T lymphocytes as CD45+/CD3+/CD4+/CD25high/CD127low; B lymphocytes as 
CD45+/CD19+; NK cells as CD45+/CD161+; M2 macrophages as CD45+/CD11b+/ 




CD163+/CD206+; M1 macrophages as CD45+/CD11b+/CD163 negative/CD206 negative; 
dendritic cells as CD45+/CD1c+; and neutrophils as CD45+/CD15+. 
The gating strategy is shown in figure III-2-4. The immune populations are represented 
hereafter as a percentage of single cells (Figure III-2). For other immune markers, namely HLA-
DR, PD-1, PD-L1, CTLA4, Tim3, CD69, IL-1, IL-2, IL-6, IL-17, IL-23/IL-12, IFN-, Granzyme B, 
TGF-, IL-8 and IL-10, we wanted to evaluate their expression level and thus a quantification 
was performed using the median fluorescent intensity (MFI). More specifically, the ratio 
between the MFI of the positive population and the MFI of the negative population was 
calculated to minimize the influence of potential fluctuations in the auto-fluorescence of the 
samples and the voltages of the flow cytometer. The negative population was superimposed 
with the unstained control. Unstained controls were mainly used due to limitations in sample 
size. Fluorescence minus one (FMO) controls were also used for some samples and similar 
results were obtained, thereby validating our analysis.  
T-distributed stochastic neighbor embedding (t-SNE) analysis was performed (section 4 of 
Chapter V) with an R plugin in FlowJo. The samples from patients’ biopsies were concatenated 
in a single file in FlowJo and the t-SNE analysis was performed in the gate of CTLs in this 
concatenated file. The objective of this analysis was to reduce the complex dimensionality of 
different patients’ tumor infiltrating CTLs and observe the distinct markers expressed in both 
HLA-DR+ and HLA-DR negative CTLs.  
 
 














Figure III-3 Gating strategy used to select the expression of different markers inside the CD45+ population.  
 




Figure III-4 Gating strategy used to select the expression of different markers inside the CD45 negative population. 
 




5. Fluorescence activated cell sorting (FACS) 
 
Fluorescence activated cell sorting (FACS) was performed in BD FACS Aria III for two different 
experiments. Namely, for the analysis of gene expression on HLA-DR+ cytotoxic T cells (CTLs) 
and HLA-DR negative CTLs by qRT-PCR (chapter V); and to evaluate the anti-tumor activity of 
HLA-DR+ cytotoxic T lymphocytes through a cytotoxicity assay (chapter VI).  
In the first case, PBMCs from buffy coats of healthy donors were stained with BD HorizonTM 
Fixable Viability Stain 450 (BD Biosciences), to select live cells, for 20 min in the dark at 4ºC. 
Followed by a wash step with PBS 1X and centrifugation at 300g for 5 min. Cell surface staining 
was executed for 15 min at room temperature with the mAbs anti-CD3-PercP, anti-CD8-PE 
and anti-HLA-DR-APC, and washed again with PBS 1X. Cells were sorted into two populations 
- CD3+/CD8+/HLA-DR+ and CD3+/CD8+/HLA-DR negative with an efficiency of 98% (Figure III-
5). The populations were sorted directly to a lysis buffer (from RNeasy Micro Kit, Qiagen) with 
1% -mercaptoethanol (Sigma Aldrich) for further processing for qRT-PCR analysis (see section 
9 of this chapter).  
 
 
Figure III-5 Gating strategy for sorting CD8+/HLA-DR positive and CD8+/HLA-DR negative 
populations. 
 
For the second case, PBMCs from buffy coats of healthy donors were also used. The staining 
was performed as above, but with anti-CD45-PercP instead of anti-CD3-PercP. The stained cell 
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suspension was resuspended in PBS 1X with 2% FBS and 10% Penicillin/Streptomycin and 
filtered through a 0.2 m mesh (Sysmex). In this case, cells were sorted in three distinct 
populations: CD45+/CD8+/HLA-DR+, CD45+/CD8+/HLA-DR negative and CD45+/CD8 negative, 
with an efficiency between 90 and 95% (Figure III-6). Cells were collected in RPMI-1640 (Gibco) 
supplemented with 10% Penicillin/Streptomycin (GE Healthcare) and 10% FBS.  
In both cases, cell debris, aggregates and dead cells were removed (Figure III-5-6). Cells were 
separated with a maximum of stringency to avoid cell population cross-contamination.  
 
Figure III-6 Sorting strategy used to collect three different populations – CD45+/CD8-, 




In order to evaluate the localization of some studied molecules in the tumor 
microenvironment, immunofluorescence was performed in selected FFPE samples, matched 
with the samples previously analyzed by flow cytometry. To start, the paraffin was removed 
in a xylene bath (10 min) and passed through a gradient of alcohol (100, 96, and 70%) and 
dH2O, 30 seconds each. Antigen retrieval was performed by placing the slides in a container 
with 1 mM EDTA pH 9 + 0.05% Tween 20 (Sigma Aldrich) and heated in a microwave at 900W 




for 30 min. During this time, new solution was added to the container if evaporation was 
observed. After the antigen retrieval, the tissue was permeabilized with PBS 1X + 0.3% Triton 
X-100 (ACROS Organics) for 30 min with shaking. Then, the slides were placed in a wet 
chamber and the tissue boundaries were marked with a hydrophobic pen (DAKO). Blocking 
was performed with PBS 1X + 0.1% Triton X-100 + 1% bovine serum albumin (BSA, Sigma 
Aldrich) + 1.5% goat serum (Sigma Aldrich) for 5h. The primary antibody was added at a 
concentration of 1:100 in blocking solution overnight at 4ºC. The primary antibodies used 
were mouse monoclonal anti-human CD8 (32-M4) from Santa Cruz Biotechnology and rabbit 
polyclonal anti-human HLA-DRA from Sigma Aldrich. 
On the next day, 4 rounds of washing with PBS 1X + 0.1% Triton X-100 was executed with 
shaking (10 min each). The secondary antibody was applied at a concentration of 1:500 in 
blocking solution for 2h in the dark at room temperature. The secondary antibodies used were 
goat anti-mouse Alexa 488 and anti-rabbit Alexa 568. 3 more rounds of washing with PBS 1X 
+ 0.1% Triton X-100 were executed with shaking (10 min each). Counterstaining was 
performed with 4′,6-diamidino-2-phenylindole (DAPI; 0.001 mg/mL in PBS 1X, Sigma Aldrich) 
for 10 min with shaking. At least 5 rounds of washing with PBS 1X were executed with shaking, 
10 min each. The slides were mounted in Fluorescent Mounting Media (DAKO). Images were 




ELISA was performed to quantify cytokines in patients’ plasma and in the supernatants of cell 
culture (described in section 11 of this chapter). For the first case, plasma was isolated from 
whole blood as described above (section 1.3 of this chapter) and the levels of IL-10 and IFN- 
were analyzed. For the second case, the cell culture supernatant was harvested and 
centrifuged at 2000 rpm for 10 min to exclude cell debris and frozen at -20ºC. Only IFN- was 
quantified in the cell culture supernatant. The IL-10 kit (Immunotools) and the IFN- kit 
(Biolegend) were used according to the manufacturer’s instructions.  
For IFN- detection, a 96 well plate was coated with the capture antibody in coating buffer (1L 
of dH20 with 8.4g NaHCO3 and 3.56g Na2CO3 pH 9.5) overnight at 4ºC. The next day, the plate 
was washed 4 times in PBS + 0.05% Tween-20 (wash buffer). Blocking with PBS 1X + 1% BSA 
was performed for 1h with shaking. The plate was washed again 4 times. 100 L of the 
standards and of the samples were added to each well and incubated for 2h with shaking, 
followed by another 4 cycles of washing. Detection antibody was added and the plate 
incubated for 1h with shaking. Another similar round of washing was performed. Avidin-HRP 
(horseradish peroxidase) was added and incubated for 30 min with shaking. This time, the 
wash cycles were performed 5 times, waiting 1 minute between washes. TMB substrate 
(Biolegend) was added to the plate and incubated in the dark for 30 min, followed by the 
addition of the stop solution (Biolegend). The absorbance was read at 450 nm and 570 nm 
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(Tecan Infinite F200 PRO). The concentration was calculated taken into account the standard 
curve values and the difference between the absorbance at 450 and 570 nm.  
For IL-10 detection, a similar protocol was used, but with a different coating buffer (only PBS 
1X) and blocking solution (PBS 1X + 2% BSA + 0.05% Tween-20). The incubation with the 
detection antibody was performed for 2h, instead of 1h as above.  
 
8. Gene expression 
 
To get more insights into the differences between CD8+ HLA-DR+ and CD8+ HLA-DR negative 
cells, quantitative real-time PCR (qRT-PCR) of several genes was performed in both 
populations sorted from healthy donors’ PBMCs. After sorting, these cells were collected 
directly to a lysis buffer supplemented with 1% -mercaptoethanol to isolate total RNA using 
the RNeasy Micro Kit from Qiagen. The lysates were transferred to QIAshredder spin column 
(Qiagen) and centrifuged for 2 min at full speed. 70% ethanol was added to the homogenized 
lysate, passed through RNeasy MinElute® spin column and centrifuged at 10000 rpm for 30 
seconds. The spin column membrane was washed and centrifuged again at the same speed 
and time. DNase I was added to the membrane for 15 min and centrifuged again at 10000 rpm 
for 30 seconds. Another washing step was performed followed by the addition of 80% ethanol 
to the membrane and centrifuged at 10000 rpm for 2 minutes. Another centrifugation at full 
speed for 5 minutes was carried out to ensure that no ethanol or buffer remained. In the end, 
14 L of RNA-free water was added to the membrane and centrifuged at 10000 rpm for 1 min. 
RNA quantification was performed in a Nanodrop (Thermo Scientific).  
The RNA was reverse transcribed to cDNA using the Transcriptor High Fidelity cDNA synthesis 
kit (Roche), according to the manufacturer’s instructions. Briefly, to 500 ng of RNA, oligo(dT) 
primers were added and kept at 65ºC for 10 min, followed by the addition of reverse 
transcriptase and two heating cycles, first at 55ºC for 30 min and then at 85ºC for 5 min.   
Quantitative real-time PCR (qRT-PCR) was performed with several primers, described in Table 
III-2, using Roche LightCycler 480 and FastStart Essential DNA Green Master Mix (Roche). 
Cyclic conditions were: 95ºC for 10min, followed by 45 amplification cycles, each consisting of 
10 sec at 95ºC, 10 sec at 56ºC, and 20 sec at 72ºC, and finally a melting step of 10 sec at 95ºC, 
60 sec at 65ºC, and 1 sec at 97ºC. 
The relative mRNA levels were normalized against the housekeeping gene RPL13A expression 









Table III-2 Genes assessed with qRT-PCR and the primers used. 
Gene Forward primer Reverse primer 
TNF AGATGATCTGACTGCCTGGG  CTGCTGCACTTTGGAGTGAT    
Granzyme B GGGGGACCCAGAGATTAAAA CCATTGTTTGGTCCATAGGAG     
Perforin GCAATGTGCATGTGTCTGTG GGGAGTGTGTACCACATGGA 
Eomes CAGCACCACCTCTACGAACA  CGCCACCAAACTGAGATGAT      
Tbet CACCTGTTGTGGTCCAAGTTT AACATCCTGTAGTGGCTGGTG 
RPL13A TGCGTCTGAAGCCTACAAGA TCCGTAGCCTCATGAGCTGTT 
 
 
9. 2D cell cultures 
 
9.1. Ex vivo stimulation assay 
 
To evaluate whether the immune cells of breast cancer patients are able to become activated 
upon stimulation, PBMCs isolated from patients and healthy donors (as described in sections 
1.3 and 2.2 of this chapter) were stimulated ex vivo by plating 1x105 cells per well in a 96 well 
plate with U bottom (Sigma Aldrich). Stimulation was performed during 4h (or overnight for 
HLA-DR expression analysis) with 35 ng/mL of phorbol 12-myristate 13-acetate (PMA, Sigma 
Aldrich) and 1 μg/mL of ionomycin (Merck Millipore). To assess intracellular cytokine levels, 
Brefeldin A (Biolegend) was added for 4h to stop the extracellular transport of these 
molecules. Cells were collected and stained with mAbs and analyzed by flow cytometry. 
9.2. Breast cancer cell lines 
 
In vitro assays were conducted with three different breast cancer cell lines: Hs 578T, MCF-7 
and MDA-MB-231. The first and the third cell lines are triple negative breast cancer; while the 
second one is positive for estrogen receptor. They were all cultured in DMEM (Biowest) 
supplemented with 10% FBS and 1% Penicillin/Streptomycin. For Hs 578T, insulin (Sigma) was 
also added at 0.005%. The cells were maintained in monolayer, either in 6 well plates or T75 
flasks in a humidified environment (37ºC, 5% CO2) until they reached a confluency of 80-90%. 
Cell passage was performed by detaching the cells with TrypLE (Gibco).  
9.3. Establishment of 2D co-culture 
 
To determine if the activation of cytotoxic T cells by tumor cells was dependent on the cell-to-
cell contact or if released soluble factors are sufficient, PBMCs from breast cancer patients 
were cultured with Hs 578T cell line or only the cell line supernatant. Hs 578T cells were 
maintained for 4 days in DMEM until they reached confluency. The cells were harvested and 
their supernatant was further centrifuged at 2000 rpm for 10 min to eliminate cellular debris 
and possible cellular antigens. For the co-culture, PBMCs were plated on a 96 well plate with 
U bottom in 4 different conditions: in monoculture (negative control), with the addition of the 
Chapter III - Materials and Methods 
58 
 
supernatant from Hs 578T culture, with a canonical stimulus of PMA and ionomycin (positive 
control), and in co-culture on a ratio of 20:1 (PBMCs:Hs 578T). PBMCs were collected 48h 
after, stained with mAbs and analyzed by flow cytometry. 
  
10. 3D cell cultures 
 
10.1. Establishment of 3D co-cultures  
 
3D cell culture was executed with a scaffold-free technique in low adherence. To achieve low 
adherence, autoclaved 1.5% of agarose (Invitrogen) in dH2O was placed in a 96 well plate (50 
L per well) and let to cool down for 20 min. 1000 MCF-7 cells or 1000 MDA-MB-231 in 200 
L of supplemented DMEM were placed on top of the agarose. The next day, 100 L of the 
medium was replaced by 100 L of fresh medium. Following the first day, the medium was 
changed every other day (Figure III-7).  
In the case of MCF-7, the spheroid was fully formed at day 3, similar to what has been reported 
(188). Then, 100 L of medium was removed and 100 L of allogenic patients’ PBMCs 
suspension (containing 1000 cells) in supplemented RPMI was added, to achieve a 1:1 ratio of 
PBMCs to the cell line (Figure III-7). PBMCs, obtained as described in section 1.3 of this 
chapter, were added either unstimulated or previously stimulated with PMA/ionomycin or by 
T cell receptor (TCR) engagement with co-stimulatory signal. For this TCR stimulation, 5 g/mL 
of mouse anti-human anti-CD3 (Biolegend) and 1 g/mL of mouse anti-human anti-CD28 
(Biolegend) antibodies were added to the PBMCs suspension. The crosslinking antibody rat 
anti-mouse IgG1 (Biolegend) was added two minutes after at a concentration of 5 g/mL.  
In order to confirm that PBMCs penetrate the spheroid, in a few experiments, these cells were 
previously stained with 5 M CellTracker™ Orange CMTMR (Invitrogen), for 30 min in 
unsupplemented RPMI at 37ºC, followed by the replacement with fresh supplemented RPMI. 
Tumor cells were stained with 5 M Cell Trace CFSE proliferation kit (Invitrogen). Briefly, cells 
in suspension in PBS 1X were stained for 20 min at 37ºC, followed by the addition of 
supplemented medium and incubation at 37ºC for 5 min. Cells were centrifuged at 1100 rpm 
for 5 min and resuspended in supplemented DMEM. The capacity of PBMCs to invade the 
spheroid was assessed 24h after in a Zeiss Axiovert 40 microscope and by confocal microscopy 
(LSM710, Zeiss). Image analysis was performed with Fiji. 
In the case of the MDA-MB-231 cell line, the spheroids were only fully formed on day 6, and 
PBMCs were added, as explained above, on this day (Figure III-7). 
Two days after the co-culture (day 5 for MCF-7 spheroids and day 8 for MDA-MB-231 
spheroids), doxorubicin (Sigma Aldrich) was added, either at 0.1 g/mL or 0.5 g/mL. DMSO 
was used as negative control. 1 g/mL of anti-PD-1 and anti-PD-L1 were added to the 
spheroids either alone or in combination with doxorubicin.  




48h later (day 7 for MCF-7 spheroids and day 10 for MDA-MB-231 spheroids), the spheroids 
were removed from the plate and the supernatant frozen at -20ºC after centrifugation at 2000 
rpm for 10 min. Spheroids were dissociated by pipetting and stained with a Live/Dead probe 
to evaluate, by flow cytometry, the anti-tumor abilities of patients PBMCS (i.e. the percentage 
of viable cancer cells) in the co-culture. From the supernatants, IFN- was quantified by ELISA.  
Spheroids' area was also quantified on the last day of co-culture by photographing at least 3 
wells per condition in a bright field (Zeiss Axiovert 40) and measuring spheroid area with Fiji 




Figure III-7 3D co-culture of breast cancer cell lines and patient-derived immune cells. (A) Scheme of 
the protocol for the 3D in vitro spheroids of MCF-7 and MDA-MB-231 cell lines in co-culture with 
patient-derived peripheral blood mononuclear cells (PBMCs). (B) Representation of the 3D culture in 
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10.2. Cytotoxicity assay 
 
To compare the cytotoxic capacity of HLA-DR+ cytotoxic T cells (CTLs) and HLA-DR negative 
CTLs, the MCF-7 3D spheroid co-culture was used. Buffy coats from healthy donors were 
obtained and PBMCs were isolated as above described (section 2.2 of this chapter). 
Stimulation was performed with 35 ng/mL of PMA and 1 μg/mL of ionomycin for 48h in 6 well 
plates with supplemented RPMI. After the stimulation, cells were collected and sorted 
(described in section 5 of this chapter). Sorted populations were cultured with the MCF-7 
spheroids (day 3) in a 1:1 ratio in the following conditions: 
- MCF-7 and HLA-DR+ CTLs 
- MCF-7 and HLA-DR+ CTLs plus CTLs negative fraction 
- MCF-7 and HLA-DR negative CTLs 
- MCF-7 and HLA-DR negative CTLs plus CTLs negative fraction  
- MCF-7 and CTLs negative fraction 
The co-culture was maintained for 4 days, after which the spheroids were collected and 
stained with Live/Dead to assess MCF-7 viability by flow cytometry.  
 
11. Statistical analysis 
 
Statistical analysis was performed in GraphPad Prism v6 and SPSS v25 (IBM). Statistical 
significance was considered for p<0.05. A comparison between samples was performed by a 
nonparametric Mann-Whitney test and correlations were calculated with Spearman r-test. For 
the comparison of the immunological parameters regarding patients’ age, histological grade, 
tumor dimension, breast cancer subtype and body mass index, a two-way ANOVA, either with 
Turkey’s multiple comparisons (for 3 groups) or Sidak’s multiple comparisons (2 groups) was 
performed.  
To assess the biomarker performance, ROC curves were performed to assign a threshold to 
stratify NACT-responders from non-responders. This analysis was executed in both cohorts 
separately and for HLA-DR expressing CTLs and Tregs. These immune markers were chosen 
since they were significantly different between responders and non-responders to NACT. The 
determined area under the curve (AUC), sensitivity and specificity were taken into account. 
The cut-off point for the HLA-DR expression level in CTLs was determined by ROC curve 
analysis, considering the expression value that corresponded to the maximum sensitivity and 
specificity. Univariate and multivariate logistic regressions were executed taking into account 
both cohorts in the same analysis. The variables used for the logistic regressions were chosen 
to represent the patients’ clinical data and also to include the immune parameters determined 
in the tumor microenvironment. Population size for the validation study was calculated with 
a 95% confidence interval taken into consideration the number of breast cancer patients 




selected for NACT in each hospital per year. Results for the biomarker study were reported 
according to the Recommendations for Tumor Marker Prognostic Studies (REMARK).  
Progression free survival and overall survival were analyzed by a Kaplan Meier curve with a 
log-rank test and hazard ratio analysis.  
Paired t-test was used for the analysis of the in vitro 2D co-culture assays; whereas 
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Chapter IV - Cytotoxic T cells expressing HLA-DR: a new biomarker for breast 
cancer aggressiveness and response to neoadjuvant chemotherapy 
 
Breast cancer remains the leading cause of cancer-related deaths among women worldwide. 
Increasing evidence suggests that anti-cancer chemotherapy is influenced by the immune 
system (189). Indeed, tumors can be heavily infiltrated by immune cells, in particular, tumor-
infiltrating lymphocytes (TILs), which have been associated with good prognosis in various 
cancers, including breast cancer (189). Several reports have been advocating that TILs, 
especially cytotoxic T lymphocytes (CTLs) due to their anti-tumor cytotoxic activity, could 
serve as a robust marker for predicting treatment response. However, the data is still 
conflicting and clinical use of TILs as a predictive biomarker is yet to occur. Moreover, tumor 
cells display several mechanisms of escape to the immune system, leading to tumor 
progression and resistance to chemotherapy. In order to tackle this question, we pursued a 
thorough characterization of the immune cells present in the tumor microenvironment to 
better understand the crosstalk between both cell types and provide an improved biomarker 
to predict response to chemotherapy.   
 
1. HLA-DR-expressing T lymphocyte populations distinguish breast cancer axillary lymph node 
invasion status 
 
To get insight into the composition and the role of the immune infiltrate in breast cancer, we 
used a flow cytometry multi-panel and analyzed several immune populations, including B 
lymphocytes, NK cells, T lymphocytes (divided in T helper cells (Th), cytotoxic T cells (CTLs) and 
regulatory T cells (Tregs)), neutrophils, dendritic cells, M1 and M2 macrophages. These 
immune populations were quantified in breast cancer patients’ biopsies and surgical 
specimens, assessed either pre- or post-treatment (see flow chart on section 1.4 of Chapter 
III).  
To better understand the relationship between the different immune populations and the 
progression of the disease, we started by dividing the patients according to the axillary lymph 
node invasion status (Figure IV-1). Patients that have disease extended into the axillary lymph 
node, normally have more advanced and aggressive breast cancer when compared to patients 
without axillary lymph node metastasis (190). We observed that, although there was high 
heterogeneity in the degree of immune infiltration between both groups of patients, the 
average value of the frequency of T lymphocytes, B lymphocytes, NK cells, neutrophils, 
dendritic cells, M1 and M2 macrophages infiltrating the tumor, assessed by flow cytometry, 
was similar between them (Figure IV-1A and B, (191)). Additionally, the average value of the 
frequency of the distinct T lymphocyte populations – helper (Th), cytotoxic (CTLs) and 
regulatory (Tregs) – were also similar between these two groups (Figure IV-1C, (191)).  





Figure IV-1 HLA-DR-expressing T cells differentiate patients with axillary lymph node metastasis from 
patients without axillary lymph node involvement. Comparison between patients without axillary 
lymph node metastasis (N-, grey dots, n=93) and patients with axillary lymph node metastasis (N+, red 
dots, n=72) regarding (A) percentage of leukocytes, T cells, B cells and NK cells in whole tumor; (B) 
percentage of dendritic cells (DCs), neutrophils, M1 and M2 macrophages in whole tumor; (C) helper 
T cells (Th), cytotoxic T cells (CTLs) and regulatory T cells (Tregs) in whole tumor. The percentage of 
each population was obtained by flow cytometry analysis with respect to the gate of single cells. (D) 
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CD69 expression level in both CD4+ T cells (both Th and Tregs population) and CTLs; (E) HLA-DR 
expression level in Th, CTLs and Tregs. The expression level is the median fluorescent intensity of 
positive population normalized to the negative population. (F) Correlation between the percentage of 
HLA-DR+ Tregs and HLA-DR+ CTLs (Spearman r=-0.2, p=0.01, n=158). *p<0.05, **p<0.01, ***p<0.001.  
 
Then, we considered the activation state of T lymphocyte populations, by the analysis of the 
expression of established T cell activation markers, CD69 and HLA-DR. CD69 is an early, 
transiently expressed activation marker, whereas HLA-DR appears later in the activation 
process but it remains in the cell surface throughout activation (75,192). Interestingly, this 
analysis revealed significant differences between patients without axillary lymph node 
invasion and patients with axillary lymph node invasion, especially regarding the expression 
of HLA-DR. Namely, HLA-DR expression level was higher in CTLs (p=0.003) and lower in Tregs 
(p=0.0007) in patients without axillary lymph node metastasis when compared to patients 
with axillary lymph node metastasis (Figure IV-1E). Furthermore, the expression of HLA-DR in 
CTLs negatively correlated with the expression of this marker in Tregs (r=-0.2, p=0.01, Figure 
IV-1F). 
The analysis of CD69 expression in T lymphocyte populations also revealed a difference 
between both groups of patients – higher CD69 in CD4+ T cells (both Th and Tregs, p=0.01) 
and in CTLs (p=0.005) in patients without axillary lymph node metastasis (Figure IV-1D).  
These results suggested that more than simply the presence and/or the quantity of immune 
cells within the tumor immune microenvironment, the quality (i.e. the activation state) of 
certain immune cells, namely CTLs and Tregs, might be relevant for cancer progression and 
aggressiveness (191).  
Although we did not discriminate between Th subsets (e.g. Th1, Th2, Th17), that might 
influence cancer differently, since CD69 expression level in CD4+ T cells had the same 
tendency as CD69 expression level in CTLs, we could assume that helper T cells present are of 
a Th1 subtype (Figure IV-1D). Nevertheless, further analysis with specific antibodies against 
the Th subsets should be performed.  
To assess the localization of HLA-DR+ CTLs we have performed immunofluorescence in 
formalin-fixed paraffin embedded (FFPE) tissue of breast cancer patients divided according to 
the axillary lymph node invasion status (Figure IV-2). Interestingly, in patients without axillary 
lymph node metastasis, a co-localization between CD8 (CTLs) and HLA-DR is visible in 
intratumor regions, whereas the co-localization is not observed outside the tumor margins. In 
patients with axillary lymph node metastasis, although there are CTLs both inside the tumor 
structure and outside, there is no co-localization with HLA-DR. Cells positive for HLA-DR can 
be other subtypes of T cells, antigen presenting cells or even tumor cells. This result points out 
that activation of CTLs occurs inside the tumor structure, where the tumor antigens are visible 
and where CTLs can exert their cytotoxic functions (191).   




Figure IV-2 HLA-DR+ cytotoxic T cells are located inside tumor structures in patients without axillary 
lymph node metastasis. Representative images of immunofluorescence experiments (n=6) performed 
in slices of paraffin tissue of surgical breast cancer samples of patients without axillary lymph node 
metastasis (Node negative) and with axillary lymph node metastasis (Node positive) for CTLs (green, 
left panel) and HLA-DR (red, middle panel). Nuclei are stained in blue with DAPI and the three stainings 
were merged (right panel). Images from the tumor structures and from the tumor-surrounding tissue 
were acquired. White arrows point to co-localization. Scale bars: 20 µm. 
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2. HLA-DR-expressing cytotoxic T cells are similar when patients’ age and body mass index, or 
tumor histological grade, dimension and breast cancer subtype are taken into consideration 
 
Besides comparing the immune features of breast tumors between patients with or without 
axillary lymph node metastasis, we performed the same comparisons between patients 
regarding their age (<50 years old and >50 years old, Figure IV-3), the breast cancer subtype 
(ER+, HER2+ or TNBC, Figure IV-4), their tumor histological grade (G1, G2 or G3, Figure IV-5), 
their body mass index (normal (18.5–24.9), overweight (25.0–29.9) or obese (>30), Figure IV-
6) and their tumor dimension (<20 mm or ≥20 mm, Figure IV-7). We have performed these 
analyses since those categories can be correlated with prognosis. For instance, it is well known 
that patients with worst prognosis are younger (pre-menopause) women, obese, with tumors 
with higher histological grade and larger than 2 cm (reviewed in 5,2).  
The main differences found were: patients with less than 50 years old have a higher 
percentage of T cells infiltrating the tumor (p<0.001), either Th (p<0.001) or CTLs (p<0.05, 
Figure IV-3); HER2+ breast cancer samples have a higher percentage of Th cells when 
comparing to TNBC (p<0.05, Figure IV-4); and tumor samples with grade 1 have less infiltrating 
leukocytes in general than tumors with grade 2 or 3 (p<0.05, Figure IV-5).  
Interestingly, HLA-DR-expressing T cell populations were not significantly different between 
these groups, highlighting the fact that this trace has potential to be used to predict breast 
cancer aggressiveness independently of breast cancer subtype, grade, tumor dimension and 
patient’s age or body mass index.  
 




Figure IV-3 HLA-DR-expressing T cells are not different between patients segregated by age. 
Comparison between patients with less than 50 years old (black dots, n=63) and patients with more 
than 50 years old (grey dots, n=115) regarding (A) percentage of leukocytes, T cells, B cells and NK cells 
in whole tumor; (B) percentage of dendritic cells (DCs), neutrophils, M1 and M2 macrophages in whole 
tumor; (C) helper T cells (Th), cytotoxic T cells (CTLs) and regulatory T cells (Tregs) in whole tumor. The 
percentage of each population was obtained by flow cytometry analysis with respect to the gate of 
single cells. (D) CD69 expression level in both CD4+ T cells (both Th and Tregs) and CTLs; (E) HLA-DR 
expression level in Th, CTLs and Tregs. The expression level is the median fluorescent intensity of 
positive population normalized to the negative population. Data is represented with the mean value. 
*p<0.05, ****p<0.0001.  




Figure IV-4 HLA-DR-expressing T cells are not different between patients with distinct breast cancer 
subtypes. Comparison between patients with estrogen receptor positive breast cancer (green dots, 
n=122), patients with HER2+ breast cancer (black dots, n=29) and patients with triple negative breast 
cancer (blue dots, n=26) regarding (A) percentage of leukocytes, T cells, B cells and NK cells in whole 
tumor; (B) percentage of dendritic cells (DCs), neutrophils, M1 and M2 macrophages in whole tumor; 
(C) helper T cells (Th), cytotoxic T cells (CTLs) and regulatory T cells (Tregs) in whole tumor. The 
percentage of each population was obtained by flow cytometry analysis with respect to the gate of 
single cells. (D) CD69 expression level in both CD4+ T cells (both Th and Tregs) and CTLs; (E) HLA-DR 
expression level in Th, CTLs and Tregs. The expression level is the median fluorescent intensity of 
positive population normalized to the negative population. Data is represented with the mean value.  
*p<0.05. 




Figure IV-5 HLA-DR-expressing T cells are not different between tumors with distinct histological 
grade. Comparison between patients grade 1 breast cancer (black dots, n=33), patients with grade 2 
breast cancer (grey dots, n=93) and patients with grade 3 breast cancer (blue dots, n=46) regarding (A) 
percentage of leukocytes, T cells, B cells and NK cells in whole tumor; (B) percentage of dendritic cells 
(DCs), neutrophils, M1 and M2 macrophages in whole tumor; (C) helper T cells (Th), cytotoxic T cells 
(CTLs) and regulatory T cells (Tregs) in the whole tumor. The percentage of each population was 
obtained by flow cytometry analysis with respect to the gate of single cells.  (D) CD69 expression level 
in both CD4+ T cells (both Th and Tregs) and CTLs; (E) HLA-DR expression level in Th, CTLs and Tregs. 
The expression level is the median fluorescent intensity of positive population normalized to the 
negative population. Data is represented with the mean value. *p<0.05. 




Figure IV-6 HLA-DR-expressing T cells are not different when patients are segregated according to 
their body mass index. Comparison between patients with normal body mass index (BMI from 18.5 to 
24.9, black dots, n=51), overweight patients (BMI from 25 to 29.9, grey dots, n=45) and obese patients 
(BMI higher than 30, blue dots, n=23) regarding (A) percentage of leukocytes, T cells, B cells and NK 
cells in whole tumor; (B) percentage of dendritic cells (DCs), neutrophils, M1 and M2 macrophages in 
whole tumor; (C) helper T cells (Th), cytotoxic T cells (CTLs) and regulatory T cells (Tregs) in whole 
tumor. The percentage of each population was obtained by flow cytometry analysis with respect to 
the gate of single cells.  (D) CD69 expression level in both CD4+ T cells (both Th and Tregs) and CTLs; 
(E) HLA-DR expression level in Th, CTLs and Tregs. The expression level is the median fluorescent 
intensity of the positive population normalized to the negative population. Data is represented with 
the mean value. 




Figure IV-7 HLA-DR-expressing T cells are not different when patients are segregated according to 
tumor size. Comparison between patients with tumors with less than 20 mm (black dots, n=82) and 
patients with tumors with more than 20 mm (grey dots, n=110) regarding (A) percentage of leukocytes, 
T cells, B cells and NK cells in whole tumor; (B) percentage of dendritic cells (DCs), neutrophils, M1 and 
M2 macrophages in whole tumor; (C) helper T cells (Th), cytotoxic T cells (CTLs) and regulatory T cells 
(Tregs) in whole tumor. The percentage of each population was obtained by flow cytometry analysis 
with respect to the gate of single cells. (D) CD69 expression level in both CD4+ T cells (both Th and 
Tregs) and CTLs; (E) HLA-DR expression level in Th, CTLs and Tregs. The expression level is the median 
fluorescent intensity of the positive population normalized to the negative population. Data is 
represented with the mean value. 
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3. HLA-DR-expressing cytotoxic T cells are associated with patients’ response to neoadjuvant 
chemotherapy 
 
Considering that the HLA-DR expression in T lymphocyte populations reflects the breast 
cancer aggressiveness, by distinguishing the axillary lymph node invasion status, we asked if 
this trait could also be useful to predict patients’ response to neoadjuvant chemotherapy 
(NACT). As previously referred, this treatment is used for inflammatory or inoperable tumors 
or patients that have locally advanced disease (tumors with more than 2 cm and/or with 
axillary lymph node metastasis). However, less than 50% of the patients have a good response 
to this treatment (142,149). As such, it is of foremost importance to be able to detect, prior 
to treatment implementation, which patients will not respond to NACT, to promptly transfer 
them to alternative therapies.  
For this reason, we have analyzed the first consecutive biopsies of patients selected to 
perform NACT. These biopsies (from 30 patients) were collected from October 2016 to June 
2018 and were included in the first cohort for the biomarker study. They were analyzed by 
flow cytometry, with the same antibody multi-panel as above. Additionally, an 
immunofluorescence protocol from FFPE tissue of biopsies of some of these patients was 
performed.  
The 30 patients were divided into responders and non-responders, according to their 
radiological and pathological outcomes. NACT-responders were classified as patients that 
achieved a pathological complete response (pCR, n=6) or that had a pathological partial 
response with less than 10% of the initial tumor still present after treatment and without 
axillary lymph node involvement (n=7). NACT non-responders included patients that still 
maintained more than 50% of the initial tumor mass after treatment (n=6), or patients that 
developed brain, liver and/or lung metastasis during NACT (n=3) or patients that had an early 
relapse after NACT (n=8).  
From the NACT-responders, 38.46% of the patients had HER2+ breast cancer, 30.79% had ER+ 
breast cancer and 30.79% had TNBC. In the case of NACT non-responders, 41.18% had ER+ 
breast cancer, 17.64% had HER2+ breast cancer and 41.18% had TNBC.  
The frequency of distinct immune cell populations – B lymphocytes, T lymphocytes and NK 
cells (Figure IV-8A), dendritic cells, neutrophils, M1 and M2 macrophages (Figure IV-8B) and 
the three T cell subsets – Th, CTLs and Tregs (Figure IV-8C), were then compared between 
NACT-responders and non-responders. No significant difference was observed in the quantity 
of these cells between both groups (191).  
The CD69 expression level was also calculated, but no difference was observed between 
NACT-responders and non-responders (Figure IV-8D). Interestingly, patients from the first 
group showed a higher level of HLA-DR in CTLs (p<0.0001) and lower level of HLA-DR in Tregs 
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(p=0.009) when compared to the patients from the second group (Figure IV-8E), suggesting 
that the level of HLA-DR in both populations of T lymphocytes influences NACT response (191). 
 
Figure IV-8 The HLA-DR level in cytotoxic T cells and regulatory T cells is associated with patients’ 
response to neoadjuvant chemotherapy.  (A) Percentage of leukocytes, T cells, B cells and NK cells in 
biopsies from breast cancer patients that responded to NACT (R, black dots, n=13) and that had no 
response (NR, red dots, n=17). (B) Percentage of dendritic cells (DCs), Neutrophils, M1 and M2 
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macrophages in the same patient’s biopsies. (C) Percentage of helper T cells (Th), cytotoxic T cells 
(CTLs) and regulatory T cells (Tregs) in the same patient’s biopsies. The percentage of each population 
was obtained by flow cytometry analysis with respect to the gate of single cells. Level of CD69 
expression in CD4 T cells (both Th and Tregs) and CTLs (D) and HLA-DR expression level in Th, CTLs and 
Tregs (E), expressed as the median fluorescent intensity of positive population normalized relatively 
to negative population. Data is represented with the mean value. **p<0.01, ****p<0.0001. 
 
In order to verify the predictive value of HLA-DR expression in CTLs and Tregs for NACT 
response, we plotted the levels of HLA-DR+ CTLs and HLA-DR+ Tregs, of the total 30 biopsies 
in one single column, regardless of the response (Figure IV-9A). Excitingly, even with a small 
sample size, a robust separation of responders (black dots) and non-responders (red dots) was 
observed, especially for the expression level of HLA-DR in CTLs. 
 
 
Figure IV-9 The HLA-DR level, especially in cytotoxic T cells, is associated with patients’ response to 
neoadjuvant chemotherapy, independently of the breast cancer subtype. (A) HLA-DR expression in 
CTLs and Tregs with data for responders (black dots, n=13) and non-responders (red dots, n=17) 
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plotted in a single column. (B) The same analysis as in (A) was performed for other markers that 
theoretically could be used in the clinic: PD-L1, PD-1, CTLA4, IL-10, IDO, and Tim3+ CTLs. (C) HLA-DR 
expression level in CTLs of NACT-responders and non-responders divided by the subtype of breast 
cancer – estrogen receptor positive (ER+), HER2 positive or triple negative (TNBC). Data is represented 
with mean value. ns – non-statistical, **p<0.01.  
 
ROC curve analysis was performed, leading to a statistically valid cut-off point for the HLA-DR 
expression level in CTLs (8.943 - value above which patients are NACT-responders) and in Tregs 
(5.655 - value beneath which patients are NACT-responders) (Table IV-1). For HLA-DR-
expressing CTLs, the area under the ROC curve was 0.959, the sensitivity was 94.12% and the 
specificity was 100%. For HLA-DR-expressing Tregs, the area under the ROC curve was 0.849, 
the sensitivity was 81.25% and the specificity was 75%. These results highlighted that, mainly, 
HLA-DR-expressing CTLs evaluated in biopsies could predict response to NACT with accuracy 
(191). To clarify the few borderline cases, the analysis of HLA-DR+ Tregs can also be useful, 
since there is a negative correlation between both markers (Figure IV-1F). 
 
Table IV-1 ROC curve parameters for HLA-DR+ cytotoxic T cells (CTLs) and HLA-DR+ regulatory T cells 
(Tregs). 
 HLA-DR+ CTLs HLA-DR+ Tregs 
Threshold Value 8.943 5.655 
AUC 0.959 0.849 
Sensitivity 94.12% 81.25% 
Specificity  100% 75% 
 
Other immune signatures of cancer immune status, namely the expression of PD-1, PD-L1, 
cytotoxic T lymphocyte-associated protein 4 (CTLA4), T cell immunoglobulin and mucin 
domain 3 (Tim3) by CTLs, IDO and IL-10, that potentially could be used as biomarkers of NACT 
response were analyzed (Figure IV-9B). Although differences could be observed between 
biopsies of NACT-responders and non-responders, none of them was statistically significant, 
as was HLA-DR in CTLs. Therefore, we did not observe the segregation of patients according 
to the level of expression of any of these molecules (Figure IV-9B) pointing the previous 
immune feature as a better biomarker of NACT response (191).  
Then, to emphasize the potential predictive value of HLA-DR expression level in CTLs we 
analyzed this trace for the three subtypes of breast cancer - HER2+, ER+ and TNBC, separately 
(Figure IV-9C). Notably, HLA-DR expression level in CTLs can segregate NACT-responders from 
NACT non-responders, independently of breast cancer subtype (191). 
 
Besides the frequency and the type of immune cells in the tumor tissue, their location could 
also be important to predict patients’ clinical outcome (194). Therefore, we have assessed, by 
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immunofluorescence, selected FFPE tissue samples matched with the previously analyzed by 
flow cytometry, and evaluated where the HLA-DR+ CTLs are mainly located. We observed that 
in biopsies of patients with good response to NACT (Figure IV-10), the location of these HLA-
DR-expressing CTLs was mainly present in intraepithelial tumor structures. Representative 
images in Figure IV-10 show a co-localization of anti-CD8 (CTLs) and anti-HLA-DR within the 
tumor, while no co-localization between these two markers was observed in the tumor 
surrounding normal tissue. Indeed, outside the tumor margins, CTLs were found but they do 
not seem to be activated, as the HLA-DR staining was more spread throughout the tissue.  
These results suggest that CTLs located in intraepithelial tumor structures are more activated 
than the CTLs found at the tumor surrounding normal tissue, probably due to high proximity 
with tumor antigens and tumor-released soluble factors, therefore suggesting that these CTLs 
should be the ones with anti-tumor cytotoxic activity. 
 




Figure IV-10 HLA-DR+ cytotoxic T cells are located inside tumor structures in patients with response 
to neoadjuvant chemotherapy. Representative images of immunofluorescence experiments (n=6) 
performed in slices of paraffin tissue of breast cancer biopsies of patients that responded to NACT and 
of NACT non-responders’ patients for CTLs (green, left panel) and HLA-DR (red, middle panel). Nuclei 
are stained in blue with DAPI and the three stainings were merged (right panel). Images from the tumor 
structures and from the tumor-surrounding tissue were acquired. White arrows point to co-
localization. Scale bars: 20 µm. 
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4. Cytotoxic T cells with high levels of HLA-DR are present in post-NACT surgical specimens of 
NACT-responders 
 
It has been reported that chemotherapeutic agents are able to alter the immune context of 
breast cancer, usually boosting anti-tumor CTLs’ activity (195). Thus, post-NACT samples (not 
necessarily matched with the previous biopsies) were also analyzed by flow cytometry. These 
specimens also revealed that non-responders have infiltrating CTLs with low levels of HLA-DR 
(p=0.009) and Tregs with high levels of HLA-DR (although not significant in this case) when 
compared to responders (Figure IV-11). This observation suggested that in a tumor immune 
microenvironment prior enriched in poorly immune-competent cells, NACT is not sufficient to 
modulate this background in a way that favors response. This further supports the idea that 
the level of HLA-DR in CTLs could predict breast cancer patients’ response to NACT (191).  
 
 
Figure IV-11 HLA-DR-expressing cytotoxic T cells are higher in tumors from NACT-responders, after 
the treatment. Level of HLA-DR in CTLs (A) and Tregs (B), assessed by flow cytometry, in responders 
(R, white bars, n=4, mean ± SEM) and non-responders (NR, black bars, n=6, mean ± SEM), expressed 
as the median fluorescent intensity of positive population normalized to the negative population. 
**p<0.01. 
 
5. Validation of HLA-DR-expressing cytotoxic T cells as a predictor of neoadjuvant 
chemotherapy response 
 
In order to establish HLA-DR-expressing cytotoxic T cells as a biomarker of breast cancer 
patients’ response to NACT, we are conducting a validation prospective study, in a second 
independent cohort of breast cancer patients (Saraiva et al, manuscript in preparation). The 
samples from these patients have been supplied by Hospital CUF Descobertas and Hospital 
Vila Franca de Xira. The validation study is being performed taking into consideration the 
REMARK criteria - reporting recommendations for tumor marker prognostic studies (196). This 
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cohort included biopsies of patients selected to perform NACT from September 2018 onwards 
(23 patients, of which, only 22 have already finished NACT). Following the REMARK criteria, 
we have calculated the population size of the validation cohort, taking into consideration the 
number of breast cancer patients selected for NACT per year in both hospitals. In each 
hospital, approximately 20% of the breast cancer cases are selected for NACT, and both have 
approximately 150 breast cancer patients per year. Therefore, the population size, with a 95% 
confidence interval and 5% margin of error is 53 patients. To achieve this number we are still 
enrolling patients.  
So far, we have divided the patients we already know the outcome, into NACT-responders and 
non-responders according to the same criteria as in the first cohort. 7 patients responded to 
NACT and from these, three patients achieved a pathological complete response. The non-
responder patients (n=15), included patients that developed bone metastasis (n=2) or that still 
had more than 50% of the initial tumor after NACT, or presented axillary lymph node 
metastasis at the time of the surgery (n=13). 
From the NACT-responders, 43% of the patients had HER2+ breast cancer and 57% had TNBC. 
In the case of NACT non-responders, 47% had ER+ breast cancer, 40% had HER2+ breast cancer 
and 13% had TNBC.  
As previously, we started by analyzing the percentage of the T lymphocyte subpopulations, 
namely CTLs and Tregs (Figure IV-12A), which were not significantly different between NACT-
responders and non-responders. Expectedly, the expression level of HLA-DR in CTLs was again 
statistical significant between both groups (p=0.03, Figure IV-12B). As before, data regarding 
HLA-DR expression level in CTLs was represented for NACT-responders and non-responders in 
a single column (Figure IV-12C) and segregation between responders and non-responders is 




Figure IV-12 HLA-DR-expressing cytotoxic T cells also predict response to neoadjuvant chemotherapy 
in the validation cohort. (A) Percentage in the whole biopsy of cytotoxic T cells (CTLs) and regulatory 
T cells (Tregs) between patients with response to NACT (black bars, n=7, mean ± SEM) and patients 
without response to NACT (red bars, n=15, mean ± SEM). This percentage is calculated by flow 
cytometry relative to the gate of the single cells. (B) HLA-DR expression level in CTLs between NACT-
responders (R, black bar, n=7, mean ± SEM) and NACT non-responders (NR, red bar, n=15, mean ± 
SEM). (C) Same analysis as in (B) but represented in the same column, where each dot represents a 
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patient – NACT-responders are represented as black dots, while NACT non-responders are represented 
as red dots. The expression level is calculated by flow cytometry and represents the median fluorescent 
intensity of the positive population normalized to the negative population. **p<0.01. 
 
With the aim of validating the results from the first cohort of patients, we used the parameters 
calculated with the ROC curve (Table IV-1) to predict which patients would respond and which 
would not respond to NACT. From the 22 patients, 4 did not fit into the prediction. Namely, 2 
patients who responded to NACT had an HLA-DR expression level in CTLs of 7 and 8.61 (slightly 
below the threshold value of 8.943 calculated in the ROC curve of the first cohort). Moreover, 
two patients without response to NACT presented tumor infiltrating CTLs with HLA-DR 
expression above the threshold value - 9.81 and 10.43.  
To analyze the differences between cohorts, a new ROC curve was executed for the second 
cohort (Table IV-2). The parameters for this ROC curve were an area under the curve (AUC) of 
0.89, with 80% sensitivity and 85.71% specificity (Table IV-2). The parameters were only 
slightly different from the ones obtained for the ROC curve of the first cohort, namely the cut-
off point for the HLA-DR expression level in CTLs was calculated as 8.63 (value above which 
patients are NACT-responders) which was close to the previous one (8.943).  
 
Table IV-2 ROC curve parameters for HLA-DR+ cytotoxic T cells (CTLs) in the second independent 





Although we could not predict the outcome of all patients enrolled in the second cohort, the 
majority (18 out of 22) responded as expected according to our model. Moreover, the cut-off 
points calculated by both ROC curves are very similar (8.943 and 8.63, respectively). Thus, in 
general, these results corroborate the previous study, highlighting the potential use of HLA-
DR-expressing CTLs at the biopsy level to predict response to neoadjuvant chemotherapy. 
Nevertheless, it is important to note that the validation study is still ongoing and that the ROC 
curve parameters of the second cohort, namely the sensitivity and even the threshold value, 
are possibly going to be improved.   
Following the REMARK criteria, and using both cohorts together, we executed univariate 
(Table IV-3) and multivariate analysis (Figure IV-13, Table IV-4). Performing univariate and 
multivariate analysis in each cohort separately would be unfeasible due to the sample size of 
each one. Univariate analyses were employed to demonstrate the relationship between the 
marker and the patients’ outcome. Besides analyzing this relationship for HLA-DR expression 
level in CTLs, we performed univariate analysis for other immunological parameters as well as 
 HLA-DR+ CTLs 
Threshold Value <8.63 
AUC 0.89 
Sensitivity 80% 
Specificity  85.71% 
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patients’ clinical data. With the multivariate analysis we were able to construct a model to 
assess if any other variable had an influence on the biomarker – HLA-DR expression level in 
CTLs.  
Table IV-3 Univariate analysis for the biomarker HLA-DR expression level in CTLs. HLA-DR expression 
level in CTLs and other immunological markers and clinical parameters were also analyzed by 
univariate analysis. p-value, odds ratio and the confidence interval of the odds ratio are represented. 




level in CTLs 
0.001 1.778 1.262-2.504 
Immune cells (CD45) 0.827 1.004 0.967-1.042 
T cells (CD3) 0.553 0.986 0.94-1.034 
B cells (CD19) 0.786 0.987 0.896-1.087 
NK cells (CD161) 0.094 0.839 0.683-1.031 
T helper cells (CD4) 0.309 0.972 0.919-1.027 
CTLs (CD8) 0.644 1.035 0.894-1.199 
Tregs 
(CD25high/CD127low) 
0.299 1.277 0.805-2.028 
M1 macrophages 0.701 0.569 0.032-10.068 
M2 macrophages 0.707 0.93 0.635-1.36 
Neutrophils (CD15) 0.283 0.893 0.727-1.098 
HLA-DR expression 
level in Tregs 
0.188 0.910 0.791-1.07 
PD-L1 0.24 1.012 0.992-1.033 
IL-10 0.107 1.039 0.992-1.089 
Age 0.723 0.992 0.948-1.038 
Body Mass Index 0.827 1.014 0.895-1.149 
Tumor dimension 0.305 1.019 0.983-1.058 
Node invasion status 0.162 0.412 0.119-1.426 
Ki67 (%) 0.141 1.017 0.994-1.041 
Grade 0.593 0.615 0.104-3.658 
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Through the univariate analysis, it is possible to observe that the HLA-DR expression level in 
CTLs is significantly different between NACT-responders and non-responders (p=0.001, Table 
IV-3). Moreover, the odds ratio for this variable is greater than 1, highlighting the tendency to 
a favorable outcome. Most of the variables used in this method had an odds ratio close to 1, 
revealing that they do not possess enough strength to employ a tendency for NACT-response. 
Nevertheless, it is possible to observe that for instance the node status, i.e. the presence of 
axillary lymph node metastasis in the patient, has an odds ratio inferior to 1, suggesting that 
patients with positive lymph node involvement have a tendency for worse response to NACT. 
The presence of Tregs, on the opposite, have a tendency to favor NACT-response. This result 
seems counterintuitive but again reveals that lymphocytes can be present in the tumor 
microenvironment but their activity can be hampered by tumor cells. Nonetheless, none of 
these variables had statistical significance, suggesting that they do not influence NACT 
response.  
The multivariate analysis was done with selected clinical characteristics of the patients and 
selected immunological markers based on previously published biomarker studies for the 
response to neoadjuvant chemotherapy. Namely, the presence of tumor infiltrating 
lymphocytes, such as different subsets of T cells (197), or the age at diagnosis may have 
predictive potential. To these published parameters, we added the breast cancer subtype and 
other variables that we found to be correlated with HLA-DR expression level in CTLs such as 
HLA-DR expression level on Tregs (Figure IV-1F) or PD-L1 expression on tumor cells (Figure IV-
17). A forest plot summarizing the odds ratio and 95% confidence interval of the different 
variables measured by the multivariate analysis is shown in Figure VI-13. 
 
Table IV-4 Multivariate analysis for the biomarker HLA-DR expression level in CTLs and other clinical 
parameters, as age, subtype of breast cancer, and percentage of different immune cell populations. 
p-value, odds ratio and the confidence interval of the odds ratio are represented.  




level in CTLs 
0.007 1.726 1.163-2.562 
Age 0.393 0.958 0.867-1.058 
Subtype 0.513 1.469 0.464-4.648 
HLA-DR expression 
level in Tregs 
0.335 0.894 0.712-1.123 
PD-L1 0.481 1.023 0.96-1.091 
CD4 0.472 0.95 0.825-1.093 
CD8 0.404 1.138 0.84-1.543 
 
Interestingly, the HLA-DR expression level in CTLs is the only statistically significant variable, 
even when taking into account all the other parameters (p=0.007). Moreover, the odds ratio 
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continues to be higher than 1, namely it is 1.726, demonstrating a favorable action towards 
response to NACT. The biomarker here proposed (HLA-DR expression level in CTLs) can predict 
response to NACT in breast cancer patients even when the patients’ age, the breast cancer 
subtype, and other immunological parameters of the tumor, such as HLA-DR expression level 
in Tregs, PD-L1 expression in tumor cells, percentage of infiltrating CD4+ and CD8+ T cells are 
taken into account.  
 
Figure IV-13 Forest plot of the effect of different immune markers and patients’ clinical data on the 
response to neoadjuvant chemotherapy. Odds ratio with a 95% confidence interval are shown and 
were calculated by a multivariate logistic regression. **p<0.01.  
 
Besides performing the multivariate analysis with chosen variables based not only on the 
literature but also on the correlations between the biomarker and other immunological 
variables, we also performed a stepwise multivariate analysis (Table IV-5). This stepwise 
analysis is an automatic method that relies mainly on the statistical significance. Interestingly, 
even with an automatic approach, the HLA-DR expression level in CTLs was the only significant 
variable to predict NACT response (p=0.008, odds ratio of 2.119), even when taking into 
account the other variables, namely the breast cancer subtype, the tumor dimension and the 
percentage of tumor infiltrating CTLs.   
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Table IV-5 Stepwise multivariate analysis that included the biomarker HLA-DR expression level in 
CTLs, the percentage of CTLs, tumor dimension and breast cancer subtype. p-value, odds ratio and 
the confidence interval of the odds ratio are represented.  




level in CTLs 
0.008 2.119 1.220-3.682 
Subtype 0.245 0.120 0.003-4.261 
Tumor dimension 0.05 1.098 1.001-1.205 
CD8 0.07 1.332 0.983-1.805 
 
To understand the correlation between the expression level of HLA-DR in CTLs and the 
probability to respond to NACT, we executed a probability curve (Figure IV-14). As it is possible 
to observe, an HLA-DR expression level in CTLs above 10 will lead to an approximately 50% of 
probability of response. Accordingly, patients with tumor infiltrating CTLs with an HLA-DR 
expression level above 15 will have approximately 90% of probability to respond to NACT. 
Additionally, this probability curve was performed dividing the patients by the breast cancer 
subtype and age. Interestingly, no significant differences in the curve were detected (results 
not shown).  
 
 
Figure IV-14 Probability of response to NACT according to the HLA-DR-expression level in tumor 
infiltrating CTLs.  
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6. High expression levels of HLA-DR in tumor infiltrating cytotoxic T cells is associated with 
progression-free survival 
 
Besides analyzing HLA-DR+ CTLs in biopsies of patients that were selected to perform NACT, 
we also analyzed this immune-related parameter in biopsies and surgical specimens of 
patients not selected for NACT (which were directed to other therapeutic settings, such as 
surgery followed by adjuvant chemotherapy). Considering these patients altogether we 
conducted a 3-year follow-up evaluation and divided them according to the expression level 
of HLA-DR in CTLs (Figure IV-15). Namely, patients were divided in HLA-DR low in CTLs (value 
below the threshold calculated in the ROC curve of the first cohort) and in HLA-DR high in CTLs 
(value above the threshold calculated in the first cohort) and a progression-free survival curve 
was executed. Interestingly, we observed that patients with HLA-DR low in CTLs start to 
progress earlier than patients with HLA-DR high in CTLs. More specifically, the hazard ratio is 
0.26 (95% confidence interval 0.1-1.04) for patients with tumors infiltrated with CTLs with low 
levels of HLA-DR and the hazard ratio for patients with tumors bearing HLA-DR high CTLs is 
3.88 (95% confidence interval 0.96-10.28). 
Although the difference between the curves was not significant yet (p=0.059), it shows a clear 
tendency, highlighting the fact that the presence of tumor infiltrating activated CTLs with high 
levels of HLA-DR not only allows a good response to NACT, but can also lead to better 
progression-free survival (Saraiva et al, manuscript in preparation).  
 
Figure IV-15 Progression-free survival of breast cancer patients. The patients were divided according 
to the HLA-DR level in intratumor cytotoxic T cells (CTLs). Specifically, two groups were created: high 
HLA-DR expression level in CTLs (black line, n=43) and low HLA-DR expression level in CTLs (red line, 
n=46). The division between groups was performed according to the threshold value calculated in the 
ROC curve of the first cohort.  
 
Additionally, we performed an overall survival curve (Figure IV-16) also using data from the 3-
years follow-up study. In this case, it is possible to observe that there is no difference between 
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patients with tumor infiltrating CTLs with high levels of HLA-DR vs patients with tumor 
infiltrating CTLs with low levels of HLA-DR. Actually, only one patient from the first category 
and two patients from the second category did not survive during this period. This observation 
is in agreement with the survival rates in breast cancer in the first years following treatment 
(137). For a better understanding of the overall survival, a 5 or 10 years follow-up evaluation 
should be performed.  
 
Figure IV-16 Overall survival of breast cancer patients. The patients were divided according to the 
HLA-DR level in intratumor cytotoxic T cells (CTLs). Specifically, two groups were created: high HLA-DR 
expression level in CTLs (black line, n=43) and low HLA-DR expression level in CTLs (red line, n=46). The 
division between groups was performed according to the threshold value calculated in the ROC curve 
of the first cohort.  
 
7. HLA-DR expression level in cytotoxic T cells negatively correlates with immunosuppressive 
and pro-tumor features of the tumor microenvironment 
 
An anti-tumor or a pro-tumor immune response is elicited not only by the immune cells within 
the tumor and their bio-effector molecules, but also by tumor antigens and the expression of 
cytokines, chemokines and other immune mediators released by the cancer tissue. Thus, the 
stimulation of anti-tumor CTLs’ activity should, at least in part, rely on the molecules present 
in the tumor milieu. Interestingly, we have observed, by flow cytometry analysis of breast 
tumors, that CTLs expressing HLA-DR were inversely correlated with immunosuppressive 
activated Tregs (also expressing HLA-DR, Figure IV-1F). Moreover, they were also negatively 
correlated with the expression of molecules from the non-immune compartment that squelch 
the anti-tumor immune program and/or enhance growth and survival of cancer cells (Figure 
IV-17). Namely, HLA-DR expression level in CTLs was negatively correlated with the expression 
level of TGF- (r=-0.34, p<0.01), which may promote the metastatic profile; PD-L1 (r=-0.36, 
p<0.0001), that inhibits activation of CTLs (198,199); IL-6 (r=-0.43, p<0.001), IL-8 (r=-0.36, 
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p<0.01) and IL-1 (r=-0.41, p<0.001) that are inflammatory cytokines that may act as growth 
factors to sustain cancer cell proliferation and invasion (81,82,200). It was also negatively 
correlated with IL-23/IL-12 (r=-0.31, p<0.01) that is pro-inflammatory but can also impair CTLs’ 
activity through the activation of Tregs (101) (Figure IV-17). 
 
 
Figure IV-17 HLA-DR-expressing T cells correlate with immunosuppressive and pro-tumor molecules 
released by tumor cells to the tumor microenvironment. Heat map of Spearman correlations between 
the expression level of HLA-DR in CTLs and the expression level of HLA-DR in Tregs; and between the 
expression level of HLA-DR in both of these cells and the expression level of pro-tumor or 
immunosuppressive molecules from the tumor environment, namely PD-L1, TGF-, IL-6, IL-1, IL-8, IL-
23/IL-12, IL-10 and IL-17. The expression level of each molecule was assessed by flow cytometry and 
represents the median fluorescent intensity of the positive population normalized to the negative 
population. The heat map is represented as a gradient from blue (negative correlations) to red (positive 
correlations). Numbers in italic represent statistical significance of p<0.01, numbers underlined 
represent p<0.001 and numbers in italic and underlined represent p<0.0001.  
 
On the other hand, the expression level of HLA-DR in Tregs was positively correlated with the 
expression of these pro-tumor molecules - IL-1 (r=0.41, p<0.001), IL-23/IL-12 (r=0.39, 
p<0.01), IL-6 (r=0.4, p<0.01) and IL-8 (r=0.31, p<0.01) – and, additionally, IL-10 (r=0.43, 
p<0.0001) and IL-17 (r=0.32, p<0.01), which could also undermine the activation of CTLs and 
lead to tumor progression (94,201) (Figure IV-17).  
When the same analysis was performed with CTLs or Tregs without accounting for HLA-DR 
expression, there was no significant correlation between these cells and these molecules of 
the tumor milieu, highlighting the importance of T lymphocytes activation and how tumor 
cells influence it, by secreting different molecules in the tumor microenvironment (191).  
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8. Circulating cytotoxic T cells maintain HLA-DR expression of tumor infiltrating cytotoxic T 
cells in breast cancer patients 
 
Envisioning the potential use of HLA-DR-expressing CTLs as a biomarker to predict breast 
cancer response to NACT, we asked if this immune trait was reflected systemically. If HLA-DR-
expressing CTLs are detected in the whole blood of breast cancer patients and if its analysis 
reflects the response to NACT, it would be a major advantage to be able to perform a liquid 
biopsy to detect the biomarker and conduct clinical decisions.  
To verify an association between the tumor immune microenvironment and peripheral blood, 
blood samples were collected from 43 matched patients, prior to treatment implementation, 
and immunophenotyped by flow cytometry. Intriguingly, we observed that the expression of 
HLA-DR in tumor infiltrating CTLs correlated with HLA-DR expression in circulating CTLs 
(r=0.43, p=0.004, Figure IV-18A, (191)). Moreover, the HLA-DR level in circulating CTLs also 
distinguished NACT-responders from non-responders (p=0.02, Figure IV-18B). HLA-DR 
expression level in systemic CTLs of healthy donors was also analyzed. Healthy donors have 
less HLA-DR expression level in CTLs when compared to NACT-responders and more compared 
to NACT non-responders. 
As we did for the analysis of HLA-DR+ CTLs in biopsies, we have plotted the value of HLA-DR 
expression of both responders and non-responders in the same column (Figure IV-18C).  Here, 
the segregation of the patients was not as good as in the case where this feature was analyzed 
in the biopsy. A ROC curve analysis was also performed for the expression of HLA-DR in 
systemic CTLs (Table IV-6) and we obtained a threshold value of 16.08, meaning that below 
this value patients would be considered NACT non-responders. The area under the ROC curve 
was 0.76 and the analysis was executed with 86.67% sensitivity and 63.64% of sensibility 
(Table IV-6).   
 
 
Figure IV-18 Systemic HLA-DR-expressing cytotoxic T cells maintain the profile of intratumor HLA-
DR-expressing CTLs and can correlate with response to neoadjuvant chemotherapy. (A) Correlation 
between expression of HLA-DR in systemic CTLs and tumor infiltrating CTLs (Spearman r=0.43, p=0.004, 
n=43). (B) HLA-DR expression in systemic CTLs in healthy donors (HD, white bar, n=13, mean ± SEM), 
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NACT-responders (R, black bar, n=12, mean ± SEM) and non-responders (NR, red bar, n=16, mean ± 
SEM). (C) HLA-DR expression level in circulating CTLs of NACT-responders (black dots, n=12) and NACT 
non-responders (red dots, n=16). The expression level is the median fluorescent intensity of the 
positive population normalized to the negative population. *p<0.05. 
 
Table IV-6 ROC curve parameters for HLA-DR-expressing circulating cytotoxic T cells (CTLs) in breast 






Thus, although there is a correlation between the expression of HLA-DR in CTLs from tumor 
and from circulation, and systemic CTLs can infer response to NACT, the analysis of HLA-DR-
expressing CTLs at the biopsy level should not be discarded, since the ROC curve obtained for 
systemic HLA-DR-expressing CTLs revealed that this potential biomarker has a weaker 
performance when assessed in blood (Saraiva et al, manuscript in preparation).  
From the whole blood of breast cancer patients, we also collected plasma to assess the 
circulating levels of the cytokines IFN- and IL-10 (Figure IV-19). These cytokines were chosen 
because IFN- reflects an activation status of CTLs, whereas IL-10 reflects an anti-inflammatory 
environment and for instance the activation status of Tregs. Besides dividing the patients in 
NACT-responders and NACT non-responders, we also divided them according to the axillary 
lymph node invasion status, as a readout of the results in section 1 of this chapter.  
Patients without axillary lymph node invasion, as well as NACT-responders, had higher levels 
of IFN- (p=0.004, p=0.01, respectively, Figure IV-19A and C) and lower levels of circulating IL-
10 (p=0.02, non-statistical, respectively, Figure IV-19B and D). These results reflect the fact 
that NACT-responders and patients without axillary lymph node metastasis have a higher 
expression level of HLA-DR in CTLs when compared to either NACT non-responders or patients 
with axillary lymph node metastasis (191).  
 
 HLA-DR+ CTLs 
Threshold Value <16.08 
AUC 0.76 
Sensitivity 86.67% 
Specificity  63.64% 




Figure IV-19 The circulating cytokines correlate with the HLA-DR-expressing T cells and can 
distinguish the axillary lymph node invasion status and response to treatment. (A) IFN- and (B) IL-
10 levels assessed by ELISA in plasma of patients without axillary lymph node metastasis (Node -, black 
bars, n=9, mean ± SEM) and with axillary lymph node metastasis (Node +, grey bars, n=12, mean ± 
SEM). IFN- (C) and IL-10 (D) levels assessed by ELISA in plasma from responders (R, white bars, n=4, 
mean ± SEM) and non-responders (NR, black bars, n=6, mean ± SEM). *p<0.05, **p<0.01. 
 
Altogether, the results from this chapter point out that the presence of CTLs and other 
immune cells in the tumor microenvironment is not sufficient to predict response to 
treatment. Tumor cells can escape the immune system by turning themselves invisible to the 
immune surveillance or by releasing factors that can diminish the immune response. The 
activation status of the CTLs, revealed by the expression of HLA-DR at their surface, is a more 
reliable biomarker to predict tumor aggressiveness but more importantly patients' response 
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Chapter V - HLA-DR+ cytotoxic T cells exhibit effector memory T cell markers 
 
After demonstrating that the presence of HLA-DR-expressing cytotoxic T cells (CTLs) in the 
biopsies is required for neoadjuvant chemotherapy (NACT) success and therefore predicts 
breast cancer patients’ response to NACT, we tried to further characterize this T cell subset. 
By deepening the knowledge about these cells, in the future, we could use this information to 
better manipulate patients’ immune system in order to boost anti-tumor immune responses. 
 
1. Patient-derived immune cells are able to increase HLA-DR when stimulated ex vivo 
 
In selected patients, especially patients that were designated to perform neoadjuvant 
chemotherapy (NACT), peripheral blood mononuclear cells (PBMCs) were isolated from their 
whole blood. After the end of the treatment, patients were divided into NACT-responders and 
non-responders. The PBMCs isolated were cultured under a canonical stimulus of 
PMA/ionomycin to clarify if they could become activated ex vivo. This activation would be 
essential to conduct several functional experiments with immune cells isolated from the 
patients’ blood, since the material provided by core biopsy or by surgery is limited. 
PBMCs isolated from buffy coats of healthy donors were used as a control. After culture with 
stimulation, the PBMCs were collected and stained for flow cytometry to detect the 
expression of HLA-DR in CTLs and of the cytokines IFN- and IL-10 (Figure V-1), known to be 
key anti-tumor and pro-tumor cytokines, respectively.  
Interestingly, even with the same stimulation protocol, the expression of HLA-DR in CTLs was 
higher in PBMCs of NACT-responders regarding PBMCs of non-responders (p=0.02) and 
healthy donors (p=0.01, Figure V-1A), demonstrating a hardwired capacity of the immune cells 
isolated from NACT-responders to become even more activated. Although NACT non-
responders have lower levels of HLA-DR in CTLs (section 3 of Chapter IV), when the PBMCs of 
these patients were stimulated ex vivo, they were able to increase HLA-DR level in CTLs even 
further when compared to PBMCs from healthy donors (p=0.03, Figure V-1A). This result 
suggests that CTLs from NACT non-responders still have the capacity to become activated and 
their low activation (low HLA-DR levels) in NACT non-responders’ biopsies should be due to 
the immunosuppressive microenvironment dictated by tumor cells (191).  
Also, stimulated PBMCs of NACT-responders have increased levels of IFN- in CTLs when 
compared to CTLs of PBMCs from NACT non-responders (p=0.01) and from healthy donors 
(non-statistical, Figure V-1B). Additionally, stimulated PBMCs of NACT-responders have lower 
levels of IL-10, produced by Th cells and/or Tregs (Figure V-1C) than stimulated PBMCs of non-
responders (p=0.01). As previously observed in the plasma of patients (section 8 of Chapter 
IV), the production of these cytokines is closely related to the activation of CTLs/Tregs, i.e. 
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more IFN- expressed in CTLs of NACT-responders’ PBMCs and more IL-10 expressed in 
Th/Tregs of NACT non-responders’ PBMCs, upon ex vivo stimulation (191).  
Altogether, these observations further support that the tumor immune features are 
maintained systemically. Moreover, the fact that PBMCs of NACT non-responder patients, 
especially the CTLs, have the ability to become activated, is a major advantage to perform 
further functional assays.  
 
 
Figure V-1 Stimulated PBMCs from NACT-responders produce more IFN- and less IL-10. (A) 
Percentage of HLA-DR positive cytotoxic T cells (CTLs), assessed by flow cytometry, of ex vivo 
stimulated PBMCs isolated from responders (R, white bar, n=5), from non-responders (NR, red bar, 
n=5) and from healthy donors (HD, black bar, n=5). (B) Percentage of CTLs expressing IFN- and (C) 
percentage of CD4+ T cells (either Th or Tregs) expressing IL-10, assessed by flow cytometry, in 
stimulated PBMCs isolated from responders (R, white bars, n=4), from non-responders (NR, black bars, 
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2. HLA-DR expression increases in cytotoxic T lymphocytes without cell-to-cell contact 
 
To assess if HLA-DR expression in cytotoxic T lymphocytes (CTLs) resulted from cellular contact 
with tumor cells or is mainly induced by cytokines in the environment, as it is suggested by 
the negative correlations between HLA-DR+ CTLs and cytokines released by tumor cells 
(section 7 of Chapter IV), we did a 2D co-culture assay (Figure V-2). In this co-culture, we tested 
isolated PBMCs from distinct patients, independently of their response to NACT, and cultured 
them in different conditions: with Hs 578T breast cancer cell line in a 20:1 proportion, with 
only the supernatant of the cell line, with a canonical stimulus of PMA/ionomycin (positive 
control), or in monoculture (negative control). The co-cultures were maintained during 48h, 
followed by PBMCs harvesting and staining for flow cytometry.  
Curiously, the supernatant of the cell line alone induced the expression of HLA-DR in CTLs 
(p=0.006), similarly to the result obtained in the co-culture (p=0.003, Figure V-2), where tumor 
cells were in direct contact with the immune cells. These results highlight the fact that 
cytokines from the tumor milieu are able to influence the activation state of CTLs, without the 
requirement of contact with the tumor cells (191).  
 
 
Figure V-2 HLA-DR increases in CTLs without cell-to-cell contact with tumor cells. Percentage of HLA-
DR+ cytotoxic T cells (CTLs), assessed by flow cytometry, in the following conditions: PBMCs in mono-
culture, co-culture of PBMCs with HS 578T cell line, PBMCs with the cell line supernatant and PBMCs 
with the canonical stimulus (PMA/ionomycin). **p<0.01, n=6.  
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3. HLA-DR+ cytotoxic T cells have increased expression level of effector immune response-
related molecules 
 
Since HLA-DR is a recognized marker of T cell activation, we set out to analyze if HLA-DR+ CTLs 
produced more molecules related to their activation, when compared to HLA-DR negative 
CTLs (Figure V-3). 
Figure V-3 HLA-DR+ cytotoxic T cells express IFN- and Granzyme B. (A) Representation of a flow 
cytometry analysis of Granzyme B and IFN- expression in HLA-DR+ cytotoxic T cells (CTLs) and in HLA-
DR negative CTLs from pre-treatment tumor samples and from PBMCs isolated from patients. (B) 
Percentage of Granzyme B in HLA-DR negative CTLs (black bar, n=6) and HLA-DR+ CTLs (grey bar, n=6) 
from PBMCs isolated from patients’ whole blood. (C) Granzyme B expression level, calculated as the 
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ratio between the median fluorescent intensity of the positive and negative population, in HLA-DR 
negative CTLs (black bar, n=6) and HLA-DR+ CTLs (grey bar, n=6) from patients’ PBMCs. **p<0.01. 
 
To achieve this task, we have analyzed by flow cytometry, specifically in those cells, the 
expression of effector immune response-related molecules, such as IFN- and Granzyme B, 
which are the most important players of activated CTLs. This analysis was performed in HLA-
DR+ and HLA-DR negative CTLs from tumors and from PBMCs of breast cancer patients (Figure 
V-3, (191)). Interestingly, in tumor infiltrating cells, only HLA-DR+ CTLs expressed high levels 
of IFN- and Granzyme B (Figure V-3A), substantiating their immune-competent profile. 
Regarding circulating cells, HLA-DR+ CTLs express significantly more IFN- and Granzyme B 
than HLA-DR negative CTLs (Figure V-3A). In fact, even if HLA-DR negative CTLs from PBMCs 
had a higher level of Granzyme B expression when compared to HLA-DR negative CTLs from 
the tumor, the percentage of HLA-DR+ CTLs from PBMCs that express Granzyme B, and the 
corresponding median fluorescent intensity, is significantly higher than in HLA-DR negative 
CTLs from PBMCs (p=0.002, Figure V-3B-C). 
After corroborating that HLA-DR+ CTLs produced more cytotoxicity-related molecules, such as 
IFN- and Granzyme B, by flow cytometry analysis, we set out to analyze other molecules 
produced by these cells by qRT-PCR. For that, we have used isolated PBMCs from buffy coats 
of healthy donors and stimulated them in culture with PMA/ionomycin, to increase the levels 
of HLA-DR in CTLs. After the stimulation, these cells were collected and sorted, by fluorescence 
activated cell sorter, in two populations – HLA-DR+ CTLs and HLA-DR negative CTLs. Both 
populations were sorted directly to lysis buffer. Then, the RNA was extracted and transformed 
in cDNA for gene expression analysis of Granzyme B, Perforin, TNF-, Eomes and Tbet (Figure 
V-4). HLA-DR+ CTLs expressed higher levels of the cytolytic proteins Granzyme B (p=0.02) and 
Perforin (p=0.03); Eomes (p=0.03) and the inflammatory cytokine TNF- (p=0.03), which also 
has anti-tumor properties, in comparison with HLA-DR negative CTLs (Figure V-4, (191)). On 
the other hand, the expression of Tbet was lower in HLA-DR+ CTLs when compared to HLA-DR 
negative CTLs (p=0.01). Eomes is a transcription factor involved in the differentiation of CTLs, 
increases upon CTLs activation, regulates IFN- response and cytotoxicity (202,203). Tbet is 
also a transcription factor required for the development of effector cells and regulates CTLs’ 
response to virus infection (204,205).  
Although so far the results point out that HLA-DR+ CTLs are effector T cells that produce 
cytotoxicity-related molecules, normally an effector T cell has a Tbethigh/Eomeshigh phenotype 
(206). Besides effector T cells, there are also exhausted T cells, central memory, effector 
memory, tissue resident memory T cells, and other subtypes that are going to be characterized 
in the next subsection. A Tbetlow/Eomeshigh profile is a characteristic of central memory, 
effector memory, exhausted T cells and terminally differentiated effector T cells which are 
active and functional, but lost the capacity to proliferate (206). To better understand the 
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profile of HLA-DR+ CTLs, we analyzed several surface markers that could distinguish between 
the subtypes of cytotoxic T cells. 
 
Figure V-4 HLA-DR+ cytotoxic T cells express more cytotoxicity-related molecules. mRNA level of TNF-
, Granzyme B (GranzB), Perforin, Eomes, and Tbet in cytotoxic T cells (CTLs) with HLA-DR (n=4, 
*p<0.05). The relative mRNA expression was performed with the expression of these genes in CTLs 
without HLA-DR (represented as 1). 
 
4. HLA-DR+ cytotoxic T cells are active, proliferating and functional T cells and some present 
exhaustion markers  
 
To deepen our knowledge regarding the profile of HLA-DR+ CTLs we have used a flow 
cytometry panel of distinct antibodies and compared the results with HLA-DR negative CTLs 
from breast cancer biopsies. The antibody panel comprised both IFN- and Granzyme B, and 
also CD69, Ki67, CD39, CD103, CD127, PD-1 and Tim3 (Figure V-6, 7, Saraiva et al manuscript 
in preparation).   
We have chosen these cell surface markers to supplement the functional/developmental 
characterization derived from the above referred gene expression analysis. Although our first 
impression, due to the high production of cytotoxicity-related molecules, such as IFN-, 
Granzyme B and Perforin, would be that HLA-DR+ CTLs are effector T cells, the fact that they 
had a Tbetlow/Eomeshigh transcription profile suggested that this conclusion might be too 
simplistic.  
As referred above, besides effector T cells, there are several other subsets of CTLs (Figure V-
5). Naïve T cells are the subtype of CTLs that have never encountered an antigen. After T cells 
are presented with an antigen, a subset will acquire memory. Between memory T cells, there 
are several subtypes, with different expression profiles and functions. Stem cell memory T 
cells (TSCM) are a subtype of memory T cells with stem cell-like properties, i.e. high self-renewal 
capacity. They have been described as an early developmental stage of memory T cells. Central 
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memory T cells (TCM) have less self-renewal capacity than TSCM and are mainly located in lymph 
nodes. Between TCM and effector memory T cells (TEM) there is a transitional subtype (TTM) that 
has a phenotype close to TEM with the loss of CCR7 expression but without effector capacity. 
TEM has a high capacity to recirculate between tissues but is mainly recruited to inflamed 
tissues. This subtype has the capacity to produce IFN- and release cytotoxicity-related 
molecules. Tissue resident memory T cells (TRM) also have effector functions but lost the 
capacity to recirculate. Terminally differentiated effector T cells (TTE) are similar to TEM, but 
instead of expressing CD45RO (a memory marker), express CD45RA (a naïve marker). 
Additionally, TTE has a lower proliferative capacity, when compared to TEM. Effector T cells (Teff) 
is the most cytotoxic subtype of CTLs, have no memory to antigens but respond to them by 
releasing cytotoxic molecules. After Teff cells have performed their cytotoxic function, the 
majority of them undergo apoptosis. Exhausted T cells (TExh) were initially effector T cells but 
due to their demanding cytotoxic function have become exhausted, and lose the capacity to 




Figure V-5 Subtypes of cytotoxic T cells (CTLs), from naïve to memory, effector (Teff) and exhausted 
(TExh). Between memory subtypes of CTLs, there are stem cell memory T cells (TSCM), central memory T 
cells (TCM), transitional memory T cells (TTM), effector memory T cells (TEM), tissue resident memory T 
cells (TRM), and terminally differentiated effector T cells (TTE). The scheme was adapted from (206) and 
produced with Biorender.  
 
To assess if HLA-DR+ CTLs fitted to one of these subtypes, we performed a thorough 
characterization of cell surface markers expression and compared the results with HLA-DR 
negative CTLs (Figure V-6). Besides quantifying the percentage of these markers in HLA-DR+ 
and negative CTLs (Figure V-6), we also performed a visual automatic analysis (Figure V-7). For 
that, we conducted a t-SNE (t-distributed stochastic neighbor embedding) analysis to reduce 
the dimensionality of the samples and distinguish visually the different markers distribution 
(Figure V-7). HLA-DR+ CTLs, produced both IFN- and Granzyme B, as opposite to HLA-DR 
negative CTLs that show no expression of these molecules (p<0.001 and p<0.0001, 
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respectively, Figure V-6). Also, in the t-SNE analysis, the expression of these two markers co-
localized with HLA-DR expression (Figure V-7A). Both IFN- and Granzyme B are produced by 
TEM, TTE and effector T cells (Table V-1).  
CD69 is an early activation marker in T cells, as referred in the introduction (section 2.5 of 
Chapter I, (71–73)). This marker is more produced by HLA-DR+ CTLs when compared to HLA-
DR negative CTLs where the presence of this marker is only observed in approximately 5% of 
the cells (p<0.05). Although HLA-DR is a late activation marker, approximately 40% of HLA-
DR+ CTLs are also positive for CD69, revealing that this marker can remain in the cell surface 
when HLA-DR expression increases (Figure V-6). With the t-SNE visualization, it is possible to 
observe this marker in the majority of HLA-DR-expressing CTLs (Figure V-7A). Furthermore, 
this result also confirms that HLA-DR negative CTLs are not active T cells. CD69 expression is 
mainly related with the TEM phenotype (Table V-1).  
 
Figure V-6 HLA-DR+ and HLA-DR negative cytotoxic T cells have differential surface markers 
expression. Percentage of CD69, IFN-, Granzyme B (GrzB), Ki67, CD39, CD103, CD127, PD-1 and Tim3 
inside the gate of HLA-DR+ cytotoxic T cells (black bars, n=16 biopsies) and HLA-DR negative cytotoxic 
T cells (grey bars, n=16 biopsies). The expression of these markers was analyzed by flow cytometry. 
Data represent mean ± SEM, *p<0.05, ***p<0.001, ****p<0.0001.  
 
Normally, when CTLs become active and recognize specific antigens, a round of proliferation 
occurs to give rise to a higher number of antigen-specific activated CTLs. As such, Ki67 (a 
proliferation marker) is expressed in approximately 65% of HLA-DR+ CTLs (p<0.05), revealing 
that these cells are highly proliferative. Nonetheless, approximately 30% of HLA-DR negative 
CTLs also express Ki67, suggesting that these cells, although not active, are still proliferating 
(Figure V-6). By the t-SNE analysis, Ki67 is expressed in HLA-DR+ CTLs and also in a smaller 
representation in HLA-DR negative CTLs (Figure V-7B), confirming the results in Figure V-6. 
Additionally, Ki67 is normally present in TCM, TTM, TEM and effector CTLs (Table V-1). 
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PD-1, Tim3 and CD127 are T cell exhaustion markers. The presence of these exhaustion 
markers is similar when comparing HLA-DR+ to HLA-DR negative CTLs. The three exhaustion 
markers are expressed by approximately 30% of HLA-DR+ CTLs (Figure V-6). By the t-SNE 
analysis, we observed that CD127 and PD-1 are also highly present in HLA-DR+ CTLs, although 
their expression is also observed in HLA-DR negative CTLs (Figure V-7B), corroborating the 
analysis of Figure V-6. This result suggests that T cell activation and exhaustion is a dynamic 
process and although HLA-DR+ CTLs are activated with the capacity to produce cytotoxicity-
related molecules, the permanent contact with tumor antigens can leave them exhausted. 
Furthermore, this result points out that HLA-DR+ CTLs are not simply effector T cells, as 
suspected given the Tbetlow/Eomeshigh transcriptional profile. Exhaustion markers, besides 
being present in exhausted T cells, are also produced by different subsets of memory T cells, 
such as TEM (Table V-1). 
We also wondered if HLA-DR+ CTLs with cytotoxic capacities against tumor cells are tumor 
infiltrating or are tissue resident CTLs. To assess this question, we analyzed the expression of 
CD103. CD103 is an integrin, also known as integrin E, essential for the retention of CTLs in 
the tissue (207). TRM cells have an advantage when compared to tumor infiltrating T cells 
because they are adapted to the tumor microenvironment. This microenvironment can have 
extreme conditions that will inhibit the function of infiltrating T cells. These extreme 
conditions include high levels of hypoxia and decreased pH due to the presence of lactate 
derived from the preferential energy metabolism based on aerobic glycolysis of tumor cells. 
TRM cells, even in the presence of such surroundings will be adapted and capable of exerting 
their functions. As such, CD103+ TRM CTLs have been reported to have an important role in 
tumor cell elimination and indeed have been categorized as a good prognostic factor in 
different types of cancer (208–211). Nevertheless, CD103 can also be upregulated in TEM, since 
they have the capacity to recirculate but are retained in inflamed tissues (206). Interestingly, 
CD103 expression is observed in both HLA-DR+ and HLA-DR negative CTLs, suggesting that 
resident CTLs, be them TRM or TEM have the capacity to become activated and respond to 
tumor-specific antigens. CD103 is present in approximately 40% of HLA-DR+ CTLs, revealing 
that this subset comprises both tissue resident and tumor-infiltrating CTLs (Figure V-6). There 
is a co-localization of CD103 and HLA-DR+ CTLs (t-SNE analysis), although its expression is also 
observed in HLA-DR negative CTLs (Figure V-7A), again corroborating the analysis of Figure V-
6.   
CD39 is an ectoenzyme capable of converting extracellular ATP and ADP to adenosine (212). 
Extracellular ATP can induce CTLs apoptosis; hence, CTLs might increase the expression of 
CD39 at their surface to escape this inhibitory mechanism (213). On the other hand, the 
presence of adenosine in the tumor microenvironment, the product of ATP hydrolysis, is 
known to be immunosuppressive, inhibiting CTLs activation and function, inducing 
suppressive immune cells such as Tregs and potentiating tumor cells proliferation and 
invasiveness capacity (reviewed in (213)). Additionally, CD39 was demonstrated to be 
increased in activated CTLs and is present in TTE, TCM and TEM (213). Although present in 
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activated CTLs, some authors claim that CD39 mark exhausted CTLs (214). CD39 is normally 
encountered in tumor infiltrating T lymphocytes (215–217) and CD39+ CTLs were shown to 
have a Tbetlow/Eomeshigh transcriptional profile (214,217). Co-expression of CD39 and CD103 
can also represent TRM (215). Here we observed that approximately 20% of HLA-DR+ CTLs are 
positive for CD39, whereas only 3% of HLA-DR negative CTLs produce this enzyme (Figure V-
6). By the t-SNE analysis, there is a representation of CD39 in HLA-DR+ CTLs (Figure V-7). Again, 
this result confirms that HLA-DR+ CTLs are a heterogeneous population with distinct levels of 
activation/exhaustion. Indeed, a proportion of these cells acquired CD39 cell surface marker, 
which is not only present in activated T cells but also in exhausted T cells.  
 
 




Figure V-7 t-SNE analysis of distinct markers gated on cytotoxic T cells (CTLs). A dimensionality 
reduction analysis (t-SNE) was performed in FlowJo software for CTLs analysed by flow cytometry in a 
concatenated file comprising the results from the different patients’ biopsies. Inside the CTLs gate, 
several surface markers were analysed. Namely, (A) HLA-DR, CD69, IFN-, Granzyme B, CD39, CD103; 
and (B) Ki67, CD127, PD-1 and Tim3. Positive regions for each marker are in red. HLA-DR+ CTLs region 
is marked with a red circle and it is represented in the other surface markers analysed.  
 
In general, the most noteworthy differences between HLA-DR+ and negative CTLs were the 
production of IFN- and Granzyme B and the expression of CD69 and Ki67, highlighting the 
higher level of CTLs activation and the capacity to produce cytotoxicity-related molecules 
(Figure V-6).  
Combining the results from this section with the results from the previous one, where the 
gene expression differences between HLA-DR+ and negative CTLs were compared, we can 
conclude that the majority of HLA-DR+ cells have an IFN- high, Granzyme B high, Perforin high, 
TNF- high, Eomes high, Tbet low phenotype, and some express CD69, Ki67, CD39, CD103, CD127, 
PD-1 and Tim3. This phenotype suggests that HLA-DR+ CTLs are functionally active, cytotoxic 
T cells, although, at least some of the cells amongst the population exhibit an intermediate 
level of exhaustion.       
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As referred throughout these results, there are several subtypes of CTLs. Namely, exhausted 
CTLs, naïve T cells, stem cell memory T cells (TSCM), central memory T cells (TCM), transitional 
memory T cells (TTM), effector memory T cells (TEM), tissue resident memory T cells (TRM) and 
terminally differentiated effector T cells (TTE). We have combined the results from this 
subsection with the gene expression analysis and, based on the literature (206,213,218,219), 
have constructed a summary of the results (Table V-1).  
 
Table V-1 Expression of different markers in HLA-DR+ CTLs and the correlation with the different 
subsets of memory T cells, effector and exhausted T cells.  
Marker HLA-DR+ CTLs T naïve TSCM TCM TTM TEM  TRM TTE Teff TExh 
Tbetlo/Eomeshi +   +  +  +  + 
TNF- +     + +  +  
Granzyme B +    + + + + +  
IFN- +     + + + +  
Perforin +    + + + + +  
CD69 +     + +    
Ki67 +   + + + +  +  
CD39 +/-   +  + +  + + 
CD103 +     + +    
CD127 + + + + + + +   + 
PD-1 +   +  +/- + +/-  + 
Tim-3 +     +/- +   + 
HLA-DR +     + +  +  
TSCM - stem cell memory T cells; TCM - central memory T cells; TTM - transitional memory T cells; TEM - 
effector memory T cells; TRM – tissue resident memory T cells; TTE - terminally differentiated effector T 
cells; Teff – effector T cells; TExh – exhausted T cells.  
 
By the analysis of the table above, we can suggest that HLA-DR+ CTLs have a predominant 
effector memory T cell phenotype. TEM cells have the capacity to home to tissues and also to 
recirculate, they have the ability to rapidly release effector molecules and differentiate in 
effector CTLs. This seem consistent with the fact that in breast cancer patients their presence 
is required for the anti-tumor response that might contribute to NACT. Other markers 
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Chapter VI - 3D system of breast cancer cells and patient-derived immune cells to 
clarify the role of HLA-DR+ cytotoxic T cells in NACT response and optimize 
alternative therapeutic strategies  
 
We have observed that HLA-DR-expressing CTLs are highly represented in biopsies of breast 
cancer with response to neoadjuvant chemotherapy (NACT, section 3 of Chapter IV, (191)). 
Additionally, we have concluded that HLA-DR+ CTLs produce more cytotoxicity-related 
molecules, namely IFN-, Granzyme B and Perforin, when compared to the HLA-DR negative 
counterpart (section 3 of Chapter V, (191)). 
To better understand the importance of HLA-DR+ CTLs in the response to the treatment, we 
developed an in vitro platform of 3D co-cultures of breast cancer cell lines and immune cells 
(peripheral blood mononuclear cells - PBMCs) isolated from the patients’ blood. Moreover, 
with this allogenic platform, we can explore new therapeutic strategies to have an alternative 
treatment for patients without response to NACT. 
 
1. Establishment of 3D co-culture of breast cancer cell line and patient-derived immune cells  
 
As referred in Chapter II, a growing body of evidence suggested that 3D cell culture systems, 
in contrast to the 2D cultures, represent more accurately the actual microenvironment where 
cells reside in tissues. Thus, the behavior of 3D cultured cells is more reflective of in vivo 
cellular responses. 
Therefore, in order to clarify the role of HLA-DR+ CTLs in the success of NACT and to validate 
this immune feature as a biomarker of patients’ response to treatment in vitro, we have 
established a platform of 3D cultures for two breast cancer cell lines -  MCF-7 and MDA-MB-
231 (Figure VI-1). Then, we optimized a co-culture with the cell lines and patients’ PBMCs, 
from both NACT-responders and non-responders (Figure VI-3).  
These 3D systems were based in tumor spheroids, since they recapitulate essential features 
present in a tumor microenvironment, namely 3D cellular aggregates of cancer cells, immune 
infiltration, nutrients and oxygen gradients from normal to hypoxic in the center of the 
structure (220). To form the 3D spheroids, we have performed a liquid overlay technique, 
which consists in coating the plate with a non-adhesive component, such as agarose, so that 
cell-cell interaction is enhanced, allowing the spontaneous formation of the 3D structure.  
Similar to what has been described for MCF-7 spheroid formation (188), spheroids of this cell 
line were completely formed after 3 days of culture, as at this point there is no visible blank 
spaces within the multicellular aggregate (Figure VI-1). MDA-MB-231 spheroids needed 
further optimization, but we were able to observe a fully formed 3D structure on day 6 (Figure 
VI-1, Saraiva et al, submitted).   




Figure VI-1 Establishment of 3D spheroids with MCF-7 and MDA-MB-231 breast cancer cell lines. 
Bright field images of MCF-7 spheroids at days 3, 5 and 7 of culture and of MDA-MB-231 spheroids at 
days 3, 6, 8 and 10. Scale bars – 50 m. 
 
Since our experiments with MCF-7 and MDA-MB-231 spheroids were performed during a 
period of 7 and 10 days, respectively, we analyzed the percentage of live cells at these time 
points (Figure VI-2A). We verified that both cell lines were more than 80% viable at day 7 and 
10 for MCF-7 and MDA-MB-231 cell lines, respectively. Moreover, we also quantified the 
spheroid area throughout the days of culture for both cell lines (Figure VI-2B-C). The spheroid 
area of MCF-7 increases from day 3 to day 5 (p<0.0001) and to day 7 (p<0.0001, Figure VI-2B); 
while the spheroid area of MDA-MB-231 increases from day 3 to day 6 (p=0.01), day 8 
(p=0.0003) and day 10 (p=0.0009, Figure VI-2C, Saraiva et al, submitted).  




Figure VI-2 3D spheroids maintain breast cancer cell lines viable, increasing the spheroid area 
throughout the culture. (A) Percentage of live MCF-7 cells on day 7 of the 3D spheroid culture (n=10) 
and percentage of live MDA-MB-231 cells at day 10 of the 3D spheroid culture (n=11). (B) Spheroid 
area of MCF-7 spheroids at day 3 (n=9), day 5 (n=8) and day 7 (n=18). (C) Spheroid area of MDA-MB-
231 spheroids at day 3 (n=4), day 6 (n=7), day 8 (n=4) and day 10 (n=10). *p<0.05, ***p<0.001, 
****p<0.0001. 
 
For the co-culture to be as physiological as possible, we added the patient-derived PBMCs 
after spheroid formation, as in vivo the immune cells are recruited to the already formed 
tumor structure. Additionally, although it is often reported in the literature co-cultures of 10:1 
ratio (PBMCs to cancer cells, (185,221)), we optimized our co-culture to have a ratio of 1:1 
(PBMCs to cancer cells). This should accurately reflect the tumor microenvironment, since we 
observed in section 1 of Chapter IV that rarely breast tumors have more than 50% of their 
mass composed by immune cells. 
Interestingly, we observed that either PBMCs from NACT-responders or from non-responders 
were able to invade both types of spheroids 24h after (Figure VI-3).  
 




Figure VI-3 Patient-derived immune cells are able to infiltrate 3D spheroids of breast cancer cell lines. 
(A) Bright field of MCF-7 spheroid (left panel), patient-derived PBMCs stained in red with a cell tracer 
dye (middle panel) and the two photos merged (right panel), at day 4 of the culture (24h after the 
addition of the PBMCs); scale bar 50 m. (B) Bright field of MDA-MB-231 spheroid (left panel), patient-
derived PBMCs stained in red with a cell tracer dye (middle panel) and the two photos merged (right 
panel), at day 7 of the culture (24h after the addition of the PBMCs); scale bar 50 m. (C) Confocal 
images of 3D spheroids of MCF-7 cell line (stained in green with CFSE) and patient-derived PBMCs 
(stained in red with a cell tracer dye), at day 4 of culture (24h after the addition of the PBMCs). Stills 
were acquired for different Z focal planes, to demonstrate the immune infiltration in a 3D structure; 
scale bar 100 m.   
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2. PBMCs from NACT-responders exhibited anti-tumor activity, contrarily to PBMCs from NACT 
non-responders 
 
Patient-derived PBMCs were added at day 3 for MCF-7 spheroids and at day 6 for MDA-MB-
231 spheroids since at these time points the cell line spheroids were completely formed. The 
co-culture was maintained for 4 more days. To assess the effect of the addition of the patient-
derived PBMCs to the 3D spheroids we analyzed the changes in spheroid area, by imaging and 
analyzing in Fiji software the spheroid area (determined by applying an automatic threshold 
to the image, Figure VI-4).  
 
 
Figure VI-4 MCF-7 spheroid area decreases with the addition of NACT-responders’ PBMCS. (A) 
Spheroid area of MCF-7 cells in monoculture (red bar, n=18), in co-culture with NACT-responders 
PBMCs (R, white bar, n=18) and in co-culture with NACT non-responders PBMCs (NR, black bar, n=18) 
at day 7 of the culture. (B) Spheroid area of MDA-MB-231 cells in monoculture (blue bar, n=12), in co-
culture with NACT-responders PBMCs (R, white bar, n=12) and in co-culture with NACT non-responders 
PBMCs (NR, black bar, n=12) at day 10 of the culture. Data is represented as mean ± SD. *p<0.05, 
**p<0.01, ****p<0.0001. 
 
Interestingly, we observed that the addition of patient-derived PBMCs from NACT-responders 
decreased the area of the MCF-7 spheroids (p=0.04), suggesting a potential effect of the 
patients’ immune cells on the viability and/or proliferation of this breast cancer cell line 
(Figure VI-4A). On the other hand, the addition of patient-derived PBMCs from NACT non-
responders increased the area of the MCF-7 spheroids (p=0.003, Figure VI-4A). This 
observation could be explained by the fact that NACT non-responders’ immune cells are 
unable, by themselves, to deploy an effect on the breast cancer cell line, and the cell line is 
capable to continue proliferating. In the case of MDA-MB-231 spheroids, no effect on the area 
of these structures was observed, either in the presence of NACT-responders or non-
responders’ PBMCs (Figure VI-4B). 
To assess if there is an effect of the PBMCs addition on the viability of the cell lines, we next 
quantified the viability of MCF-7 and MDA-MB-231 at the end of the culture, using a live/dead 
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dye and analyzing by flow cytometry (Figure VI-5). As expected based on the area analysis, in 
the co-culture of MCF-7 with NACT-responders’ PBMCs, the viability of the cell line is 
decreased (p=0.03), highlighting the cytotoxic activity of the immune cells present in the blood 
of breast cancer patients with response to NACT (Figure VI-5A). Contrarily, the addition of 
NACT non-responders’ PBMCs has no effect on the viability of the MCF-7 cell line, 
demonstrating that the immune cells from the blood of breast cancer patients with no 
response to NACT have less cytotoxic capacities and potentially more tumor-protective 
abilities (Figure VI-5A).  
Although no effect on the MDA-MB-231 spheroid area was observed when NACT-responders’ 
PBMCs were added, there is a significant reduction on the viability of this cell line (p=0.03, 
Figure VI-5B), similarly to MCF-7, confirming that immune cells from the blood of NACT-
responders indeed possess cytotoxic activity, independently of the breast cancer cells present 
in the co-culture. Moreover, the addition of NACT non-responders’ PBMCs had no effect on 
the viability of MDA-MB-231 cells, emphasizing that these PBMCs should have a more tumor-
protective phenotype.  
 
 
Figure VI-5 NACT-responders’ PBMCs are able to reduce the viability of the breast cancer cell lines in 
a 3D conformation. (A) Percentage of live MCF-7 cells in monoculture (red bar, n=10), in co-culture 
with NACT-responders’ PBMCs (R, white bar, n=6) and in co-culture with NACT non-responders’ PBMCs 
(NR, black bar, n=5), at day 7 of the culture. (B) Percentage of live MDA-MB-231 cells in monoculture 
(blue bar, n=11), in co-culture with NACT-responders’ PBMCs (R, white bar, n=6) and in co-culture with 
NACT non-responders’ PBMCs (NR, black bar, n=6) at the day 10 of the culture. Data are represented 
as mean ± SD. *p<0.05. 
 
Moreover, here we demonstrate that the established allogenic co-cultures of tumor cell 
spheroids and patients’ immune cells are a powerful tool to study ex vivo anti-tumor immune 
responses. Indeed, we were able to generate a precise and reproducible co-culture setting 
and a reliable readout based on assessing the spheroid area and tumor cells’ viability at the 
end of the co-culture (Saraiva et al, manuscript in preparation).  
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3. HLA-DR+ cytotoxic T cells have the capacity to reduce the viability of tumor cells  
 
To this point, the experiments with the 3D system were performed with the total PBMCs 
isolated from the patients’ blood. Since we have observed that HLA-DR+ CTLs, mainly present 
in NACT-responders (section 3 of Chapter IV), have a cytotoxic profile, due to the production 
of cytotoxic-related molecules, namely Granzyme B, IFN- and Perforin (section 3 of Chapter 
V), we hypothesized that HLA-DR+ CTLs were the cell type responsible for the above observed 
reduction of cancer cells’ viability. So, to further tackle this question, we developed an 
experiment to specifically evaluate the cytotoxic ability of HLA-DR+ CTLs, compared with HLA-
DR negative CTLs, taking advantage of the established 3D co-culture protocol of breast cancer 
cell lines and allogenic PBMCs.  
Particularly in this experiment, we opted for PBMCs isolated from buffy coats of healthy 
donors instead of using patient-derived PBMCs, due to the limitation of the number of cells in 
these samples. Therefore, we isolated PBMCs from the buffy coats of healthy donors, 
stimulated them in vitro to obtain activated CTLs and then sorted (by fluorescence activated 
cell sorting) HLA-DR+ CTLs, HLA-DR negative CTLs and the other PBMCs (except CTLs). This last 
population comprises antigen presenting cells (monocytes and B cells) and CD4+ T cells and 
will be labeled herein as CTLs negative fraction. With these sorted populations we could test 
specifically the effect of HLA-DR+ (relatively to HLA-DR negative CTLs) in the viability of the 
MCF-7 cells, and confirm their cytotoxic capacity. Moreover, with the addition of the CTLs 
negative fraction, which includes antigen presenting cells, we could analyze if antigen 
presentation of tumor antigens is necessary to deploy a cytotoxic response or if HLA-DR+ CTLs 
were sufficiently activated and capable by themselves to eliminate the allogenic tumor cells.  
In summary, we performed the co-culture of MCF-7 cells in the following conditions: 
MCF-7 with i) HLA-DR+ CTLs; 
        ii) HLA-DR negative CTLs; 
        iii) CTLs negative fraction;  
        iv) HLA-DR+ CTLs and the CTLs negative fraction;  
        v) HLA-DR negative CTLs and the CTLs negative fraction. 
After the addition of these populations at day 3, the co-culture was maintained for another 4 
days, after which the spheroids were collected and their viability analyzed by flow cytometry 
(Figure VI-6A). Interestingly, the addition of HLA-DR+ CTLs to the MCF-7 spheroid (condition i) 
reduced significantly their viability (p=0.01), contrarily to the addition of HLA-DR negative CTLs 
(condition ii), which did not affect the MCF-7 viability, suggesting that HLA-DR+ CTLs indeed 
possess cytotoxic abilities. The addition of the CTLs negative fraction (condition iii) also did 
not affect the viability of the cell line. However, when the CTLs negative fraction was added in 
combination with HLA-DR+ CTLs (condition iv) or with HLA-DR negative CTLs (condition v), the 
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viability of the tumor cells reduced significantly (p=0.03 and p=0.01, respectively). Thus, 
although HLA-DR negative CTLs by themselves have no cytotoxic capacity, it seems that the 
presence of antigen presenting cells and CD4+ T cells in the co-culture, allow their activation, 
leading to higher cytotoxic profile and the capacity to reduce the viability of the tumor cells.   
In conclusion, HLA-DR+ CTLs are already reactive and have cytotoxic capacity without the 
contribution of antigen presenting cells and CD4+ T cells. HLA-DR negative CTLs do not have 
this cytotoxic capacity, but this property can be reverted if HLA-DR negative CTLs are assisted 
by other immune cells (Saraiva et al, manuscript in preparation).   
We also analyzed the viability of the PBMCs in this co-culture assay, since there is a report 
claiming that HLA-DR+ CTLs have a suppressive role and that are cytotoxic against autologous 
immune cells (222). In our experiment, even when HLA-DR+ CTLs are in co-culture with the 
CTLs negative fraction, there is no loss on the viability of these cells (Figure VI-6B), supporting 
the fact that these cells are reactive T cells with cytotoxicity against tumor cells and not against 




Figure VI-6 HLA-DR+ CTLs are responsible for the reduction of breast cancer cell lines viability. (A) 
Viability of MCF-7 spheroids either in monoculture (grey bar, n=5) or in co-culture with sorted immune 
populations – HLA-DR+ CTLs (white bar, n=8), HLA-DR+ CTLs with the CTLs negative fraction (white 
dotted bar, n=7), HLA-DR negative CTLs (red bar, n=8), HLA-DR negative CTLs with the CTLs negative 
fraction (red dotted bar, n=7) and only the CTLs negative fraction (black bar, n=7). (B) Viability of the 
PBMCs in the same culture conditions as in (A). Data are represented as mean ± SEM, *p<0.05. 
 
This experiment corroborates the idea that PBMCs from NACT-responders exhibit cytotoxic 
properties against tumor cells due to the higher expression of HLA-DR in CTLs. Moreover, in 
the light of these results, we hypothesized that in NACT non-responders, the tumor 
microenvironment is immunosuppressive and the tumor cells escape the immune system by 
releasing immunosuppressive cytokines or by expressing immune checkpoints, for instance. 
So, in this case, the antigen presenting cells adopt a more tolerogenic profile, impairing the 
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activation of the CD4+ T cells, and consequently of CTLs (therefore not allowing the increase 
of their HLA-DR level). 
PMBCs from healthy donors, on the other hand, were not in an immunosuppressive 
environment. Thus, we could obtain, in vitro, cytotoxic abilities of sorted HLA-DR negative CTLs 
in the presence of autologous antigen presenting cells and CD4+ T cells. 
 
4. PBMCs from NACT-responders act synergistically with doxorubicin against tumor cells  
 
After verifying that PBMCs from NACT-responders are able per se to decrease the viability of 
breast cancer cell lines (section 2 of this Chapter), we performed a drug assay on the cancer 
spheroids with doxorubicin (one of the chemotherapeutic agents used in NACT regimens), in 
the presence of patients’ PBMCs. Our objective with this experiment was to analyze the 
influence of patients’ PBMCs on drug-tumor elimination. Specifically, we intended to 
determine if the immune cells from NACT-responders’ blood had a synergistic effect with the 
drug and, oppositely, if the immune cells from NACT non-responders’ blood were unable to 
reduce the viability of the breast cancer cells even in the presence of doxorubicin. This would 
replicate the clinical observations.  
Thus, briefly, doxorubicin was added 2 days after the establishment of the co-culture (day 5 
for MCF-7 spheroids and day 8 for MDA-MB-231 spheroids) and the co-cultures were 
maintained for 2 more days (day 7 for MCF-7 spheroids and day 10 for MDA-MB-231 
spheroids, Figure VI-7). It is known that the elimination of tumor cells by chemotherapeutic 
drugs can release tumor antigens to the medium and activate the immune response, in a 
process called immunogenic cell death. So the doxorubicin concentration used in the 3D 
culture (0.5 g/mL for MCF-7 spheroids and 0.1 g/mL for MDA-MB-231 spheroids) was 
chosen after several optimization steps, so that we could observe an effect of the drug on the 
viability of the breast cancer cell lines without compromising considerably the viability of the 
patient-derived PBMCs.  
 




Figure VI-7 NACT-responders’ PBMCs reduce the viability of the breast cancer cell lines and the 
addition of doxorubicin potentiates this effect. (A) Percentage of live MCF-7 cells in monoculture 
(MCF-7, red bar, n=10), in co-culture with NACT-responders’ PBMCs without the addition of 
doxorubicin (R, white bar, n=6), and with the addition of doxorubicin (R(doxo), white dotted bar, n=5), 
in co-culture with NACT non-responders’ PBMCs (NR, black bar, n=5) and with the addition of 
doxorubicin (NR(doxo), grey bar, n=5), at day 7 of culture. (B) Percentage of live MDA-MB-231 cells in 
the same conditions as in (A) (n=11 for MDA-MB-231, n=6 for R, n=4 for R(doxo), n=6 for NR and n=4 
for NR(doxo)) at day 10 of culture. (C) Spheroid area of the different conditions for MCF-7 spheroids 
(n=18 per condition) at day 7 of culture. (D) Spheroid area of the different conditions for MDA-MB-231 
spheroids (n=12 per condition), at day 10 of culture. Data is represented as mean ± SEM, *p<0.05, 
**p<0.01, ***p<0.001.      
 
As previously observed, the addition of NACT-responders’ PBMCs to either MCF-7 or MDA-
MB-231 spheroids has an impact on the viability of the breast cancer cells (p=0.03, Figure VI-
7A-B). NACT-responders’ PBMCs in the presence of doxorubicin also decreased the viability of 
both cell lines, having an obvious synergistic effect, more pronounced for MDA-MB-231 
spheroids (p=0.03, p=0.002, respectively, Figure VI-7A-B). For MCF-7 spheroids, the addition 
of NACT non-responders’ PBMCs even in the presence of doxorubicin has no effect on the 
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viability of the breast cancer cells (Figure VI-7A), highlighting the fact that immune cells 
isolated from non-responder patients are immunosuppressed. The viability of MDA-MB-231 
spheroids suffered a reduction when NACT non-responders’ PBMCs were added in the 
presence of doxorubicin (p=0.03); although no obvious reduction was observed without 
doxorubicin (Figure VI-7B). So, in this case, the loss of viability of the cancer cells is related 
with the effect of the doxorubicin and not with the cytotoxic activity of the immune cells, 
probably because MDA-MB-231 cell line is less resistant to chemotherapeutic agents when 
compared to MCF-7, especially in a 3D conformation (223). The addition of doxorubicin to the 
cell lines (without the co-culture with patient-derived PBMCs) showed a small decrease in 
their viability, although not significantly (data not shown). 
The spheroid area was also quantified for the different culture conditions (Figure VI-7C-D). For 
MCF-7 spheroids, both the addition of NACT-responders’ PBMCs with or without doxorubicin 
decrease the spheroid area (p=0.004 and p=0.04, respectively, Figure VI-7C). On the other 
hand, the addition of NACT non-responders’ PBMCs increased the spheroid area (p=0.003), 
while the addition of doxorubicin to this co-culture had no effect on the spheroid area when 
compared to the monoculture condition (Figure VI-7C). For MDA-MB-231 spheroids, only the 
presence of doxorubicin decreased the spheroid area for both co-culture with NACT-
responders’ PBMCs (p=0.0002) and with NACT non-responders’ PBMCs (p=0.02, Figure VI-7D), 
confirming the viability results.  
Overall, we were able to perform a 3D co-culture assay with spheroids of breast cancer cell 
lines and patient-derived PBMCs. With this platform, we confirmed with an in vitro approach 
that PBMCs isolated from the blood of NACT-responders are cytotoxic and can eliminate 
tumor cells. This effect is potentiated with the addition of the chemotherapeutic agent. On 
the other hand, PBMCs isolated from NACT non-responders maintain their 
immunosuppressed phenotype and are unable to execute cytotoxic functions against tumor 
cells even in the presence of doxorubicin.  
Taking in consideration that PBMCs from NACT-responders have CTLs with higher levels of 
HLA-DR than PBMCs from NACT non-responders, these in vitro assays helped to understand 
the role of these cells in the success of NACT treatment. Additionally, as the results here 
presented mirrored the clinical observations (HLA-DR+ CTLs at the biopsy are essential for the 
chemotherapeutic success), these experiments also validate the potential use of this immune 
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5. PBMCs from NACT non-responders are able to act against tumor cells if previously 
stimulated  
 
Since the difference observed between patients with response to NACT and without response 
to this treatment relies on the presence of activated CTLs (higher levels of HLA-DR, section 3 
of Chapter IV), we asked if the CTLs of NACT non-responders’ PBMCs could be activated ex 
vivo (as previously demonstrated in section 1 of Chapter V), therefore increasing their HLA-DR 
expression, and potentially reverting their immunosuppressed phenotype. 
To achieve this aim we have stimulated patients’ PBMCs with the canonical stimulus of PMA 
and ionomycin. PMA is able to diffuse through the cell membrane and activate protein kinase 
C; whereas ionomycin is a calcium ionophore and triggers the intracellular release of calcium. 
The stimulation with these compounds is receptor-independent and leads to the activation of 
several signaling pathways, likely resulting in T cell activation and production of several 
inflammatory cytokines.  
However, the stimulation with PMA/ionomycin is non-specific and can boost a general 
immune response. Thus, to have a targeted T cell stimulation, similar to a specific antigen 
stimulation, we used a T cell receptor (TCR) stimulus. Namely, we used anti-CD3 (5 g/mL) 
and anti-CD28 (1 g/mL) antibodies with a crosslinking agent (anti-mouse IgG1, 5 g/mL) that 
allow the stimulation of the T cells alone. This specific stimulation could then be used in future 
experiments envisioning a potential clinical use. 
So, PBMCs from NACT-responders and non-responders, previously stimulated as above 
referred, were added to the 3D spheroids, similarly to the protocol mentioned in section 2 of 
this Chapter. 
First, we quantified the percentage of HLA-DR+ CTLs that we could obtain in patients’ PBMCs 
after stimulation. We observed that with both methods, the percentage of HLA-DR+ CTLs 
increased, i.e. CTLs became activated not only in NACT-responders but also in non-responders’ 
PBMCs. However, TCR engagement led to a slightly higher percentage of HLA-DR+ CTLs when 
compared to PMA/ionomycin stimulation (Figure VI-8A).   
In MCF-7 spheroids, the addition of NACT-responders’ PBMCs previously stimulated with 
PMA/ionomycin, significantly decreases the viability of the tumor cells (p=0.004). Additionally, 
when doxorubicin was also used, the percentage of live MCF-7 cells decreased even more 
(p<0.0001), corroborating the synergistic effect of NACT-responders’ PBMCs with the 
chemotherapeutic agent (Figure VI-8B). 
Remarkably, NACT non-responders’ PBMCs were able to transform their previously 
suppressed phenotype in an activated one, when stimulated with PMA/ionomycin, therefore 
becoming cytotoxic and able to decrease the viability of MCF-7 cancer cells (p<0.0001 when 
compared to the condition without stimulation or doxorubicin). When both stimulation and 
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doxorubicin were employed, the viability of MCF-7 cells reduced even further (p<0.0001), 
similar to the effect of NACT-responders’ PBMCs (Figure VI-8B).     
 
Figure VI-8 NACT non-responders’ PBMCs previously stimulated with PMA/ionomyccin or by TCR 
engagement are capable of reducing the breast cancer cell lines’ viability. (A) Percentage of HLA-DR+ 
cytotoxic T cells (CTLs) in PBMCs of NACT-responders (R, white bar, n=12), NACT-responders with a 
canonical stimulation of PMA/ionomycin (R St, white bar, n=10), NACT-responders with TCR 
stimulation (R TCR, white bar, n=4), NACT non-responders (NR, black bar, n=11),  NACT non-responders 
stimulated with PMA/ionomycin (NR St, black bar, n=12) and NACT non-responders with TCR 
stimulation (NR TCR, black bar, n=6). (B) Viability of MCF-7 cells in co-culture with NACT-responders’ 
PBMCs (R, white bars, n=4-11) or with NACT non-responders’ PBMCs (NR, black bars, n=6-11) in the 
Chapter VI - Results 
124 
 
presence/absence of doxorubicin (Doxo), with or without previous canonical stimulation 
(PMA/ionomycin) and with or without previous TCR stimulation. (C) Viability of MDA-MB-231 cells in 
co-culture with NACT-responders’ PBMCs (R, white bars, n=4-10) or with NACT non-responders’ PBMCs 
(NR, black bars, n=6-12) in the presence/absence of doxorubicin (Doxo), with or without previous 
canonical stimulation (PMA/ionomycin) and with or without previous TCR stimulation. (D) IFN- 
production of stimulated NACT-responders’ PBMCs with PMA/ionomycin (R (St), white bar, n=11) or 
with TCR stimulation (R (TCR), white bar, n=4); and stimulated NACT non-responders’ PBMCs with 
PMA/ionomycin (NR (St), black bar, n=12) or with TCR stimulation (NR (TCR), black bar, n=6) after 4 
days of co-culture with MCF-7 cells. (E) IFN- production of stimulated NACT-responders’ PBMCs with 
PMA/ionomycin (R (St), white bar, n=6) or with TCR stimulation (R (TCR), white bar, n=4); and 
stimulated NACT non-responders’ PBMCs with PMA/ionomycin (NR (St), black bar, n=9) or with TCR 
stimulation (NR (TCR), black bar, n=6) after 4 days of co-culture with MDA-MB-231 cells. Data is 
represented as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
When PBMCs either from NACT-responders or non-responders were TCR-stimulated, results 
were similar to the ones abovementioned. Namely, NACT-responders and non-responders’ 
PBMCs reduced the viability of MCF-7 cells (p=0.01 and p=0.0003, respectively, Figure VI-8B). 
The addition of doxorubicin had a synergistic effect with the TCR stimulation for NACT-
responders’ PBMCs and especially for non-responders’ PBMCs (p=0.049 and p=0.0002, 
respectively, Figure VI-8B).  
Regarding 3D co-culture systems with MDA-MB-231 cell line, similar results were obtained 
(Figure VI-8C). Namely, PMA/ionomycin stimulated PBMCs, either from NACT-responders or 
non-responders, decreased significantly the percentage of viable cancer cells, compared to 
unstimulated/no doxorubicin condition (p=0.0002 and p<0.0001, respectively, Figure VI-8C). 
As previously reported, the addition of the chemotherapeutic agent (doxorubicin) to the 
stimulated PBMCs further improved the anti-tumor effect of these cells (p<0.0001 for co-
culture with NACT-responders and non-responders, Figure VI-8C), corroborating, also in this 
cell line, the synergistic effect between activated immune cells and doxorubicin. 
With the TCR stimulation we could obtain the same results. Actually, co-culture with NACT-
responders or non-responders’ PBMCs led to a significant reduction of the breast cancer cell 
line viability (p=0.049, p=0.0001, respectively, Figure VI-8C). Again, the addition of doxorubicin 
proved the synergistic effect with stimulated PBMCs from both groups of patients, in reducing 
the viability of cancer cells (p=0.002 for co-culture with NACT-responders’ PBMCs and 
p=0.0001 for co-culture with NACT non-responders’ PBMCs, Figure VI-8C).  
An additional readout of the stimulation of the PBMCs and, consequently increased activated 
CTLs (higher percentage of HLA-DR+ CTLs), is their ability to release IFN-. Hence, we have 
quantified this molecule in the supernatant of the MCF-7 and MDA-MB-231 3D co-cultures 
(Figure VI-8D-E). As expected, stimulated PBMCs (with PMA/ionomycin or by TCR 
engagement) from either NACT-responders or non-responders produce IFN-, in both cell lines 
co-culture.  
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However, the PBMCs from NACT-responders stimulated with PMA/ionomycin are able to 
release higher levels of IFN- to the medium when compared to NACT non-responders’ PBMCs 
with the same stimulation method (p=0.01 for MCF-7 spheroids and for MDA-MB-231 
spheroids, Figure VI-8D-E), showcasing the hardwired capacity of PBMCs derived from NACT-
responders’ patients to become highly activated. The same was not observed for PBMCs 
stimulated by TCR engagement. Actually, there was no difference in the IFN- detected in the 
3D culture with NACT-responders’ PBMCs or non-responders’ PBMCs with TCR stimulation for 
either co-culture with MCF-7 (Figure VI-8D) or MDA-MB-231 cell lines (Figure VI-8E). This 
result further illustrates that TCR engagement is sufficient to activate equivalently the PBMCs 
from both NACT-responders and non-responders.          
When comparing both stimulation methods, we concluded that not only the TCR engagement 
is able to increase the percentage of HLA-DR+ CTLs in PBMCs derived either from NACT-
responders and non-responders’ blood (Figure VI-8A), but also leads to a higher production of 
IFN- when PBMCs from both groups of patients are in co-culture with breast cancer cell lines 
(Figure VI-8D-E). Nevertheless, stimulation by TCR engagement of NACT non-responders’ 
PBMCs resulted in slightly less reduction of the tumor cells’ viability, when compared to 
PMA/ionomycin stimulated PBMCs 
 
Taken together, the results obtained in this section highlight the fact that it is possible to 
effectively stimulate CTLs and boost their anti-tumor activity, even in CTLs isolated from the 
blood of NACT non-responders, which present a higher immunosuppressed phenotype. This 
suggests that the stimulation of the immune cells could be a potential therapeutic strategy to 
be given in combination with NACT agents, particularly for non-responder breast cancer 
patients and ameliorate the treatment of conventional chemotherapy (Saraiva et al, 
manuscript in preparation).  
     
6. Immune checkpoint blockade combined with doxorubicin is not sufficient to revert the 
immunosuppressed phenotype of NACT non-responders’ PBMCs  
 
As previously observed, we were able to increase the immune response/tumor cell 
elimination of NACT non-responders’ PBMCs with the PMA/ionomycin stimulation and by TCR 
engagement. Nevertheless, in a search for a therapeutic strategy already utilized in a clinical 
setting, we used immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1. Although 
this approach is still not used in early breast cancer (it is only accepted for metastatic TNBC), 
it is widely administered in lung cancer and melanoma patients, for instance. It is known that 
tumor cells are able to escape the immune system and can employ the immune checkpoints 
to dampen CTLs cytotoxic function. Briefly, tumor cells can express PD-L1 which binds to PD-
1 present in the surface of CTLs. Considering that CTLs from NACT non-responder patients are 
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likely to be more affected by the inhibitory immune checkpoints, our rationale was to use 
antibodies against either PD-1 or PD-L1 to impede the suppression on their CTLs, potentially 
provoked by the tumor cells, and consequently increasing the activation level of these cells 
(Figure VI-9).  
 
 
Figure VI-9 Immune checkpoint blockade with anti-PD-1 and anti-PD-L1 is not sufficient to release 
the immunosuppressive phenotype of NACT non-responders’ PBMCs to be able to reduce the 
viability of breast cancer cells. (A) Representation of flow cytometry analysis of PD-L1 expression on 
both breast cancer cell lines – MCF-7 and MDA-MB-231. (B) Viability of MDA-MB-231 cells in co-culture 
with NACT non-responders’ PBMCs (NR, black bars, n=6) in the presence of different combinations 
between doxorubicin, anti-PD-1 and anti-PD-L1. Data is represented as mean ± SEM, **p<0.01. 
 
First of all, we analyzed the expression of PD-L1 in the breast cancer cell lines used previously 
– MCF-7 and MDA-MB-231 (Figure VI-9A). Although both were positive for PD-L1, only 
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approximately 5% of MCF-7 cells were positive for this surface marker, whereas more than 
95% of MDA-MB-231 were PD-L1 positive (Figure VI-9A). Thus, we decided to use immune 
checkpoint blockade only in this cell line. Moreover, due to the need to search for alternative 
strategies especially for NACT non-responder patients, for this experiment we decided to 
focus only in the PBMCs isolated from these patients to perform the 3D co-culture. We used 
both antibodies (anti-PD-1 and –PD-L1) alone or in combination with doxorubicin in the same 
platform as previously explained.  
In MDA-MB-231 spheroids (Figure VI-9B), the percentage of viable cells did not reduce when 
the blocking antibodies alone were added to the co-culture. With the addition of doxorubicin 
in combination with anti-PD-1 or PD-L1, NACT non-responders’ PBMCs were capable to 
decrease the tumor cells’ viability (Figure VI-9B). Nevertheless, although the cell line used was 
PD-L1 positive, the potential blockade of PD-1/PD-L1 axis per se did not impact the viability of 
the cancer cells. 
Moreover, as an alternative readout of the possible CTLs’ activity, due to the release of the 
immunosuppressive brakes possibly employed by immune checkpoints, we also analyzed IFN-
 levels in the supernatant of the 3D co-culture in this experiment. However, no visible IFN- 
secretion was detected in the co-culture of MDA-MB-231 cells with NACT non-responders’ 
PBMCs in the presence of immune checkpoint inhibitors, corroborating that the blockade of 
PD-1/PD-L1 axis did not contribute to improve of CTLs’ function. 
The obtained results could be explained by the fact that all the CTLs isolated from the NACT 
non-responders’ PBMCs used in these assays had a low percentage of PD-1 at their surface. 
Actually, approximately 5% of the CTLs were PD-1 positive, which could not be sufficient to be 
influenced by the immune checkpoints’ blockade here tested (Figure VI-10). 
 
Figure VI-10 PD-1 positive cytotoxic T cells (CTLs) are scarce in immune cells isolated from patients’ 
blood. Percentage of PD-1 positive CTLs in PBMCs from NACT-responders (R, white bar, n=4) and from 
NACT non-responders’ PBMCs (NR, black bar, n=4). Data is represented as mean ± SEM.  
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Nevertheless, we have to take into account that at least some breast cancer patients could 
have increased PD-1 expression in their tumor infiltrating CTLs (even if not in circulating CTLs). 
Therefore, we cannot exclude that immune checkpoint blockade, alone or in combination with 
chemotherapeutic agents, could be advantageous in particular cases.  
In addition, we demonstrated that the 3D model here establish is also a remarkable tool to 
test several immunomodulatory drugs or antibody combinations, in a throughput manner. In 
fact, breast cancer patients, with immunosuppressed CTLs, where the suppressing PD-1/PD-
L1 axis is absent, might have alternative suppressive mechanisms increased, such as high 
expression of CTLA4 or Tim3 in T cells. Therefore, we can use this 3D platform to assess the 
response to other therapeutic strategies, namely, the combination of chemotherapy and 
other blocking antibodies, such as the anti-CTLA4, -Tim3 or – Galectin 9 (Tim3 ligand in tumor 
cells), to name a few.  
 
Altogether, we have demonstrated in this chapter that we are able to recapitulate clinical 
observations, such as the response to neoadjuvant chemotherapy, with an in vitro approach. 
This platform developed in a 3D structure composed by breast cancer cell lines and patient-
derived immune cells (PBMCs) revealed that PBMCs isolated from NACT-responders are 
cytotoxic against tumor cells; while PBMCs isolated from NACT non-responders did not show 
this effect. The immunosuppressive effect of NACT non-responders’ PBMCs could be reverted 
by the immune stimulation with PMA/ionomycin and/or by TCR engagement. This platform 




















































Chapter VII – General Discussion  
 
Breast cancer is the most common cancer type in women worldwide and accounts for up to 
15% of cancer-related deaths in women around the globe (224). Currently, breast cancer 
patients have approximately an 85 to 99% overall survival (depending on the breast cancer 
subtype) when the disease is in an early stage (141). When the disease is locally advanced, i.e. 
tumors with a size of >2 cm and/or with disease extended to the axillary lymph node, the 
treatment relies on neoadjuvant chemotherapy (NACT), independently on the breast cancer 
subtype. Although NACT is effective in reducing the size of the primary tumor to allow for 
more conservative surgery instead of mastectomy, disease down-staging and pathological 
complete response (pCR) is achieved by less than 50% of the patients (142,149). For instance, 
from the total of 52 breast cancer patients that performed NACT whose samples we have 
included in the biomarker study, only 20 patients indeed responded to this treatment, 
meaning that 62% of the patients received this aggressive treatment for 6 months without any 
benefit.  
As such, there is an urgent clinical need to find new biomarkers that could predict response 
to NACT and, additionally, to find new and alternative therapies for NACT non-responders, 
since the alternative first line treatment nowadays is surgery which is not possible in all cases. 
Recently, there has been an international effort to find new predictive markers for response 
to NACT. These markers have been mainly related to immune cell infiltration. Namely, tumor 
infiltrating lymphocytes (TILs) has been pointed as predictive biomarkers of response in a 
neoadjuvant setting (152,154–156). However, while some studies use this biomarker for the 
three subtypes of breast cancer, others only found a positive correlation with response for 
TNBC patients. Additionally, combining all the lymphocytes for prediction seems 
counterintuitive since there are effector lymphocytes with cytotoxicity capacity against tumor 
cells (such as the cytotoxic T cells – CTLs), but also immunosuppressive and tumor-promoting 
lymphocytes, namely regulatory T cells (Tregs). Another issue is the fact that TILs are assessed 
by immunohistochemistry and several antibodies can be used to detect TILs. Although a TILs 
working group was created to standardize TILs assessment (151), there is no translation to a 
clinical setting and TILs as a predictive factor in breast cancer response to NACT is not yet used.  
Another predictive marker that has been studied is the neutrophil to lymphocyte ratio (NLR), 
analyzed in circulation. Similarly to the TILs, some studies use NLR for the prediction of NACT 
response for the three subtypes of breast cancer, while others use only for TNBC patients or 
only ER+ breast cancer patients. Moreover, the cut-off point or the threshold for NLR is 
controversial and, again, no translation for a clinical setting was yet established (163–169).  
Hence, in this thesis, we aimed to uncover new biomarkers that could be used to predict 
breast cancer patients' response to NACT. To tackle this question, we also focused on the 
infiltration of the immune cells to the tumor bed, but instead of analyzing all lymphocytes 
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together, have divided them into different populations and analyzed different activation 
and/or suppression molecules. Our main hypothesis was that lymphocytes, and especially the 
anti-tumor CTLs per se, could not have a predictive function since their anti-tumor capacity 
could be suppressed by an impeditive tumor microenvironment. Thus, more than the 
presence of CTLs, their activation status could be important. 
In this thesis we also establish a new platform, using 3D cellular structures, to clarify in vitro 
the clinical results and develop alternative therapeutic strategies for NACT non-responders. 
To achieve both aims we have used fresh patients’ material, from biopsies, surgical specimens 
and blood.  
 
1. HLA-DR expressing cytotoxic T cells as a biomarker of response to neoadjuvant 
chemotherapy in breast cancer patients 
 
Considering that HLA-DR-expressing T cells could distinguish breast cancer aggressiveness (see 
Figure IV-1) but were not different when patients’ age, body mass index, and tumor 
histological grade, dimension and breast cancer subtype were stratified (see Figures IV-3-7), 
we wanted to investigate whether this marker could also distinguish breast cancer patients’ 
response to NACT. For this, we have evaluated a cohort of 30 patients and analyzed their 
biopsies before NACT implementation. After NACT we divided the patients into responders 
and non-responders. Our criteria for this separation was different from the RECIST (Response 
Evaluation Criteria in Solid Tumors) criteria, which is used in some clinical studies. In RECIST, 
the response is divided into complete response, partial response, progressive disease and 
stable disease (225). Complete response is evaluated as no tumor and non-pathological lymph 
nodes present; partial response comprises tumors with at least 30% reduction in diameter; 
the progressive disease is used when the tumor has a diameter increase of at least 20% or 
when new lesions occur; stable disease refers to when no tumor diameter change occurred. 
Although these criteria were published to standardize how clinicians evaluated response, 
there are still few clinical trials or biomarker studies that use these criteria, as most of them 
prefer to use pCR and no-pCR.  
In the case of the cohorts evaluated in these thesis, no progressive disease nor stable disease 
was found. As such, we decided to use a dichotomy of responder and non-responder, instead 
of dividing in complete or partial response. Actually, since pCR following NACT is difficult to 
occur (142,149), we decided to join patients who achieved pCR and patients bearing no lymph 
node metastasis and with a tumor mass less than 10% of the initial mass, which is clinically a 
significant response to treatment. 
As it occurred for the aggressiveness status, the only difference found was for the expression 
level of HLA-DR in T cells, especially in CTLs. which was higher in NACT-responders when 
compared to NACT non-responders (see Figure IV-8). Interestingly, we observed that this 
biomarker segregated NACT-responders from non-responders independently of the breast 




cancer subtype, which is an advantage when comparing to other predictive biomarker studies, 
only focused on TNBC patients. This attention can be explained by the fact that TNBC has no 
targeted therapy and, as such, there is an effort to find new biomarkers of response and 
alternative treatments especially for breast cancer patients with this subtype. Nevertheless, 
we have to take into account that TNBC represents around 15% of all breast cancer cases and 
that ER+ and HER2+ breast cancer patients are also selected for NACT, frequently without any 
advantage. Actually, in our first cohort of patients, approximately 60% of NACT non-
responders were not TNBC patients.  
In order to find a threshold for HLA-DR-expressing CTLs, we performed a ROC curve (Table IV-
1). With this analysis, we obtained a threshold of 8.943, value beneath which patients would 
be NACT non-responders, with high sensitivity (94.12%) and specificity (100%). Of the 30 
samples evaluated, only one did not fit the model.  
We also analyzed a few post-NACT surgical specimens of non-matched patients. We observed 
that even after the chemotherapy treatment, patients that responded to the treatment had a 
higher expression level of HLA-DR in CTLs, contrarily to non-responders. As referred in the 
introduction, chemotherapeutic agents can modulate the immune response, either by 
inducing the immunogenic cell death of tumor cells, which will consequently increase anti-
tumor specific responses, or by recruiting CTLs and pro-inflammatory myeloid cells and 
eliminating Tregs. Altogether, chemotherapy should induce activation of CTLs, therefore 
increasing their HLA-DR level and effector function, contributing to the elimination of tumor 
cells. Interestingly, here it seems that in NACT non-responders the chemotherapy is not able 
to boost an anti-tumor immune response, probably due to the enrichment of suppressive 
mechanisms, evidencing the importance of an immune infiltrate with particular features, i.e 
high frequency of activated CTLs/poor immunosuppressive mechanisms, to assist NACT 
treatment. Nevertheless, to truly observe the chemotherapeutic effect on the HLA-DR 
expression level in CTLs, both biopsies and matched post-NACT surgical specimens (from the 
same patient) should have been analyzed. However, we could not performed this analysis due 
to limitations in obtaining these samples.  
A biomarker study should follow the REMARK (Reporting recommendations for tumor marker 
prognostic studies) criteria, since it was an international effort to standardize how biomarker 
studies should be reported to have less non-translatable biomarkers (196). For that, validation 
in a second independent cohort and specific statistical evaluation should be performed. A 
validation, so far with 22 patients, corroborate that HLA-DR-expressing CTLs are able to 
differentiate between responders and non-responders (see Figure IV-12). Using the threshold 
value calculated in the ROC curve of the first cohort, only 4 patients did not fit in the 
parameters, by a short margin. As such, we calculated a new ROC curve to assess the 
differences in this model, and the threshold was different by only 3 decimal points (8.943 and 
8.63, see Table IV-2).   
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Moreover, by grouping all the pre-NACT analysis (30 from the initial cohort and 22 from the 
validation cohort), we assure that HLA-DR-expressing CTLs is a strong factor for response 
prediction, since it is the only statistical significant marker by univariable analysis (see Table 
IV-3) and it is an independent predictive factor by multivariable analysis (see Table IV-4 and 
Figure IV-13). This means that even when taking into account patients’ age, breast cancer 
subtype and other tumor immune-related markers, HLA-DR-expressing CTLs will be a clinically 
relevant predictive biomarker. Therefore, even with a small sample population size we were 
able to create a predictive statistical model that allow us to infer a priori  if a patient will 
benefit or not from NACT (Figure IV-14).  
Although HLA-DR expression level in CTLs is a validated and independent predictive factor for 
the response to NACT, this treatment is administered only to approximately 20-25% of the 
breast cancer patients in the hospitals with whom we collaborate. Hence, a prognostic marker 
that correlates with survival, should also be considered to embrace all breast cancer patients, 
independently on the treatment implemented. As such, we did an analysis with patients that 
undergone NACT and patients that first undergone surgery followed by adjuvant 
chemotherapy and performed a 3 years follow-up (see Figures IV-15 and 16). Intriguingly, 
patients with an HLA-DR expression level above the threshold calculated in the ROC curve of 
the first cohort show a higher progression-free survival. Nonetheless, for significant results, 
more patients should be followed-up. Additionally, no differences were found for overall 
survival. This last result can be explained by the fact that overall survival in early breast cancer 
patients is very high, accounting for approximately 95% of patients in the first years following 
diagnosis (141,224). For a more conclusive result, patients should be followed for 5-10 years. 
In conclusion, HLA-DR expression level in CTLs besides being predictive for NACT response, it 
also showed a tendency to be prognostic (correlated with progression-free survival) for breast 
cancer patients where NACT or surgery followed by adjuvant chemotherapy was 
administered. 
HLA-DR is an antigen presenting molecule expressed at high levels on professional antigen 
presenting cells, but its expression on effector T lymphocytes upon their activation has also 
been intensively described in some diseases, such as auto-immune diseases and viral 
infections (176,177). The increase of HLA-DR at CTLs’ surface, upon stimulation, could also be 
required to boost the anti-tumor immune response. Indeed, HLA-DR+ CTLs were found to have 
the machinery needed for antigen processing and loading on HLA-DR molecules and, 
additionally, could express CD86 and CD80, which are the co-stimulatory molecules of antigen 
presenting cells that are necessary for the proper T cell effector function (37). Moreover, it 
was described that T cell-T cell synapsis occurs to allow T cells to secrete IFN- towards each 
other, compelling the differentiation of more protective T cells (76). These T cell-T cell 
interactions and mutual antigen presentation can be essential for mounting a suitable anti-
tumor response. 
HLA-DR molecule, by itself, assessed in tumor cells, has been reported to serve as a favorable 
prognostic marker for other types of cancers, such as colorectal carcinoma (226) or glioma 




(227). It was even shown that HLA-DR+ melanoma cells predict the response to anti-PD-1/PD-
L1 immunotherapy (228). However, to our knowledge, the expression of HLA-DR in CTLs, 
besides its extensive application in the study of viral infections and chronic inflammatory 
diseases, was never recommended as a biomarker in cancer. 
The fact that not all tumor infiltrating CTLs acquire HLA-DR in a process of T cell activation, 
despite being in the presence of tumor cells, can be multifactorial. As previously stated, 
tumors have the capacity to escape the immune system. This escape can be performed, for 
instance, by the release of anti-inflammatory cytokines (such as IL-10 or TGF-), or by the 
activation of immune checkpoints, such as the PD-1/PD-L1 axis, both will prevent the 
cytotoxicity function of CTLs (Figure VII-1). When these escape mechanisms are not yet 
engaged, CTLs can become activated when they recognize an antigen, and produce effector 
molecules such as Granzyme B, leading to tumor cell elimination (Figure VII-1). 
 
Figure VII-1 Mechanisms of CTLs’ activation and deactivation when encountering a tumor cell. 
Deactivation or suppression can be induced by escape mechanisms of tumor cells, such as the 
production of anti-inflammatory cytokines (IL-10 and TGF-) or the activation of immune checkpoints, 
such as PD-L1. T cell activation occurs when T cells recognize an antigen and these inhibitory 
mechanisms are not released. Activation leads to an increase in HLA-DR production and the release of 
effector cytotoxicity molecules that will eliminate tumor cells. Figure performed in Biorender.  
 
Actually, we observed that HLA-DR expression level in CTLs negatively correlated with 
immunosuppressive and pro-tumor molecules released by tumor cells, such as TGF- PD-L1, 
IL-6, IL-8, IL-1, and IL-23/IL-12 (see Figure IV-17). As stated in the introduction, tumor cells 
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have the capacity to produce all these cytokines to help in tumor-promoting actions, such as 
the production of metalloproteinases (which are enzymes important for extracellular matrix 
degradation and consequent tumor invasion), angiogenesis (to induce tumor growth with the 
arrival of more nutrients) and activation of immunosuppressive cells, such as M2 macrophages 
or Tregs that will prevent CTLs cytotoxicity function.  
As such, we may say that the HLA-DR expression in CTLs is a reflection and a consequence of 
the general tumor immune status. Indeed, an immunosuppressed environment will be unable 
to stimulate an appropriate immune response and should not give rise to high levels of HLA-
DR in CTLs. As cell-to-cell contact and tumor-specific antigen presentation by antigen 
presenting molecules are required to elicit a specific cytotoxic T cell response against the 
tumor cells, we may infer that, in vivo, the antigens presented by tumor cells, alongside with 
the soluble factors, contribute to CTLs’ effector function.  
 
Altogether, the results from Chapter IV respond to our main objective – to find a new 
biomarker that could predict breast cancer patients’ response to NACT. To highlight the 
importance of this immune trace – HLA-DR-expressing CTLs - and how it can differentiate 
between responders and non-responders, we elaborated the scheme of Figure VII-2.  
When comparing HLA-DR-expressing CTLs to other biomarkers, such as TILs or the NLR it has 
several advantages. The drawbacks of TILs and NLR are (152,154–156), (163–169): 
- their effectiveness is mainly on one subtype of breast cancer (TNBC); 
- the fact that they are represented as a single population of cells, when in fact they 
encompass distinct immune cell populations with different functions, for instance, 
pro and anti-tumor T cells; 
- analysis based on immunohistochemistry (TILs) or blood sampling (NLR);  
- non-reproducible technical issues to assess the biomarkers – different antibodies 
for TILs or different cut-off points for NLR; 
- the fact that some studies claim that they are predictive, while others claim they 
are only prognostic. 
HLA-DR+ CTLs goes further as a predictive biomarker, firstly because it is a population of T 
cells with cytotoxic properties (CTLs) against tumor cells, which are activated (expressing high 
levels of HLA-DR). These activated CTLs reflect the overall immune status present in the tumor 
microenvironment, contrarily to TILs or the NLR. In fact, even if the tumor is enriched with 
effector T cells, they can be inhibited by molecules expressed by the tumor cells or by 
regulatory immune cells. As such, only the activated (HLA-DR+) CTLs will lead to anti-tumor 
immune responses. 
Secondly, this biomarker is analyzed by flow cytometry, and although we cannot distinguish 
intratumor CTLs from stromal CTLs, as it is possible with immunohistochemistry (IHC), it is 
more representative of the whole biopsy than IHC, where only a slice of the biopsy mass, and 
not the whole 3D conformation, is used. Actually, several reports claim that stromal TILs are 




more important than the tumor infiltrating to predict response to NACT (reviewed in (229)), 
while others report the opposite (230). With the flow cytometry, we can quantify both 
together, reducing the heterogeneity between studies.  
Thirdly, it is a powerful predictive factor, which is possible to observe in two different cohorts 
of patients, by the ROC curve parameters, the univariable and the multivariable analysis. 
Moreover, it is an immune trait that also show promising results as a long-term prognostic 
biomarker. Nevertheless, to achieve that, a higher follow-up with more patients and during 5-
10 years needs to be performed.  
Lastly, it is a predictive factor independently of the breast cancer subtype and other clinical 
parameters, such as patients’ age, reflecting the capacity to be used in all breast cancer 
patients submitted to NACT.   
 
Figure VII-2 Model of HLA-DR-expressing CTLs as a predictive biomarker for NACT response. In 
patients with response to NACT, the tumor is infiltrated with several types of immune cells, including 
cytotoxic T cells (CTLs) that are active and express high levels of HLA-DR. Activated CTLs release 
cytotoxicity-related molecules, such as Granzyme B and Perforin, inducing tumor cell death. In NACT 
non-responders, the tumor can still be infiltrated with different immune cells, but due to the release 
of immunosuppressive molecules by the tumor cells, CTLs are inhibited and the level of HLA-DR is 
reduced. Figure performed in Biorender.  
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The main limitation of this study is the low sample size when comparing to biomarker studies 
that are conducted in parallel with clinical trials. However, we have to take into consideration 
that the patients who performed NACT are approximately 20% of the breast cancer patients 
enrolled in the hospitals with whom we collaborate to obtain the biopsy samples (HCD and 
HVFX). Additionally, we have used fresh biopsies and for that the radiologists have to perform 
an extra biopsy shot, besides the biopsy for Pathological diagnostic. After the biopsy is 
collected, we have to wait at least 6 months (the duration of NACT) to obtain the response to 
the treatment. Nevertheless, even with a small sample size, we have obtained remarkable 
results with great statistical power that allow the elaboration of a robust model, emphasizing 
that HLA-DR-expressing CTLs, assessed by flow cytometry, have a great potential to be used 
in clinical practice as a biomarker to predict NACT response.  
Nevertheless, the future implementation of this biomarker in a clinical setting would be 
challenging. Although analyzing HLA-DR-expressing CTLs by flow cytometry is an advantage to 
obtain statistically relevant results, more representative from the whole biopsy (much more 
cells are analyzed per sample), this method is not routinely used in Hospitals' Pathology 
departments, as IHC is, for instance. Nevertheless, due to the significant results emphasized, 
we believe that an implementation in a clinical setting would be truly valuable to breast cancer 
patients. Our idea for the pipeline used to assess HLA-DR-expressing CTLs prior to treatment 
implementation is described in Figure VII-3. If patients have a low HLA-DR expression level in 
CTLs, different therapeutic strategies could be implemented, such as, a combination of 
chemotherapy with immune checkpoint inhibitors (as the PD-1/PD-L1 axis) or other immune 
modulators, even personalized vaccines or adoptive T cell transfer with activated autologous 
CTLs. Of course, none of these alternative treatments are yet optimized for breast cancer 
patients (although some new strategies are in clinical trials), but the implementation of this 
analysis in a near future at least could help clinicians to promptly direct patients with operable 
tumors to surgery, instead of recommend a 6 month-regime of an aggressive chemotherapy 
without any benefit for the patient. 
To further corroborate our claims, we are still enrolling patients for the validation cohort to 
have a stronger representation of breast cancer patients. Additionally, we have optimized a 
platform to demonstrate in vitro that HLA-DR+ CTLs are required for NACT success and also 
analyze new therapeutic strategies that could help NACT non-responder patients (Chapter VI).  
 





Figure VII-3 Flowchart of clinical decisions that could be implemented with the use of HLA-DR-
expressing CTLs as a predictive biomarker to assess breast cancer patients’ response to NACT. In 
biopsies of breast cancer patients (candidates to perform NACT) immune profiling is executed by flow 
cytometry. The patients are then divided into bearing tumors with high expression level of HLA-DR in 
CTLs and low expression level of HLA-DR in CTLs. The first group of patients has a prediction for a good 
response to NACT since they present an effective anti-tumor immune response. As such, conventional 
NACT can be administered to these patients. Patients with low levels of HLA-DR in CTLs have a deficient 
anti-tumor immune response and, consequently, a prediction for a poor response to NACT. These 
patients should be directed to surgery, if possible. If not possible, alternative therapeutic strategies 
should be implemented, such as adoptive T cell transfer, the use of standard chemotherapy combined 
with immune checkpoint inhibitors or personalized vaccines. 
 
2. HLA-DR+ cytotoxic T cells produce cytotoxic molecules and exhibit effector memory T cell 
markers  
 
Recent reports highlighted the importance of an analysis of the variations between a T cell 
subset profile/function (memory, effector, exhaustion) for the development of individual T 
cell-based immunotherapies. Thus, in order to better understand the profile of HLA-DR+ CTLs, 
envisaging their potential therapeutic value, we performed a thorough characterization of 
these cells, comparing to HLA-DR negative CTLs. First of all, we used isolated cells from the 
peripheral blood of patients and healthy donors to conduct these experiments, since the 
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material provided by biopsies or surgical specimens was limited. We observed that a culture 
of ex vivo peripheral blood mononuclear cells (PBMCs) in contact with a stimulus could 
increase the percentage of HLA-DR+ CTLs in NACT-responder patients but surprisingly, also in 
non-responders (see Figure V-1). Additionally, the stimulated PBMCs could produce higher 
levels of IFN-, which is the main cytokine produced by activated CTLs (see Figure V-1). 
We also observed that this increase in HLA-DR+ CTLs was possible not only with a canonical 
stimulation, but also when PBMCs are in the presence of tumor cells (in this case a breast 
cancer cell line – Hs 578T) or even only in the presence of the factors released by the tumor 
cells to the extracellular medium (see Figure V-2). This result suggest that, in the tumor 
microenvironment, CTLs respond not only to the cellular contact derived from the connection 
between the T cell receptor (TCR) in CTLs and MHC I bearing antigens in tumor cells, but also 
to the soluble molecules released by the tumor cells. These molecules could be, for instance, 
cytokines, which mirrors our clinical result (see Figure IV-17) showing that the presence of 
immunosuppressive cytokines produced by the tumor cells was negatively correlated with the 
expression level of HLA-DR in CTLs.  
The production of IFN- above described was induced in PBMCs by stimulation in vitro. We 
also assessed the levels of IFN- and Granzyme B directly in both intratumor and circulating 
HLA-DR+ CTLs (see Figure V-3). Both molecules were highly produced by HLA-DR+ CTLs when 
compared to HLA-DR negative CTLs, highlighting that HLA-DR is indeed a marker of T cell 
activation. Moreover, TNF-, Perforin and Eomes were up-regulated in HLA-DR+ CTLs, 
whereas T-bet was down-regulated in these cells (see Figure V-4). Effector T cells are defined 
as T-bethigh/Eomeshigh (206), which is not representative of these cells. With the profile T-
betlow/Eomeshigh, HLA-DR+ CTLs could be either exhausted T cells, central memory (TCM), 
effector memory T cells (TEM) or terminally differentiated effector T cells (TTE) (206). Additional 
flow cytometry analysis (see Figure V-6, 7) revealed that the majority of HLA-DR+ CTLs are 
proliferative cells (high levels of Ki67) and some present exhaustion markers, such as PD-1. 
This result points out that HLA-DR+ CTLs are in distinct levels of activation, and at least part of 
these cells could become exhausted due to the constant contact with tumor antigens. Indeed, 
in the past years, T cell exhaustion has been a topic of debate. While in the past exhausted 
CTLs were characterized as CTLs that had lost the capacity to produce cytokines (namely IFN-
), had reduced proliferation and cytotoxicity function; now, these cells were shown to still 
have the capacity to release cytotoxic molecules and kill target cells (215,231). However, the 
reduced proliferative capacity of exhausted CTLs is still consensual in the field. As we observed 
that most HLA-DR+ CTLs are positive for Ki67, these cells cannot be typical exhausted T cells. 
TCM cells were shown to have high levels of CD127, low levels of HLA-DR and no Granzyme B 
production (218). As such, HLA-DR+ CTLs are also not representative of TCM subtype. The 
differences between TEM cells and TTE CTLs are based on CD127 (low expression in TEM and no 
expression in TTE), Ki67 (only present in TEM), CD103 (only present in TEM) and HLA-DR (only 
present in TEM) (218). Moreover, while both TTE and TEM produce IFN-, only TEM is able to 
produce TNF- (218). Hence, HLA-DR+ CTLs appear to be closer to a TEM phenotype.  




Nevertheless, additional markers should be used to classified HLA-DR+ CTLs as effector 
memory CTLs. For instance, CD45RO that marks memory immune cells should be assessed. 
CCR7 and CD62L, which are upregulated in TCM, are not expressed in TEM and could also 
improve the segregation of these subsets of memory T cells. CD28 is highly expressed in TEM 
and TCM but not in TTE. Besides continuing the characterization of the surface markers, a more 
detailed transcriptional profile should also be pursued. Actually, the transcription factor Hobit 
is mainly expressed in TRM; TCF-1 is mainly present in TCM; KLF7 is upregulated in TEM, and KLF2 
is downregulated in TRM and upregulated in TEM (232,233). Increasing the complexity of the 
markers and transcription factors analyzed it will be possible to better discriminate if HLA-DR+ 
CTLs are indeed TEM.  
Besides bearing differences in the surface markers and gene expression, the different CTLs 
subtypes have distinct metabolic states. Naïve T cells that have never encountered an antigen 
have low metabolic demand and perform mainly oxidative phosphorylation to obtain energy 
(234). On the opposite, after activation by antigen presentation, effector CTLs have a high 
energy demand and rewire their metabolism to rely mainly on aerobic glycolysis with lactate 
production (235). Memory CTLs also have different metabolic demands. Although they are in 
a steady-state, TEM cells have a high mitochondrial mass to rapidly produce energy after 
antigen encounter (235,236). Similarly to effector CTLs, TEM cells rely on aerobic glycolysis and 
also oxidative phosphorylation (235,236). The other memory subtypes of T cells, such as TCM 
and TRM cells, on the other hand, have a metabolic adaptation based on fatty acid oxidation 
(235). Hence, the analysis of the gene expression of different enzymes involved in the distinct 
metabolic pathways can be another way to better identify to which category HLA-DR+ CTLs 
belong to.   
Although effector CTLs have a high cytotoxic capacity and are the ultimate anti-tumor immune 
cell population, they undergo fast apoptosis after performing their function. Additionally, the 
constant contact with antigen stimulation will turn the effector CTLs in exhausted with a 
progressive loss of their effector function. Besides effector and exhausted cells, a percentage 
of CTLs are memory T cells.  
Tumor-immune microenvironment reports in the literature have been reiterating that from 
the different memory subsets, tissue resident memory T cells are the ones with the greatest 
capacity to act against tumor cells (207,208), despite being unable to recirculate. Although 
these cells are better adapted to the tumor microenvironment and can release cytotoxicity-
related molecules, they are also able to produce IL-17 (237), which has been shown to induce 
the production of metalloproteinases, essential for the extracellular matrix degradation and 
tumor invasion (99). Additionally, IL-17 is known to stimulate Tregs, which would inhibit CTLs 
cytotoxicity function (94).  
Effector memory T cells are the memory subtype with higher cytotoxic phenotype, 
proliferative capacity and can efficiently eliminate target cells (206). The phenotype of 
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effector memory CTLs is an advantage in the process of tumor cells elimination, since they are 
long-lived, retain in inflamed tumors and are capable of performing cytotoxic functions (206). 
 
3. Clarification of the role of HLA-DR+ cytotoxic T cells in NACT response and optimization of 
alternative therapeutic strategies  
 
In order to better understand the role of HLA-DR+ CTLs in the response to NACT and to develop 
a platform for screening new alternative therapies for NACT non-responders, we have 
constructed a 3D allogenic co-culture model of breast cancer cell lines and patient-derived 
immune cells.  
We have used 3D models since they better replicate the complexity of a tumor 
microenvironment than classical 2D cultures. For instance, 3D cultures allow for different cell 
types to be cultured together and replicate essential tumor features, such as a hypoxia 
gradient towards the center of the structure and increased cell-cell contacts (182,183,220). 
With the aim of developing a platform for assessing therapeutic strategies, our 3D systems 
have to be simple at the same time, to allow a throughput screening. As such, we have used a 
scaffold-free technique, by reducing the contact of the cells to the culture plastic. Additionally, 
since we intended to use the same platform to assess different patients’ response to 
alternative treatments, we have developed a co-culture of breast cancer cell lines with 
allogenic patient-derived immune cells, which have been shown by others to still possess 
cytotoxicity functions against target cells (184,185).  
We have used two breast cancer cell lines – MCF-7 and MDA-MB-231 because they were 
isolated from patients with distinct breast cancer subtypes, ER+ and TNBC, respectively. 
Additionally, both can be cultured in 3D and they may have different chemo-sensitivities 
(188,223). Patient-derived immune cells were isolated from the blood (peripheral blood 
mononuclear cells – PBMCs) and both NACT-responders and non-responders patients’ PBMCs 
were used for the co-culture. We have observed that both responders and non-responders 
derived PBMCs were able to infiltrate the tumor spheroids (see Figure VI-3).  
Our first aim with this 3D platform was to clarify the role of HLA-DR+ CTLs in the tumor 
microenvironment and their influence in NACT efficacy. We already knew from Chapter V that 
HLA-DR+ CTLs had higher production of cytotoxicity-related molecules, such as Granzyme B, 
but lacked the proof that they had the capacity to eliminate tumor cells. To better clarify their 
cytotoxic abilities, we added only sorted HLA-DR+ CTLs to a MCF-7 spheroid, and observed a 
significant decrease in the viability of the cell line (see Figure VI-6). Moreover, no effect was 
observed with the addition of sorted HLA-DR negative CTLs alone or sorted CTLs negative 
fraction, highlighting that indeed HLA-DR+ CTLs are the immune subset with the capacity to 
eliminate tumor cells. Additionally, we observed that the cytotoxic function of HLA-DR+ CTLs 
was only directed to tumor cells and not autologous immune cells since the co-culture of HLA-




DR+ CTLs and the CTLs negative fraction revealed that the majority of the total PBMCs remain 
viable (see Figure VI-6B).  
This result was not in agreement with two published reports from the same group claiming 
that HLA-DR+ CTLs are cytotoxic against autologous PBMCs (222,238), and thus have a 
suppressive role. In these reports, the authors show that HLA-DR+ CTLs are similar to typical 
Tregs, are positive for PD-1, TIGIT and CTLA-4, and can inhibit the proliferation of responding 
PBMCs and eliminate them when in co-culture. For this elimination, cell-to-cell contact must 
occur either via CTLA4 (238) or PD-1 (222). Moreover, the authors also claim that HLA-DR 
marks activated and proliferating CTLs and that they express IFN- and TNF-, but not 
Granzyme B. However, our results prove that, in our developed platform, HLA-DR+ CTLs are 
cytotoxic against tumor cells and not autologous cells. The suppressive role of HLA-DR+ CTLs 
against autologous PBMCs was only demonstrated in vitro (with isolated cells from human 
peripheral blood) and may not be representative of an in vivo phenotype. Actually, to our 
knowledge, this group is the only one claiming that HLA-DR+ CTLs are a suppressive cell type. 
There are other reports describing a suppressive role of CD8+ T cells, but never associated 
with HLA-DR expression (239,240).  
Interestingly, when the CTLs negative fraction, that comprised antigen presenting cells and 
helper T cells, was added to the spheroids together with HLA-DR negative CTLs, these non-
activated CTLs became able to eliminate tumor cells, similarly to HLA-DR+ CTLs alone. Our 
hypothesis here is that antigen presenting cells are able to uptake tumor antigens, process 
and present them to helper T cells.  Then, helper T cells will become activated and produce 
IFN-, that in turn will stimulate the CTLs, contributing to their activation (acquiring high 
expression levels of HLA-DR) and gain of cytotoxic function against tumor cells (Figure VII-4). 
To test this hypothesis, represented in Figure VII-4, different co-culture experiments could be 
performed. For example, instead of sorting the CTLs negative fraction, the CD4+ T cells (Th) 
and the APCs (for instance, CD14+ cells) could be sorted. Then, with the MCF-7 3D spheroids, 
a co-culture with HLA-DR negative CTLs and Th cells could be performed and, in another 
experiment, HLA-DR negative with only the APCs could be added to the MCF-7 spheroids. The 
viability of the MCF-7 cells would then be analyzed. With this assay, we could assess if both 
cell types are necessary to activate HLA-DR negative CTLs (turning them into HLA-DR+) and 
confirm our hypothesis. Additionally, to assess the specific role of HLA-DR, namely if the 
expression of this molecule in CTLs leads to antigen presentation to Th cells, thus boosting 
IFN- production and cytotoxic capacity of CTLs, in a positive feedback loop, a blocking 
antibody against HLA-DR in sorted T cells (containing both Th and CTLs) in co-culture with 
spheroids could be added. IFN- released to the extracellular environment could then be 
quantified as well as the viability of the breast cancer cell line.  
 




Figure VII-4 Activation of CTLs by IFN- released by helper T cells that were stimulated by antigen 
presenting cells. In a tumor microenvironment, antigen presenting cells (APCs) can recognize tumor 
antigens and present them by class II MHC to helper T cells (Th). This presentation will stimulate Th 
response, which comprises the release of IFN-. This cytokine is a known inducer of cytotoxic T cells 
(CTLs) and will activate them, increasing their HLA-DR expression level. Activated CTLs will be able to 
perform their effector cytotoxic function and release Granzyme B and Perforin. These cytotoxicity-
related molecules will induce tumor cell apoptosis. It is also known that besides being an activation 
marker, HLA-DR presence in CTLs could act as a T cell-T cell synapsis, maybe even by the antigen 
presentation to Th cells, increasing the secretion of IFN- to the environment. Figure performed in 
Biorender.  
 
So, why does this cycle (Figure VII-4) don’t occur always in a tumor microenvironment? We 
have seen that in a tumor microenvironment, tumor cells are capable of releasing several 
tumor-protective mechanisms, such as immunosuppressive cytokines and inhibitor molecules 
(e.g. PD-L1). Hence, even the antigen presenting cells and/or the helper T cells could be 
hampered in this impeditive microenvironment and be unable to stimulate CTLs. We could 
hypothesize that treatment with personalized vaccines, such as dendritic vaccines, would help 
to present specific tumor antigens to helper T cells, which would stimulate CTLs, increasing 
their HLA-DR which will contribute to improve their own activation/function. Nevertheless, 
for this treatment to be effective, a combination with immune checkpoint inhibitors, for 
instance, has to be considered so that the inhibitory microenvironment is refrained. 
Having assessed the cytotoxic function of HLA-DR+ CTLs, we analyzed what was the effect of 
adding the whole PBMCs to the 3D spheroids of MCF-7 and MDA-MB-231 cell lines. 
Interestingly, when the addition of the NACT-responders’ PBMCs was performed, we 




observed a significant decrease in the breast cancer cells’ viability, without the need for 
chemotherapeutic agents (see Figure VI-5). This effect was not observed for NACT non-
responders’ PBMCs, emphasizing the immunosuppressed phenotype of the immune cells 
isolated from patients who did not respond to chemotherapy (known to possess low levels of 
HLA-DR in CTLs). Interestingly, the NACT-responders’ PBMCs acted in synergy with doxorubicin 
(a chemotherapeutic agent normally used on NACT, see Figure VI-7) leading to an even greater 
effect on the viability of the breast cancer cells. This effect was not observed for the co-culture 
of the cell lines with NACT non-responders' PBMCs and doxorubicin. This result proves that 
we are able to replicate clinical observations in vitro.  
Thus, we can conclude that we have constructed a reliable 3D platform to further test new 
therapeutic strategies, especially for the NACT non-responder patients. 
We have seen in Chapter IV that the main difference between NACT-responders and non-
responders was the expression level of HLA-DR in CTLs. Thus, we hypothesized that increasing 
this HLA-DR level in CTLs of NACT non-responders would revert their immunosuppressed 
phenotype, therefore increasing the anti-tumor function of these cells.  
To achieve this we have used two different strategies – stimulation with PMA/ionomycin or 
TCR engagement. PMA/ionomycin is a canonical, receptor-independent stimulation that will 
activate protein kinase C and increase calcium influx (241). This method will lead to overall 
immune cells activation (including CTLs), proliferation, and release of inflammatory cytokines 
(241). T cell receptor stimulation with co-stimulatory signaling, on the other hand, is a more 
specific stimulation method that reproduces the natural activation of T cells. The TCR signaling 
cascade is a complex pathway that ultimately leads to T cell activation, proliferation, increased 
function and release of cytokines (242). As the TCR engagement is a specific T cell stimulation 
it can explain the fact that HLA-DR levels in CTLs and IFN- production are increased with this 
method, when compared to PMA/ionomycin (see Figure VI-8-A, D, E). Nevertheless, with both 
methods we were capable to increase the percentage of HLA-DR+ CTLs. 
Interestingly, NACT non-responders’ PBMCs previously stimulated by either method are able 
to eliminate tumor cells and this effect is synergistic with the addition of doxorubicin (see 
Figure VI-8-B, C), similarly to NACT-responders' PBMCs.  
Moreover, we tried to revert the immunosuppression phenotype of NACT non-responders’ 
PBMCs by a more translatable approach. To achieve this, we used immune checkpoint 
inhibitors, to remove the tumor impeditive action on the function of T cells. These inhibitors 
are already used in the treatment of several cancer types and are FDA approved in breast 
cancer only for patients with metastatic TNBC (118). 
To perform this, we used antibodies against PD-1 and PD-L1 alone or in combination with 
doxorubicin. However, we were not able to revert the immunosuppressed phenotype of NACT 
non-responders’ PBMCs (see Figure VI-9). The lack of immune checkpoint blockade specific 
effect can be explained by the low percentage of PD-1 at the surface of CTLs. We have to take 
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into account, however, that breast cancer patients are very heterogeneous, and in some 
cases, PD-1 expression can be increased in CTLs, especially in intratumor CTLs, and immune 
checkpoint blockade could be a strategy for these patients.    
Altogether, the main output from these results is the developed 3D platform, that could be 
used as a tool to test different therapeutic strategies. Actually, there are other 
immunomodulatory drugs besides the PD-1/PD-L1 axis blockade. Antibodies against CTLA4 or 
Tim3 are other possible strategies, to release the immunosuppressive action on CTLs. Indeed, 
CTLA4 is already used to treat other types of cancer (Ipilimumab is FDA approved, (118)). 
Inhibiting indoleamine 2,3-dioxygenase (IDO), an enzyme that is related to 
immunosuppression of APCs (243), could also potentiate the circuit represented in Figure VII-
4. Small drugs with immunomodulatory properties, could also be tested, as it is the case of 
the agonist for Ox40, that it might augment CTLs’ cytotoxic activity (244). 
Moreover, it would be interesting to perform these assays with CTLs isolated from TILs. 
Conceivably, CTLs from the tumor are already hardwired to fight specific tumor cells, due to 
the presence of specific tumor antigens, but are being suppressed by the tumor 
microenvironment, therefore bearing higher expression of PD-1 and other immune 
checkpoints, than peripheral CTLs. Hence, the immune checkpoint blockade therapy could be 
more effective in this case. Additionally, 3D co-culture experiments with tumor cells from the 
patient, instead of breast cancer cell lines, and autologous immune cells would give a more 
representative view of the interactions between tumor and immune cells. Here, a 
combination of stimulated CTLs with immune checkpoint blockade could be tackled, for 
instance.   
Nevertheless, with the results shown so far in this thesis, we could envisage that stimulation 
of PBMCs (including CTLs with high levels of HLA-DR), should be considered as an alternative 
strategy to increase HLA-DR expression in CTLs in NACT non-responder patients.  
Ideally, CTLs from the blood of the patients – where a high number of cells can be isolated, 
could be stimulated ex vivo by TCR engagement, increasing the levels of HLA-DR and the 
consequent production of cytotoxicity molecules. These cells could then be reinfused into the 
patients and have a more targeted approach against tumor cells. Nevertheless, the use of 
these cells as a therapeutic strategy is still far from being clinically tested. Several experiments 
should be performed to test the safety and efficacy of stimulated CTLs. Namely, stimulated 
CTLs should be further tested to clarify their expression profiles and their half-life. Moreover, 
these cells should be cultured with other cell types, including autologous immune cells, to 
determine if their cytotoxicity is only towards tumor cells or if they could have any side effects.  
Actually, adoptive T cell transfer was already used in a metastatic ER+ breast cancer patient, 
as depicted in section 6.3.2 of Chapter I (173). Although this treatment was effective for this 
breast cancer patient it is a very personalized medicine approach, were tumor antigens of 
each patient have to be detected and reactive TILs against them screened. Moreover, it is 
necessary to take into account that this treatment has high costs due to the specific 




techniques to find tumor antigens, such as whole exome sequencing and RNAseq, and that it 
is a very demanding and time-consuming to perform these techniques and to expand tumor-
specific T cells in culture. As such, all efforts to discover new, effective, straight forward, less 
expansive alternatives should be considered to improve breast cancer treatment and patients’ 
quality of life. 
 
4. Concluding remarks  
 
Overall, with this thesis, we discovered a new biomarker to predict breast cancer patients’ 
response to NACT that can be more precise than the classical TILs and NLR. This biomarker – 
HLA-DR-expression level in CTLs, mainly assessed at the biopsy level, but with a systemic 
reflection, can accurately distinguish a priori patients that will respond to the treatment from 
the ones who will not respond. HLA-DR+ CTLs were shown to be active, with production of 
IFN-, Perforin and Granzyme B, and with cytotoxicity against tumor cells and not autologous 
immune cells. Precise biomarkers to predict response to NACT are a medical need, due to the 
high percentage of non-responder patients, but the biomarker studies should run in parallel 
with the finding of new treatments, due to the lack of alternative therapeutic strategies. The 
alternative treatment available nowadays would be surgery followed by radiotherapy and/or 
adjuvant chemotherapy. However, patients selected for NACT include patients with 
inflammatory and inoperable tumors, and for those surgery without prior tumor down-staging 
is impossible.  
This thesis also aimed to develop a new platform to perform a screening of new therapeutic 
strategies, especially for patients without response to NACT. First of all, an in vitro validation 
of the need of HLA-DR+ CTLs for NACT success was performed. Additionally, we observed that 
increasing the HLA-DR levels in CTLs derived from the blood of non-responder patients could 
improve their anti-tumor response and showed a synergistic effect with doxorubicin – a NACT 
agent.  
Nevertheless, further studies need to be performed, namely there is a need to increase the 
sample size for the biomarker study and to perform 3D cultures with patient-derived tumors 
to have a more physiological platform to test several therapeutic strategies.   
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Prediction of breast cancer response to Neoadjuvant Chemotherapy (NACT) is an urgent
need to promptly direct non-responder patients to alternative therapies. Infiltrating T
lymphocytes, namely cytotoxic T lymphocytes (CTLs) have been appointed as predictors
of response. However, cancer cells have the ability to dampen CTLs’ activity and
thus, the prognostic value of the CTLs, per se, is debatable. Here, we disclose that
more than the occurrence of CTLs, it is their activation state, revealed by HLA-DR
expression, that can accurately predict response to NACT. Flow cytometry analysis of
breast cancer biopsies showed that the frequency of CTLs and other lymphocytes were
similar regardless disease stage and between NACT responders and non-responders.
However, only breast cancer patients without axillary lymph node metastasis and
NACT responders have HLA-DRhi CTLs. Interestingly, HLA-DR levels in tumor CTLs
is correlated with HLA-DR levels in systemic CTLs. These HLA-DR+ CTLs produce
IFN-γ and Granzyme B, enlightening their effector and probable anti-tumor activity profile.
Moreover, the level of HLA-DR in CTLs is negatively correlated with the level of HLA-DR in
T regulatory lymphocytes and with immunosuppressive and pro-tumor molecules in the
tumor microenvironment. Hence, HLA-DR levels in CTLs is a highly sensitive and specific
potential predictive factor of NACT-response, which can be assessed in blood to guide
therapeutic decisions.
Keywords: breast cancer, cytotoxic T lymphocytes, HLA-DR, prediction, neoadjuvant chemotherapy
INTRODUCTION
Breast cancer remains one of the main causes of cancer-related deaths in women worldwide
(1). The disease can be divided in three different subtypes—hormone-positive (estrogen and/or
progesterone—ER+ and/or PR+), human epidermal growth factor receptor 2 (HER2) positive and
triple negative breast cancer (TNBC), which lacks the three mentioned markers. In the past years,
advances in breast cancer treatment have been made, namely with the introduction of preoperative
neoadjuvant chemotherapy (NACT) in selected cases of advanced tumors (with tumor size larger
than 2 cm and/or disease extension to axillary lymph node) or inflammatory breast cancer. This
treatment is effective in reducing the size of the primary tumor, allowing breast conservation in
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selected cases, and some patients achieve a pathological complete
response (pCR) (2). However, this only happens in less than
50% of the patients (3, 4) and residual disease after NACT is a
strong predictor of relapse (2, 5). Hence, it is essential to find a
good marker of response to NACT, in order to promptly direct
patients to alternative therapies, therefore avoiding the misuse of
resources and the potential toxicity associated with NACT.
Increasing evidence suggests that anti-cancer chemotherapy
is influenced by the immune system (6). Indeed, tumors can
be heavily infiltrated by immune cells, in particular, tumor
infiltrating lymphocytes (TILs), which have been associated
with good prognosis in various cancers, including breast
cancer (6). Several reports have been advocating that TILs,
especially cytotoxic T lymphocytes (CTLs), due to their anti-
tumor cytotoxic activity, could serve as a robust marker
for predicting pCR rate after NACT (7). However, even
with an effort to standardize TILs evaluation (8), data
are still conflicting, and other reports describe that TILs
and their subsets could not show any predictive value,
particularly in hormone-positive subtype (6), possibly because
these patients are further treated with endocrine therapy for
years. Furthermore, T regulatory cells (Tregs), by suppressing
the effector immune response, are normally associated with poor
prognosis. However, they are still described to have an ambiguous
role (9).
Actually, tumor cells have mechanisms to escape the immune
system, and the activity of CTLs can be hampered by them.
For instance, tumors may express inhibitory molecules like
programmed death-ligand 1 (PD-L1) which bind the inhibitory
receptor programmed death 1 (PD-1) in CTLs, inducing negative
regulatory pathways that limit the activity of these cells (10,
11). Other inhibitory immune checkpoints, such as cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) and the secretion
of immunosuppressing molecules, such as IL-10, TGF-β or
Indoleamine 2, 3-Dioxygenase (IDO), could also directly or
indirectly (by recruiting and activating Tregs), negatively impact
CTLs’ activity (10, 11).
Considering the aforementioned, the presence of CTLs per
se provides limited information regarding NACT outcome, and
the activation level of these cells, as a result of the overall tumor
immune status, should be taken into account in order to better
predict response to NACT.
HLA-DR is recognized as a marker of T cell activation (12, 13)
and has been shown to be increased in CTLs in autoimmune
diseases (14) and in patients with HIV infection (15).
In this work, by flow cytometry analysis of fresh samples,
we demonstrated that a subset of CTLs expressing HLA-
DR is enriched in breast cancer without axillary lymph node
metastasis comparing with breast cancer with axillary lymph
node metastasis, although the average frequency of CTLs is
similar between groups. Furthermore, biopsies from NACT
responders also have HLA-DRhi CTLs, while no differences
were observed concerning the density of CTLs between NACT
responders and non-responders. Interestingly, the profile of
HLA-DRhi CTLs was negatively correlated with high levels of
pro-tumor and immunosuppressive molecules in the tumor
immune microenvironment.
TABLE 1 | Characteristics of patients enrolled in this study (age, body mass
index, and menopause).
Age Median−58 (range: 35–87)
Body mass index (BMI) Median−26.03 (range: 17.04–39.74)
Post-menopause 62.30%
ER+ (PR –/+) 68%







Ki67 Median−21.75% (range: 2–98.4%)
Dimension (mm) Median−25 (range: 7–90)
Axillary lymph node invasion status Negative−51.09%
Positive−48.91%
Response (if NACT) Good response−43.33%
Bad response−56.67%
Clinical data, such as subtype of breast cancer, grade, Ki67, tumor dimension, node status
and response to treatment are also described.
Therefore, we propose that HLA-DR+ CTLs have the
potential to be used in clinical settings to predict breast cancer




Forty-eight fresh biopsies and ninety-six non-matched
surgical samples of breast cancer (BC) patients were collected in
saline solution. Matched peripheral blood from 31 BC patients
was collected in Vaccutainer tubes with EDTA (BD Biosciences).
Whole blood from 13 healthy donors was also collected for
comparison studies. For in vitro studies, patients’ peripheral
blood mononuclear cells (PBMCs) were isolated by a Ficoll
gradient (Merck Milipore) and PBMCs from buffy coats of 5
healthy donors, donated by Instituto Português do Sangue e da
Transplantação, were used for control purposes. Formalin-fixed
paraffin embedded (FFPE) tissue was collected from 12 matched
patients divided according to the axillary lymph node invasion
status and response to neoadjuvant chemotherapy (NACT). A
summary of the patients characteristics are given in Table 1.
Fresh samples were handled within 1-day post collection.
Fresh tumors and biopsies were mechanically dissociated with a
BDMedicon (BD Bioscience), filtered and washed once with PBS
1X. PBMCs after isolation were cryopreserved in 90% fetal bovine
serum (FBS, Biowest) and 10% dimethyl sulfoxide (DMSO, Sigma
Aldrich) until further use.
Samples were gathered from Hospital CUF Descobertas,
Hospital Prof. Doutor Fernando Fonseca and Hospital de Vila
Franca de Xira. For each patient, written informed consent and
approval by the Ethical Committee of the hospitals and of the
NOVAMedical School were obtained. The study is in compliance
with the Declaration of Helsinki.
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Antibodies
For flow cytometry analysis, tumor and blood samples were
stained with a cocktail of monoclonal mouse anti-human
conjugated antibodies (mAbs): anti-CD45-PercP (clone HI30),
anti-CD3-PercP (HIT3a), anti-CD3-APC (UCHT1), anti-CD19-
PE (HIB19), anti-CD15-PE (HI98), anti-CD161-FITC (HP-
3G10), anti-CD4-FITC (OKT4), anti-CD8-PE (HIT8a), anti-
HLA-DR-APC (L243), anti-CD127-PE-Cy7 (A019D5), anti-
CD1c-APC-Cy7 (L161), anti-CD163-PE (GHI/61), anti-CD206-
APC-Cy7 (15–2), anti-PD-1-FITC (EH12.2H7), anti-PD-L1-
APC (29E2A3), anti-CTLA4-PE (L3D10), anti-CD69-APC-
Cy7 (FN50), anti-Tim3-APC (F38-2E2), anti-IL-8-APC (E8N1),
anti-IFN-γ-PE (4S.B3), anti-IFN-γ-APC-Cy7 (4S.B3), anti-
Granzyme B-FITC (QA16A02), anti-IL-1β-FITC (JK1B-1), anti-
IL-2-PE-Cy7 (MQ1-17H12), anti-IL-6-APC (MQ2-13A5), anti-
IL-17-FITC (BL168), anti-IL-23/IL-12-PE (C11.5), anti-TGF-β-
APC (TW4-6H10), all from Biolegend; anti-IDO-PE (eyedio)
and anti-IL-10-FITC (BT-10), both from eBioscience; anti-
CD25-PE (MEM-181) and anti-CD11b-FITC (LT11) from
ImmunoTools.
The antibodies used for immunofluorescence were: mouse
monoclonal anti-human CD8 (32-M4) from Santa Cruz
Biotechnology and rabbit polyclonal anti-human HLA-DRA
from Sigma Aldrich.
Flow Cytometry
BC samples were stained with BD HorizonTM Fixable Viability
Stain 450 (BD Biosciences) and with the cocktail of antibodies,
fixed and permeabilized with Fix/Perm kit (eBiosciences)
followed by intracellular staining. For whole blood, staining with
antibodies was followed by a step of red blood cells lysis with RBC
lysis buffer (Biolegend).
For immunophenotyping we classified cytotoxic T
lymphocytes as CD45+/CD3+/CD8+; helper T lymphocytes as
CD45+/CD3+/CD4+; regulatory T lymphocytes as CD45+/
CD3+/CD4+/CD25hi/CD127lo; B lymphocytes as CD45+/
CD19+; NK cells as CD45+/CD161+; M2 macrophages as
CD45+/CD11b+/CD163+/CD206+; M1 macrophages as
CD45+/CD11b+/CD163negative/CD206negative; dendritic
cells as CD45+/CD1c+; and neutrophils as CD45+/CD15+.
Data was acquired in BD FACS Canto II cell analyzer
with FACSDiva Software v8.0.1 (BD Biosciences) and the
results were analyzed using FlowJo software v10. The data
is presented as percentage of the populations in respect
to the gate of single cells, following the gate strategy
represented in Figure S1. To analyze the expression levels
of HLA-DR in CTLs or Tregs, we considered the median
fluorescent intensity of positive population and normalized
it to the negative population, as previously described (16).
The negative population was superimposed with the unstained
control.
Ex vivo Stimulation Assay
Isolated PBMCs were cultured in 96 well-plates with U bottom
(Sigma Aldrich) with RMPI-1640 (Gibco) supplemented with
10% FBS and 1% Penicillin/Streptomycin (GE Healthcare).
Stimulation was performed during 4 h (or overnight for HLA-
DR expression) with 35 ng/mL of phorbol 12-myristate 13-
acetate (PMA, Sigma Aldrich) and 1µg/mL of ionomycin (Merck
Milipore). Brefeldin A (Biolegend) was added for 4 h to stop
the extracellular transport. Cells were collected and stained with
mAbs and analyzed by flow cytometry.
Immunofluorescence
Immunofluorescence was performed in formalin-fixed paraffin
embedded tissues (FFPE). Paraffin was removed in xylene
(10min) and passed through a gradient of alcohol (100, 96,
and 70%) and dH2O. Antigen retrieval was performed in 2
cycles of 15 mins each with 1mM EDTA (Sigma Aldrich) with
0.05% Tween-20 (Sigma Aldrich) in the microwave (900W).
The slides were permeabilized with PBS 1X + 0.3% Triton
X-100 (ACROS Organics) and blocked with PBS 1X + 0.1%
Triton X-100+ 1% bovine serum albumin (BSA, Sigma Aldrich)
+ 1.5% goat serum (Sigma Aldrich). Staining with primary
antibody (1:100) was performed overnight at 4◦C followed by
the incubation with secondary antibody for 2 h in the dark at
room temperature. Counterstaining was performed with 4′,6-
diamidino-2-phenylindole (DAPI; 0.001 mg/mL in PBS, Sigma-
Aldrich) and the slides were mounted in Fluorescent Mounting
Media (DAKO). Images were taken in a confocal microscope
(LSM710, Zeiss) and analyzed in Fiji software (17).
ELISA
The patients’ plasma was isolated from whole blood and frozen
for further cytokine analysis. The quantity of secreted cytokines
was measured using ELISA technique, namely human IL-10
(ImmunoTools) and IFN-γ (Biolegend) kits were used according
to the manufacturer’s instructions. Cytokine concentration was
calculated using the specific standard curves.
Cell Sorting
PBMCs were stained with the viability dye followed by the
mAbs anti-CD3-PercP, anti-CD8-PE and anti-HLA-DR-
APC. Cells were sorted in CD3+/CD8+/HLA-DR+ and
CD3+/CD8+/HLA-DRnegative in a FACS Aria III (BD
Biosciences) with an efficiency of 98% (Figure S2).
qRT-PCR
Total RNA of sorted cells was extracted using RNeasy Micro Kit
(Qiagen) and reverse transcribed with Transcriptor High Fidelity
cDNA synthesis kit (Roche). Quantitative real-time PCR (qRT-
PCR) was performed with several primers, described in Table 2,
using Roche LightCycler 480 and FastStart Essential DNA Green
Master Mix (Roche). Cyclic conditions were: 95◦C for 10min,
followed by 45 amplification cycles, each consisting of 10 s at
95◦C, 10 s at 56◦C, and 20 s at 72◦C, and finally a melting step
of 10 s at 95◦C, 60 s at 65◦C, and 1 s at 97◦C.
The relative mRNA levels were normalized against the values
obtained for the housekeeping gene RPL13A and calculated by
the formula 2−1Ct × 1000 that gives us the number of mRNA
molecules of the gene of interest per 1000 molecules of the
endogenous control (17, 18).
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TABLE 2 | Genes assessed with qRT-PCR and the primers used.
Gene Forward primer Reverse primer
TNFα AGATGATCTGACTGCCTGGG CTGCTGCACTTTGGAGTGAT




In vitro Co-culture Assay
HS 578T cell line was maintained for 4 days in DMEM
(Biowest) with 10% FBS and 1% Penicillin/Streptomycin. After
that period, the supernatant and cells were harvested for the
co-culture. The supernatant was further centrifuged at 2000
rpm for 5min to eliminate cellular debris and possible cellular
antigens. PBMCs were plated on a 96 well plate U bottom in 4
conditions: monoculture, with the addition of the supernatant
from HS 578T culture, with a canonical stimulus of PMA and
ionomycin, and in co-culture on a ratio of 20:1 (PBMCs:HS
578T). PBMCs were collected 48 h after and analyzed by flow
cytometry.
Statistical Analysis
Statistical analysis was performed in GraphPad Prism v6 and
statistical significance was considered for p < 0.05. Comparison
between samples was performed by a nonparametric Mann-
Whitney test and correlations were calculated with Spearman
r-test. ROC curves were performed to assign a threshold to
divide NACT responders from non-responders. This analysis
was executed for both HLA-DR expressing CTLs and Tregs.
The determined area under the curve, sensitivity and specificity
were taken into account. The cut-off point for the HLA-DR
expression level in CTLs was a parameter also determined
by ROC curve analysis, considering the expression value that
corresponded to the maximum of sensitivity and specificity.
Paired t-test was used for the analysis of the co-culture
assay.
RESULTS
Clinical and Pathological Characteristics
For this study, 144 fresh samples (137 pre-treatment - 48
biopsies and 89 surgical specimens - and 7 post-NACT surgical
specimens) were collected prospectively. Data from these patients
are displayed in Table 1. Most patients have estrogen receptor
(ER) positive breast cancer, have high body mass index and are
post-menopausal.
These samples, except the post-NACT specimens, were used
in the first phase of the study for a global analysis of tumor
infiltrating immune populations. Then, aiming to find an
adequate biomarker of response to NACT, from these samples,
we used the first consecutive biopsies (n = 30) of patients that
were selected for NACT and related the activation status of their
lymphocytes with their response to treatment.
HLA-DR-expressing T Lymphocyte
Populations Can Distinguish Breast Cancer
Axillary Lymph Node Invasion Status
In the first phase of the study, and to get insight into the
composition and the role of immune infiltrate in breast cancer
(BC), we used a flow cytometry multipanel and analyzed several
immune populations (gate strategy in Figure S1) in 137 BC
patients prior to treatment implementation (48 biopsies and 89
surgical specimens). First, these patients were divided according
to the axillary lymph node invasion status. Patients without
axillary lymph node metastasis had a similar immunophenotype
when compared with patients with axillary lymph node
metastasis (Figures 1A–C). Indeed, although there was high
heterogeneity in the degree of immune infiltration between
patients, the average value of the frequency of T lymphocytes, B
lymphocytes, NK cells (Figure 1A), neutrophils, dendritic cells,
M1 andM2macrophages (Figure 1B) infiltrating the tumor, were
similar between the two groups of patients. Additionally, the
average value of the frequency of T lymphocyte populations—
helper (Th), cytotoxic (CTLs), and regulatory (Tregs)—were
similar between these two groups (Figure 1C).
Then, we considered the activation state of T lymphocyte
populations, by the analysis of established T cell activation
markers, CD69 and HLA-DR. Interestingly, this analysis
revealed significant differences between patients without axillary
lymph node invasion and patients with axillary lymph node
invasion, regarding the expression of HLA-DR. Namely, HLA-
DR expression level was higher in CTLs (p = 0.008) and lower
in Tregs (p = 0.001) in patients without axillary lymph node
metastasis when compared to patients with axillary lymph node
metastasis (Figures 1D,F). Furthermore, the expression of HLA-
DR in CTLs was negatively correlated with the expression of this
marker in Tregs (r =−0.54, p < 0.0001, Figures 1E, 6).
No differences were observed between patients of the two
groups regarding HLA-DR expression in Th cells, but we did
not discriminate between Th subsets (e.g., Th1, Th2, Th17), that
might influence cancer differently.
The analysis of CD69 expression in T lymphocyte populations
did not lead to the same result obtained by the analysis of HLA-
DR (data not shown). This may be due to the fact that CD69 is
an early, transiently expressed, activation marker of T cells (18),
while HLA-DR is increased later in the activation process of T
cells (19), remaining in the cell surface.
Besides dividing the patients regarding the presence or
absence of axillary lymph node invasion, we have also divided
them regarding breast cancer subtype (ER+, HER2+, or TNBC),
grade (G1, G2, or G3), age (<50 years old or >50 years old),
tumor dimension (<20 or >20mm) and body mass index (low,
normal or overweight). HLA-DR expression in T cell populations
was not significantly different in these other comparisons (results
not shown).
Thus, independently of BC subtype, expression of HLA-DR
in distinct T cell populations can differentiate patients with
axillary lymph node metastasis (HLA-DRhi Tregs) from patients
without axillary lymph node metastasis (HLA-DRhi CTLs).
These results suggested that more than simply the presence
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FIGURE 1 | HLA-DR expression in CTLs and Tregs can distinguish between patients without axillary lymph node metastasis (N–) and patients with axillary lymph node
metastasis (N+) contrarily to the percentage of distinct cell populations. (A) Percentage of leukocytes, T cells, B cells and NK cells in the tumor bulk from patients
without axillary lymph node metastasis (N–, gray triangles, n = 70, mean) and patients with axillary lymph node metastasis (N+, black dots, n = 67, mean).
(B) Percentage of dendritic cells (DCs), Neutrophils, M1 and M2 macrophages in the same populations. (C) Percentage of distinct T cell populations (helper T cells -
Th, cytotoxic T cells - CTLs and regulatory T cells - Tregs) in the tumor from both groups of patients. The percentage of each population was obtained in respect to
the gate in single cells (Figure S1). (D) Level of HLA-DR in Th, CTLs and Tregs in the tumor from patients with and without axillary lymph node invasion, expressed as
the median fluorescent intensity of positive population normalized relatively to negative population (**p < 0.01). (E) Correlation between HLA-DR+ CTLs and
HLA-DR+ Tregs in breast cancer samples (Spearman r = −0.54, p < 0.0001). (F) Representation of a flow cytometry analysis of HLA-DR expression gated on CTLs
and Tregs and differences between a tumor from a patient without axillary lymph node metastasis and a tumor from a patient with axillary lymph node metastasis.
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and/or the quantity of immune cells within the tumor immune
microenvironment, the quality (i.e., the activation state) of
certain immune cells, namely CTLs and Tregs, might be relevant
for cancer progression.
HLA-DRhi CTLs Are Associated With
Response to Neoadjuvant Chemotherapy
Considering that the HLA-DR expression in T lymphocyte
populations allows the distinction of axillary lymph node
invasion status, we asked if this trait could also be useful to
predict patients’ response to NACT. NACT was identical in
all patients and was composed of 4 cycles of anthracyclines
(doxorubicin) and cyclophosphamide, followed by 12 weeks of
paclitaxel. Only the addition of trastuzumab during paclitaxel
administration differed in HER2 patients. Biopsies from 30
patients that underwent NACT were here analyzed (pre-
treatment) by flow cytometry and, after the treatment, patients
were divided in responders and non-responders, according to
their radiological and pathological outcome. NACT responders
were classified as patients that achieved a pathological complete
response (pCR, n= 6) or that had a pathological partial response
with less than 10% of the initial tumor still present after treatment
and without axillary lymph node involvement (n = 7). NACT
non-responders included patients that still maintained more
than 50% of the initial tumor mass after treatment (n = 6),
or patients that developed brain, liver and/or lung metastasis
during NACT (n = 3) or patients that had an early relapse after
NACT (n= 8). Patients considered NACT responders were either
ER+ (30.77%), HER2 (38.46%), or TNBC (30.77%). Interestingly,
NACT responders showed higher levels of HLA-DR in CTLs
(p = 0.0003) and lower levels of HLA-DR in Tregs (p = 0.009)
when compared to the non-responders (Figure 2B). Again, the
percentage of T lymphocyte populations was not statistically
different between the two groups (Figure 2A). This finding is
independent of BC subtype (Figure S3). Indeed, the percentage
of CTLs, per se, was not sufficient to discriminate responders
from non-responders, across all three BC subtypes, while HLA-
DR expression levels in CTLs can segregate both groups,
especially in ER+ and TNBC (Figure S3). In HER2 breast
cancer, HLA-DR levels in CTLs was still higher in responders,
comparing with non-responders, although not statistically
significant. This may be explained by the fact that we only
have 3 samples from non-responders, including the only sample
where the HLA-DRhi in CTLs did not correspond to a NACT
responder.
In order to verify the predictive value of HLA-DR expression
in CTLs for NACT response, in general, we plotted the levels
of HLA-DR in CTLs and Tregs, of the total 30 biopsies in one
single column, regardless of the response (Figure 2C). Excitingly,
even with a small sample size, a robust separation of responders
(black triangles) and non-responders (gray dots) was observed
according to the expression level of HLA-DR, especially in CTLs
(Figure 2C).
Additionally, ROC curve analysis was performed, leading to
a statistically valid cut-off point for the HLA-DR expression
level in CTLs (8.943 - value above which patients are NACT
responders) and in Tregs (5.655 - value beneath which patients
are NACT responders). For HLA-DR-expressing CTLs, the area
under the ROC curve was 0.959, the sensitivity was 94.12% and
the specificity was 100%. For HLA-DR-expressing Tregs, the area
under the ROC curve was 0.849, the sensitivity was 81.25% and
the specificity was 75%. These results highlighted that, mainly,
HLA-DR-expressing CTLs evaluated in biopsies could predict
response to NACT with accuracy. To clarify the few borderline
cases, the analysis of HLA-DR+ Tregs can also be useful, since
there is a strong negative correlation between both markers
(Figure 1E).
It has been reported that chemotherapeutic agents are able to
alter the immune context of breast cancer, usually boosting anti-
tumor CTLs’ activity (20). Thus, post-NACT surgical samples,
non-matched with the pre-NACT samples, were analyzed by flow
cytometry. These specimens revealed that non-responders have
infiltrating CTLs with low levels of HLA-DR (p= 0.04) and Tregs
with high levels of HLA-DR (non-statistical) when compared to
responders (Figure S4), similar to specimens collected before the
treatment.
Other immune signatures of cancer immune status, namely
PD-1, PD-L1, CTLA4, T cell immunoglobulin and mucin
domain 3 (Tim3), IDO and IL-10, that potentially could be
used as biomarkers of NACT response were analyzed in the
pre-treatment biopsies. Although differences could be observed
between biopsies of NACT responders and non-responders,
none of them was statistically significant, as was HLA-DR in
CTLs. Moreover, we did not observe a segregation of these
groups of patients according to the level of expression in any
of these molecules in the tumor environment (Figure 2D). This
emphasizes that HLA-DRhi CTLs (with HLA-DR above the
threshold value) could potentially be implemented in the clinic
to distinguish NACT responders from non-responders.
HLA-DR-expressing CTLs Are Located
Preferably in Intraepithelial Tumor
Structures Than in the Surrounding Normal
Tissue
Besides the frequency and the type of immune cells in the tumor
tissue, their location could also be important to predict patients’
clinical outcome (21). For instance, it was found that disease-
free survival time is statistically shorter in colorectal carcinoma
patients without TILs in the center of the primary tumor mass
(22).
Therefore, we have assessed, by immunofluorescence,
selected formalin-fixed paraffin embedded (FFPE) tissue samples
matched with the previously analyzed by flow cytometry, and
evaluated where the HLA-DR+ CTLs are mainly located. We
observed that either in surgical samples from patients without
axillary lymph node metastasis and in biopsies of patients
with good response to NACT (Figure 3), HLA-DR-expressing
CTLs were mainly present in intraepithelial tumor structures.
Representative images in Figure 3 show a co-localization of
anti-CD8 and anti-HLA-DR within the tumor, while no co-
localization between these two markers was observed in the
tumor surrounding normal tissue. Indeed, outside the tumor
Frontiers in Immunology | www.frontiersin.org 6 November 2018 | Volume 9 | Article 2605
Saraiva et al. HLA-DRhi CTLs Predict NACT Response
FIGURE 2 | HLA-DR level in CTLs is a predictive factor of patients’ response to neoadjuvant chemotherapy (NACT). (A) Percentage of CTLs and Tregs in biopsies
from breast cancer patients that responded to NACT (R, black bar, n = 13, mean ± SD) and that had no response (NR, gray bar, n = 17, mean ± SD). The
percentage of each population was obtained in respect to the gate in single cells (Figure S1). (B) Level of HLA-DR in CTLs and Tregs in responders and
non-responders, expressed as the median fluorescent intensity of positive population normalized relatively to negative population (**p < 0.01, ***p < 0.001).
(C) HLA-DR expression in CTLs and Tregs with data for responders and non-responders plotted in a single column (black triangles and gray dots, respectively).
(D) The same analysis as in (C) was performed for other markers that theoretically could be used in the clinic: PD-L1, PD-1, CTLA4, IL-10, IDO and Tim3.
margins, CTLs were found, but no co-localization with HLA-DR
occurred, as HLA-DR staining was more spread throughout
the tissue. These results indicate that HLA-DR+ CTLs are
located in intraepithelial tumor structures rather than in the
surrounding normal tissue. This may suggest that the presence
of HLA-DR+ CTLs in a high proximity with tumor antigens
and tumor-released soluble factors, could lead to a more efficient
anti-tumor activity.
Circulating CTLs Maintain HLA-DR of
Tumor Infiltrating CTLs in BC Patients
To verify an association between the tumor immune
microenvironment and peripheral blood, blood samples
were also collected from 31 patients, prior to treatment
implementation, and immunophenotyped by flow cytometry.
Intriguingly, we observed that the expression of HLA-DR in
tumor infiltrating CTLs correlated with HLA-DR expression in
circulating CTLs (r = 0.58, p = 0.001) (Figure 4A). Moreover,
circulating CTLs have higher levels of HLA-DR in NACT
responders comparing with non-responders and healthy donors
(Figure 4B, p < 0.05), therefore allowing the distinction between
responders and non-responders (Figures 4B,C). Curiously,
non-responders have even lower levels of HLA-DR in circulating
CTLs than healthy donors (Figure 4B, p < 0.01).
IFN-γ and IL-10 levels in pre-treatment patients’ plasma,
assessed by ELISA, revealed that patients without axillary lymph
node invasion, as well as NACT responders, had higher levels
of IFN-γ (p = 0.004, p = 0.01, respectively, Figures 4D,F)
and lower levels of circulating IL-10 (p = 0.02, non-statistical,
respectively, Figures 4E,G), which is in agreement with the
presence of more activated or less activated circulating CTLs,
correspondingly.
Peripheral blood mononuclear cells (PBMCs) were isolated
from the blood of NACT responders and non-responders, at
the time of biopsy, and cultured under a canonical stimulus,
to clarify if they could recapitulate the characteristics of the
tumor infiltrating immune cells ex vivo, when exposed exactly
to the same conditions. PBMCs isolated from healthy donors
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FIGURE 3 | HLA-DR-expressing CTLs are localized in intraepithelial tumor structures of patients without axillary lymph node metastasis and in NACT responders.
Representative images of immunofluorescence experiments (n = 6) performed in slices of paraffin tissue of surgical BC samples of patients without axillary lymph
node metastasis (Node negative) and biopsies of NACT responders (Responders) for CTLs (green, Left panel) and HLA-DR (red, Middle panel). Nuclei are stained in
blue with DAPI and the three staining were merged (Right panel). Images from the tumor structures and from the tumor-surrounding tissue were acquired. Scale
bars: 20µm.
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FIGURE 4 | The profile of HLA-DR expression and cytokine production of intratumor CTLs is maintained in systemic CTLs. (A) Correlation between expression of
HLA-DR in systemic CTLs and tumor infiltrating CTLs (Spearman r = 0.58, p < 0.001). (B) HLA-DR expression in systemic CTLs in healthy donors (HD, gray bar,
n = 13, mean ± SD), NACT responders (R, white bar, n = 4, mean ± SD) and non-responders (NR, black bar, n = 5, mean ± SD), assessed by flow cytometry and
representing the median fluorescent intensity of positive population normalized relatively to the negative population. (C) Representative flow cytometry analysis of
HLA-DR in systemic T cells from blood collected at the time of biopsy of responders and non-responders. IFN-γ (D) and IL-10 (E) levels assessed by ELISA in plasma
of patients without axillary lymph node metastasis (gray bar, n = 9, mean ± SEM) and with axillary lymph node metastasis (black bar, n = 12, mean ± SEM). IFN-γ (F)
and IL-10 (G) levels assessed by ELISA in plasma from responders (R, white bar, n = 4, mean ± SEM) and non-responders (NR, black bar, n = 6, mean ± SEM). (H)
Expression of HLA-DR, assessed by flow cytometry, and representing the median fluorescent intensity of positive population normalized relatively to the negative
population, in CTLs and Tregs of ex vivo stimulated PBMCs isolated from healthy donors (HD, gray bar, n = 5, mean ± SEM), from responders (R, white bar, n = 4,
mean ± SEM) and from non-responders (NR, black bar, n = 5, mean ± SEM). *p < 0.05, **p < 0.01, ns, non-statistical.
were used as control. Interestingly, the expression of HLA-DR
in CTLs was higher in stimulated PBMCs of NACT responders
regarding stimulated PBMCs of non-responders (p = 0.02,
Figure 4H). This observation further supports that the tumor
immune features are maintained systemically and blood could
be used to specifically assess HLA-DR+ CTLs, which is a major
advantage for its potential use as a biomarker of response to
NACT.
HLA-DR-expressing CTLs Have Increased
Expression Levels of Effector Immune
Response-Related Molecules
To corroborate that HLA-DR+ CTLs are activated lymphocytes
with an anti-tumor activity profile, we assessed in pre-
treatment samples, infiltrated HLA-DR+ CTLs and HLA-DR
negative CTLs, the expression, by flow cytometry, of other
effector immune response-related molecules, such as IFN-γ and
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Granzyme B, which are the most important players of activated
CTLs. Interestingly, only HLA-DR+ CTLs expressed high levels
of IFN-γ and Granzyme B (Figure 5A), substantiating their
immune competent profile. Furthermore, we have analyzed the
expression level of these molecules also in HLA-DR+ CTLs
and HLA-DR negative CTLs from patients PBMCs (isolated
from pre-treatment blood). Similar to tumor, circulating HLA-
DR+ CTLs express more IFN-γ and Granzyme B than HLA-
DR negative CTLs (Figure 5A). Even if HLA-DR negative CTLs
from PBMCs had a higher level of Granzyme B expression when
compared to HLA-DR negative CTLs from tumor, the percentage
of HLA-DR+ CTLs from PBMCs that express Granzyme B, and
the corresponding median fluorescent intensity, is significantly
higher than in HLA-DR negative CTLs from PBMCs (p < 0.01,
data not shown).
Additionally, to further understand differences between HLA-
DR+ CTLs and HLA-DR negative CTLs, CTLs with and without
HLA-DR expression isolated from the blood were studied by
qRT-PCR. In this case, the expression of Granzyme B, Perforin,
TNFα and Eomes were assessed. HLA-DR+ CTLs expressed
higher levels of the cytolytic proteins Granzyme B (p= 0.02) and
Perforin (p = 0.03); Eomes (p = 0.03), involved in differentiation
of effector CTLs and the inflammatory cytokine TNFα (p= 0.03),
which also has anti-tumor properties, in comparison with HLA-
DR negative CTLs (Figure 5B).
Also, ex vivo stimulated PBMCs of responders (shown
to express more HLA-DR in CTLs than PBMCs of non-
responders—Figure 4H) have increased levels of IFN-γ
(p= 0.01) in CTLs and lower levels of IL-10 (p= 0.01), produced
by Th cells and/or Tregs respectively (Figures 5C,D), than
stimulated PBMCs of non-responders.
Altogether, these results suggest that CTLs with expression of
HLA-DR are active and effector lymphocytes that might have
a protective anti-tumor effect, which is in accordance to their
higher prevalence in BC without axillary lymph node metastasis
and/or in NACT responders.
HLA-DR Expression Level in CTLs
Negatively Correlates With the
Immunosuppressive and Pro-Tumor
Features of the Tumor Milieu
An anti-tumor or a pro-tumor immune response is elicited not
only by the immune cells within the tumor and their bioeffector
molecules, but also by tumor antigens and the expression of
cytokines, chemokines and other immune mediators released
by the cancer tissue. Thus, the stimulation of anti-tumor
CTLs’ activity should, at least in part, rely on the molecules
present in the tumor milieu. Interestingly, we have observed,
by flow cytometry analysis of pre-treatment BC samples,
that CTLs expressing HLA-DR were inversely correlated with
immunosuppressive activated Tregs (also expressing HLA-DR,
Figures 1E, 6). Moreover, they were also negatively correlated
with the expression of molecules from the non-immune
compartment that may co-opt the expression of typically innate
immune system-associated molecules to squelch the anti-tumor
immune program and/or enhance growth and survival of cancer
cells (Figure 6). Namely, HLA-DR expression level in CTLs
was negatively correlated with the expression level of TGF-β
(r = −0.45, p < 0.01), which increases the metastatic profile;
PD-L1 (r = −0.44, p < 0.0001), that inhibits infiltration and/or
activation of CTLs (23, 24); IL-6 (r = −0.51, p < 0.001), IL-8
(r = −0.56, p < 0.001) and IL-1β (r = −0.49, p < 0.001) that
are inflammatory cytokines that may act as growth factors to
sustain cancer cell proliferation and invasion (25–27). It was also
negatively correlated with IL-23/IL-12 (r = −0.56, p < 0.0001)
that is pro-inflammatory but can also impair CTLs’ activity
through the activation of Tregs (28) (Figure 6). On the other
hand, the expression level of HLA-DR in Tregs was positively
correlated with the expression of these pro-tumor molecules -
IL-1β (r = 0.47, p < 0.01), IL-23/IL-12 (r = 0.43, p < 0.01),
IL-6 (r = 0.48, p < 0.01) and IL-8 (r = 0.47, p < 0.001) – and,
additionally, IL-10 (r = 0.44, p < 0.0001) and IL-17 (r = 0.45,
p < 0.01), which could also undermine the activation of CTLs
and lead to tumor progression (29, 30) (Figure 6).
When the same analysis was performed with CTLs or Tregs
without accounting for HLA-DR expression, there was no
significant correlation between these cells and these molecules of
the tumor milieu (results not shown).
To better understand the contribution of cytokines or other
soluble factors present in the tumor milieu in the activation of
CTLs, we used a co-culture assay of HS 578T breast cancer cell
line with peripheral blood mononuclear cells (PBMCs) isolated
from patients. The assay was performed in several conditions:
PBMCs with HS 578T cell line, PBMCs with the supernatant
of the cell line alone, PBMCs plus a canonical stimulus, which
served as a positive control, or just PBMCs. Curiously, the
supernatant of the cell line alone increased the expression of
HLA-DR in CTLs (Figure S5).
Altogether, these data are in agreement with the supposition
that CTLs (and Tregs) bearing HLA-DR reflect the overall
immune status of the BC milieu.
DISCUSSION
Chemotherapy failure is the main reason for disease progression,
recurrence and cancer-related death. In the case of breast cancer
(BC), less than 50% of the patients have a pathological complete
response to neoadjuvant chemotherapy (NACT) (3, 4). Although
some efforts have been made in the past years, such as the
introduction of tumor infiltrating lymphocytes (TILs) as possible
biomarkers of response, especially in TNBC and HER2+ BC (7),
there is still no validated biomarker being routinely used in the
clinic.
The belief that NACT outcomemay depend on the presence of
TILs is related to the fact that chemotherapy leads to the release
of immunogenic signals, promoting immunogenic cell death,
which can potentially boost an anti-tumor immune response
(31). However, TILs are functionally heterogenic. For instance,
cytotoxic T lymphocytes (CTLs) have been strongly associated
with patient survival and response to therapy (7); regulatory
T cells (Tregs) have been associated with both good and bad
prognosis (6, 9); T helper 1 (Th1) cells have been related with
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FIGURE 5 | HLA-DR in CTLs reflects their activation and functional status. (A) Representation of a flow cytometry analysis of Granzyme B and IFN-γ expression in
HLA-DR+ CTLs and in HLA-DR negative CTLs from pre-treatment tumor samples and from PBMCs isolated from patients. (B) mRNA level of TNFα, Granzyme B
(GranzB), Perforin and Eomes in HLA-DR+ CTLs (black bars) and HLA-DR negative CTLs (white bars). mRNA level is expressed as the permillage (‰) of the
expression of the endogenous positive control (n = 4). (C) Percentage of CTLs expressing IFN-γ and (D) percentage of CD4+ T cells expressing IL-10, assessed by
flow cytometry, and representing the median fluorescent intensity of positive population normalized relatively to the negative population, in stimulated PBMCs isolated
from healthy donors (HD, gray bar, n = 5, mean ± SEM), from NACT responders (R, white bar, n = 4, mean ± SEM) and from non-responders (NR, black bar, n = 5,
mean ± SEM). *p < 0.05.
favorable clinical outcomes (32); whereas Th2 cells have been
reported to be associated with dampening of the anti-tumor
response (33). Therefore, it is controversial that simply the degree
of lymphocytic infiltration, assessed by immunohistochemistry in
sections of paraffin embedded tissue, has a predictive value of BC
patients’ response to NACT. Even infiltrating CTLs, per se, lack
the robustness that a predictive biomarker should have, because
their function can be hampered by tumor cells, through several
mechanisms. For instance, by expressing inhibitory molecules
like PD-L1 or by secreting immunosuppressive molecules such
as IL-10, TGF-β and IDO.
Thus, it is still crucial to establish a more accurate BC
“immunological status” that reflects the overall strength of
individual patients’ anti-tumor immune response that will
ultimately influence NACT efficiency.
In this study, we went beyond immunohistochemistry
evaluation of TILs in BC and analyzed, by flow cytometry,
T lymphocyte immune signatures, that could show their
activated/exhausted or anergic state and molecules present in the
tumor environment that are representative of the global tumor
immune status.
We found that CTLs expressing high levels of HLA-
DR, mainly located in intraepithelial tumor structures, are
characteristic of BC without axillary lymph node metastasis
and are strongly associated with good response to NACT
treatment, contrasting with CTLs with low or null expression
of this molecule. HLA-DR is an antigen presenting molecule
expressed at high levels on professional antigen presenting
cells, but its expression on effector T lymphocytes upon
their activation has also been intensively described in
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FIGURE 6 | HLA-DR expression level in CTLs and Tregs is differentially correlated with the immunosuppressive and pro-tumor features of the tumor environment. Heat
map of Spearman correlations between the expression level of HLA-DR in CTLs and the expression level of HLA-DR in Tregs; and between the expression level of
HLA-DR in both of these cells and the expression level of pro-tumor or immunosuppressive molecules from the tumor environment, namely PD-L1, TGF-b, IL-6, IL-1b,
IL-8, IL-23/IL-12, IL-10, and IL-17. The expression level of each molecule was assessed by flow cytometry and represents the median fluorescent intensity of positive
population normalized relatively to the negative population. The heat map is represented as a gradient from blue (negative correlations) to red (positive correlations).
Numbers in italic represent statistical significance of p < 0.01, numbers underlined represent p < 0.001 and numbers in italic and underlined represent p < 0.0001.
some diseases, such as auto-immune diseases and viral
infections (14, 15).
In the context of HIV patients, it has been described that
these HLA-DR+ CTLs exhibit a decreased proliferative potential
although retaining their cytolytic potential (34, 35). Additionally,
in severe aplastic anemia, an elevated number of HLA-DR+
CTLs detected in patients’ peripheral blood are responsible for
the excessive apoptosis of hematopoietic cells (36). However,
a suppressive effect of a subset of HLA-DR+ CTLs was also
reported (37). Here we confirmed that HLA-DR+ CTLs express
immune signatures of functionally activated, and not suppressive
CTLs, such as the production of IFN-γ, Granzyme B, Perforin,
TNFα, and Eomes. Thus, the infiltrating CTLs bearing HLA-DR
found in the analyzed samples should have an active participation
in the anti-tumor response, in conformity with the fact that
they were more elevated in patients without axillary lymph node
metastasis and with a better capacity to respond to NACT.
Tregs are recognized blockers of CTLs’ function and it is
known that HLA-DR also identifies functionally mature Tregs
(13). Thus, not surprisingly, HLA-DR expression level in Tregs
negatively correlates with its expression level in CTLs and is
associated with BCwith axillary lymph nodemetastasis andmore
abundant in biopsies of NACT non-responders.
In line with these former results, we also presented data
that negatively correlate the level of HLA-DR in CTLs with
the level of IL-6, IL-1β, IL-8, and IL-23/IL-12, which are
inflammatory cytokines that, at certain level in the tumor
microenvironment, could help the anti-tumor immune response
(38), but whose upregulation might also favor tumor progression
and metastasis (25–28). HLA-DR in CTLs was also inversely
correlated with the level of PD-L1 and TGF-β, which are,
respectively, a well-known inhibitory immune checkpoint and
an anti-inflammatory cytokine, which coordinately work to
dampen CTLs’ activity, directly or through the activation of
Tregs (23, 24). Likewise, HLA-DR expression in Tregs positively
correlated with all the aforementioned molecules from the tumor
milieu and, additionally, with IL-10 and IL-17, which also have
immunosuppressive functions (29, 30, 39).
In vitro experiments, with the supernatant of BC cell lines,
highlighted the fact that soluble factors released by tumor cells
are important to increase HLA-DR in CTLs, suggesting that these
tumor microenvironment molecules can modulate the immune
response and influence the activation state of CTLs, without the
requirement of contact with tumor cells.
In the other way around, we may say that the HLA-
DR expression in CTLs is a reflection of the general tumor
immune status. Indeed, an immunosuppressed environment will
be unable to stimulate an appropriate immune response and
should not give rise to HLA-DRhi CTLs. As cell-to-cell contact
and tumor-specific antigen presentation by antigen presenting
molecules are required to elicit a specific cytotoxic T cell response
against the tumor cells, we may infer that, in vivo, the antigens
presented by tumor cells, alongside with the soluble factors,
contribute to CTLs’ effector function.
The increase of HLA-DR at CTLs’ surface, upon stimulation,
could also be required to boost the anti-tumor immune response.
Indeed, HLA-DR+ CTLs were found to have the machinery
needed for antigen processing and loading on HLA-DR
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molecules and, additionally, could express CD86 and CD80,
which are the co-stimulatory molecules of antigen presenting
cells that are necessary for the proper T cell effector function (40).
Moreover, it was described that T cell-T cell synapsis occur to
allow T cells to secrete IFN-γ toward each other, compelling the
differentiation of more protective T cells (41). These T cell-T cell
interactions and mutual antigen presentation can be essential for
mounting a suitable anti-tumor response.
Notably, we observed that HLA-DR expression on tumor
infiltrating CTLs correlates to its expression in circulating
CTLs and, additionally, the analysis of HLA-DR level on CTLs
isolated from the patients’ blood could also be associated with
BC axillary lymph node invasion status and assist in the
prediction of patients’ response to NACT. Ex vivo assays indeed
corroborate that systemic CTLs maintain the profile encountered
in the tumor mass, as under similar stimulation, CTLs from
NACT responders increase even more their HLA-DR level and
produce more IFN-γ than CTLs from NACT non-responders.
These results imply that tumor immune status, reflected by
the HLA-DR level in CTLs, could also be easily assessed in
blood.
HLA-DR molecule, by itself, assessed in tumor cells, has been
reported to serve as a favorable prognostic marker for other types
of cancers, such as colorectal carcinoma (42) or glioma (43).
It was even shown that HLA-DR+ melanoma cells predict the
response to anti-PD-1/PD-L1 immunotherapy (44). However,
to our knowledge, the expression of HLA-DR in CTLs, besides
its extensive application in the study of viral infections and
chronic inflammatory diseases, was never recommended as a
biomarker in cancer. Our data suggest that HLA-DR+ CTLs,
assessed by flow cytometry, in BC patients prior to NACT, is
a sensitive and specific potential predictive factor for NACT
response. Moreover, this trait can be easily assessed in blood,
repeatedly if necessary. Further studies should be conducted in
an independent population, in order to validate the predictive
performance of HLA-DR+ CTLs in assisting the selection
of patients that will truly benefit from NACT, or promptly
directing them to alternative therapeutic strategies, such as the
combination of immunotherapies with standard chemotherapy.
Additionally, this marker also have the potential to be used
in clinical trial design to randomize good/bad responders to
evaluate novel treatments.
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Supplementary figure S1 – Representative dot plots of the gating strategy used in the flow cytometry 
analysis of breast cancer samples. Positive and negative populations were always selected taken into 










Supplementary figure S2 - Representative dot plots of the gating strategy used for fluorescence 


















Supplementary figure S3 – HLA-DR levels in CTLs can predict response to NACT, independently of 
breast cancer subtype. (A) Percentage of CTLs in pre-treatment biopsies of NACT-responders (R, black 
triangles) and non-responders (NR, grey dots) divided in the three breast cancer subtypes – Estrogen 
receptor positive (ER+), HER2 amplified (HER2) and triple negative breast cancer (TNBC). (B) HLA-DR 
expression levels in CTLs in responders and non-responders for the three subtypes of breast cancer. 
The expression level of HLA-DR was assessed by flow cytometry and represents the median 
fluorescent intensity of positive population normalized relatively to the negative population. 











Supplementary figure S4 – Profile of HLA-DR expression in CTLs and Tregs after neoadjuvant 
chemotherapy (NACT). Level of HLA-DR in CTLs (A) and Tregs (B), assessed by flow cytometry, in 
responders (R, white bars, n=3, mean ± SEM) and non-responders (NR, black bars, n=4, mean ± SEM), 
expressed as the median fluorescent intensity of positive population normalized relatively to the 

















Supplementary figure S5 – HLA-DR expression in CTLs in a co-culture of PBMCs with a breast cancer 
cell line. HLA-DR+ CTLs, assessed by flow cytometry, in the following conditions: PBMCs in mono-
culture, co-culture of PBMCs with HS 578T cell line, PBMCs with the cell line supernatant and PBMCs 
with the canonical stimulus (PMA/ionomycin). Data are expressed as the percentage of HLA-DR+ CTLs 
in these conditions (**p<0.01, n=6).  
 
 
 
 
 
 
 
 
